<SEC-DOCUMENT>0001047469-18-006698.txt : 20181012
<SEC-HEADER>0001047469-18-006698.hdr.sgml : 20181012
<ACCEPTANCE-DATETIME>20181012160311
ACCESSION NUMBER:		0001047469-18-006698
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181212
FILED AS OF DATE:		20181012
DATE AS OF CHANGE:		20181012

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		181120265

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>a2236896zpre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CATABASIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=499266,FOLIO='blank',FILE='DISK130:[18ZEO1.18ZEO48901]BA48901A.;4',USER='CHE109865',CD='11-OCT-2018;17:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>[PRELIMINARY COPY&#151;SUBJECT TO COMPLETION]  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF SPECIAL MEETING OF STOCKHOLDERS<BR>
To be held on December&nbsp;12, 2018  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are cordially invited to attend the Special Meeting of Stockholders (the "</FONT><FONT SIZE=2><B><I>Special Meeting</I></B></FONT><FONT SIZE=2>") of Catabasis
Pharmaceuticals,&nbsp;Inc. scheduled to be held on Wednesday, December&nbsp;12, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Special Meeting, the stockholders will consider and vote on the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
approve an amendment to our certificate of incorporation to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-15, with the exact
ratio to be set within that range at the discretion of our board of directors before June&nbsp;30, 2019 without further approval or authorization of our stockholders and with our board of directors
able elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion (the "</FONT><FONT SIZE=2><B><I>Reverse Split
Proposal</I></B></FONT><FONT SIZE=2>"); </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
approve an amendment and restatement of our 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 8,500,000 shares on a
pre-split basis and to provide for certain other amendments (the "</FONT><FONT SIZE=2><B><I>Plan Amendment Proposal</I></B></FONT><FONT SIZE=2>"); and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
transact any other business properly brought before the Special Meeting or any adjournment or postponement thereof. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to take advantage of the Securities and Exchange Commission rules that allow us to furnish proxy materials to our stockholders on the internet. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
proxy statement for the Special Meeting was first mailed to our stockholders on or about October&nbsp;[29], 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
board of directors unanimously believes that (i)&nbsp;the Reverse Split Proposal and (ii)&nbsp;the Plan Amendment Proposal are in our company's best interests and those of our
stockholders. Accordingly, our board of directors recommends a vote (i)&nbsp;FOR the Reverse Split Proposal and (ii)&nbsp;FOR the Plan Amendment Proposal, as outlined in the attached Proxy
Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
of record at the close of business on October&nbsp;19, 2018, the record date for the Special Meeting, are entitled to notice of, and to vote at, the Special Meeting or any
adjournment or postponement of the Special Meeting. Whether or not you expect to attend the Special Meeting in person, please vote your shares by proxy as promptly as possible to ensure your
representation and the presence of a quorum at the Special Meeting. In addition to returning your proxy card by mail, you may vote your shares on the internet by visiting www.proxyvote.com or by
telephone by calling 800-690-6903 and following the recorded instructions. Your vote is important regardless of the number of shares you own. If you send in your proxy card or vote by telephone or the
internet and then decide to attend the Special Meeting to vote your shares in person, you may still do so. Your proxy is revocable in accordance with the procedures set forth in the Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for
your shares to be voted. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="294pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g111573.jpg" ALT="GRAPHIC" WIDTH="159" HEIGHT="73">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Cambridge,
Massachusetts<BR>
October&nbsp;[&nbsp;&nbsp;&nbsp;&nbsp;], 2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=426305,FOLIO='blank',FILE='DISK130:[18ZEO1.18ZEO48901]BC48901A.;14',USER='CHE109865',CD='11-OCT-2018;17:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG48901A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg48901_catabasis_pharmaceuticals,_inc__cat02543"> </A>
<BR></FONT><FONT SIZE=2><B>  Catabasis Pharmaceuticals,&nbsp;Inc.<BR>  Proxy Statement<BR>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG48901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#INF"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INFORMATION ABOUT THE SPECIAL MEETING AND VOTING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#INF"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#INF"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Information About the Special Meeting and Voting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#INF"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_purpose_of_the_special_meeting"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purpose of the Special Meeting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_purpose_of_the_special_meeting"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_board_of_directors_recommendation"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors Recommendation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_board_of_directors_recommendation"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_notice_of_internet_availability_of_proxy_materials"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notice of Internet Availability of Proxy
Materials</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_notice_of_internet_availability_of_proxy_materials"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_who_can_vote_at_the_special_meeting"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Who Can Vote at the Special Meeting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_who_can_vote_at_the_special_meeting"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_difference_between_a__stockhol__dif03838"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Difference Between a "Stockholder of Record" and a Beneficial
Owner of Shares Held in "Street Name"</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_difference_between_a__stockhol__dif03838"><FONT SIZE=2><BR>
3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_how_to_vote"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>How to Vote</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_how_to_vote"><FONT SIZE=2><BR>
3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_quorum"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Quorum</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_quorum"><FONT SIZE=2><BR>
4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_ballot_measures_consid__cc402174"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ballot Measures Considered "Routine" and "Non-Routine"</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_ballot_measures_consid__cc402174"><FONT SIZE=2><BR>
4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_votes_required_to_approve_reve__vot03448"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Votes Required to Approve Reverse Stock Split Proposal and Plan
Amendment Proposal</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_votes_required_to_approve_reve__vot03448"><FONT SIZE=2><BR>
4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_method_of_counting_votes"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Method of Counting Votes</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_method_of_counting_votes"><FONT SIZE=2><BR>
4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_revoking_a_proxy;_changing_your_vote"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revoking a Proxy; Changing Your Vote</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_revoking_a_proxy;_changing_your_vote"><FONT SIZE=2><BR>
5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_costs_of_proxy_solicitation"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Costs of Proxy Solicitation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_costs_of_proxy_solicitation"><FONT SIZE=2><BR>
5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cc48901_voting_results"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Voting Results</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc48901_voting_results"><FONT SIZE=2><BR>
5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_proposal_no._1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 1: TO APPROVE AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO EFFECT A
REVERSE STOCK SPLIT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_proposal_no._1"><FONT SIZE=2><BR>
6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_general"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_general"><FONT SIZE=2><BR>
6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_criteria_to_be_used_for_decisi__cri02669"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Criteria to be Used for Decision to Apply the Reverse Stock
Split</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_criteria_to_be_used_for_decisi__cri02669"><FONT SIZE=2><BR>
7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_reasons_for_the_reverse_stock_split"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reasons for the Reverse Stock Split</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_reasons_for_the_reverse_stock_split"><FONT SIZE=2><BR>
7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#CRA"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Risks Associates with the Reverse Stock Split</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#CRA"><FONT SIZE=2><BR>
8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ERS"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of the Reserve Stock Split</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ERS"><FONT SIZE=2><BR>
9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_authorized_shares_of_common_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Authorized Shares of Common Stock</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_authorized_shares_of_common_stock"><FONT SIZE=2><BR>
10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_procedure_for_effecting_the_reverse_stock_split"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Procedure for Effecting the Reverse Stock
Split</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_procedure_for_effecting_the_reverse_stock_split"><FONT SIZE=2><BR>
11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_fractional_shares"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fractional Shares</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_fractional_shares"><FONT SIZE=2><BR>
11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_no_appraisal_rights"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>No Appraisal Rights</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_no_appraisal_rights"><FONT SIZE=2><BR>
11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_accounting_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_accounting_matters"><FONT SIZE=2><BR>
11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_federal_income_tax_consequences"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Federal Income Tax Consequences</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_federal_income_tax_consequences"><FONT SIZE=2><BR>
12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ce48901_vote_required_and_board_of_directors_recommendation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vote Required and Board of Directors
Recommendation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce48901_vote_required_and_board_of_directors_recommendation"><FONT SIZE=2><BR>
13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg48901_proposal_no._2"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 2: TO APPROVE AN AMENDED AND RESTATED 2015 STOCK INCENTIVE
PLAN</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg48901_proposal_no._2"><FONT SIZE=2><BR>
14</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg48901_why_we_are_requesting_stockhol__why03012"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Why We Are Requesting Stockholder Approval of the Amended and
Restated 2015 Plan</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg48901_why_we_are_requesting_stockhol__why03012"><FONT SIZE=2><BR>
14</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg48901_vote_required_and_board_of_directors_recommendation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vote Required and Board of Directors
Recommendation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg48901_vote_required_and_board_of_directors_recommendation"><FONT SIZE=2><BR>
16</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=468583,FOLIO='blank',FILE='DISK130:[18ZEO1.18ZEO48901]BG48901A.;8',USER='CHE109865',CD='11-OCT-2018;17:13' -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg48901_summary_of_the_amended_and_restated_2015_plan"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Summary of the Amended and Restated 2015 Plan</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg48901_summary_of_the_amended_and_restated_2015_plan"><FONT SIZE=2>16</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg48901_u.s._federal_income_tax_consequences"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Federal Income Tax Consequences</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg48901_u.s._federal_income_tax_consequences"><FONT SIZE=2><BR>
20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cg48901_plan_benefits"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plan Benefits</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cg48901_plan_benefits"><FONT SIZE=2><BR>
22</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ci48901_principal_stockholders"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRINCIPAL STOCKHOLDERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ci48901_principal_stockholders"><FONT SIZE=2><BR>
23</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_executive_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_executive_compensation"><FONT SIZE=2><BR>
27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_summary_compensation_table"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Summary Compensation Table</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_summary_compensation_table"><FONT SIZE=2><BR>
27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_overview/compensation_philosophy"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Overview/Compensation Philosophy</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_overview/compensation_philosophy"><FONT SIZE=2><BR>
27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_narrative_disclosure_to_summary_compensation_table"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Narrative Disclosure to Summary Compensation
Table</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_narrative_disclosure_to_summary_compensation_table"><FONT SIZE=2><BR>
28</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_outstanding_equity_awa__ck402048"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding Equity Awards at 2017 Fiscal Year End Table</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_outstanding_equity_awa__ck402048"><FONT SIZE=2><BR>
30</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_employment_agreements,_severan__emp02667"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Employment Agreements, Severance and Change in Control
Arrangements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_employment_agreements,_severan__emp02667"><FONT SIZE=2><BR>
31</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_severance_plan"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Severance Plan</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_severance_plan"><FONT SIZE=2><BR>
31</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_401(k)_retirement_plan"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>401(k) Retirement Plan</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_401(k)_retirement_plan"><FONT SIZE=2><BR>
33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_securities_authorized_for_issu__sec02789"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Securities Authorized for Issuance under Equity Compensation
Plans</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_securities_authorized_for_issu__sec02789"><FONT SIZE=2><BR>
34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_director_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIRECTOR COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_director_compensation"><FONT SIZE=2><BR>
34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck48901_compensation_committee__ck402488"><p style="font-family:times;margin-top:12pt;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee Interlocks and Insider
Participation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck48901_compensation_committee__ck402488"><FONT SIZE=2><BR>
36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cm48901_householding"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HOUSEHOLDING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cm48901_householding"><FONT SIZE=2><BR>
37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cm48901_stockholder_proposals"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>STOCKHOLDER PROPOSALS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cm48901_stockholder_proposals"><FONT SIZE=2><BR>
37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cm48901_other_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OTHER MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cm48901_other_matters"><FONT SIZE=2><BR>
37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#la48901_appendix_a"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>APPENDIX A&#151;CATABASIS PHARMACEUTICALS,&nbsp;INC. CERTIFICATE OF AMENDMENT TO RESTATED
CERTIFICATE OF INCORPORATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#la48901_appendix_a"><FONT SIZE=2><BR>
A-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#lc48901_appendix_b"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>APPENDIX B&#151;CATABASIS PHARMACEUTICALS,&nbsp;INC. AMENDED AND RESTATED 2015 STOCK INCENTIVE
PLAN</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#lc48901_appendix_b"><FONT SIZE=2><BR>
B-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1044185,FOLIO='blank',FILE='DISK130:[18ZEO1.18ZEO48901]BG48901A.;8',USER='CHE109865',CD='11-OCT-2018;17:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca48901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>[PRELIMINARY COPY&#151;SUBJECT TO COMPLETION]  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139<BR>
617-349-1971  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>FOR THE SPECIAL MEETING OF STOCKHOLDERS<BR>
to be held on December&nbsp;12, 2018  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement and the proxy card contain information about the Special Meeting of Stockholders of Catabasis Pharmaceuticals,&nbsp;Inc. (the
"</FONT><FONT SIZE=2><B><I>Special Meeting</I></B></FONT><FONT SIZE=2>") to be held on Wednesday, December&nbsp;12, 2018 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State
Street, Boston, Massachusetts 02109. The board of directors of Catabasis Pharmaceuticals,&nbsp;Inc. is using this proxy statement to solicit proxies for use at the Special Meeting. In this proxy
statement, unless expressly stated otherwise or the context otherwise requires, the use of "Catabasis," "our," "we" or "us" refers to Catabasis Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance
with the recommendation of our board of directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at
the meeting by giving our corporate secretary written notice to that effect. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
proxy statement and proxy card are first being made available to stockholders on or about October&nbsp;[29], 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Important Notice Regarding the Availability of Proxy Materials for<BR>
the Special Meeting of Stockholders to be Held on December&nbsp;12, 2018:  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>The notice of the Special Meeting and this proxy statement are<BR>
available for viewing, printing and downloading at www.proxyvote.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=310522,FOLIO='1',FILE='DISK130:[18ZEO1.18ZEO48901]CA48901A.;5',USER='CHE109865',CD='11-OCT-2018;17:13' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc48901_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="INF"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> IMPORTANT INFORMATION ABOUT THE SPECIAL MEETING AND VOTING  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_purpose_of_the_special_meeting"> </A>
<A NAME="toc_cc48901_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose of the Special Meeting    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Special Meeting, our stockholders will consider and vote on the following matters: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
approve an amendment to our certificate of incorporation to effect a reverse stock split at a ratio not less than 1-for-5 and not greater than 1-for-15, with the
exact ratio to be set within that range at the discretion of our board of directors before June&nbsp;30, 2019 without further approval or authorization of our stockholders, and with our board of
directors able elect to abandon such proposed amendment and not effect the reverse stock split authorized by stockholders, in its sole discretion (the "</FONT><FONT SIZE=2><B><I>Reverse Split
Proposal</I></B></FONT><FONT SIZE=2>");
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
approve an amendment and restatement of our 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 8,500,000 shares on a
pre-split basis and to provide for certain other amendments (the "</FONT><FONT SIZE=2><B><I>Plan Amendment Proposal</I></B></FONT><FONT SIZE=2>"); and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
transact any other business properly brought before the Special Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we are not aware of any business to come before the meeting other than the first two items noted above. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_board_of_directors_recommendation"> </A>
<A NAME="toc_cc48901_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Recommendation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors unanimously recommends that you vote: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the </FONT><FONT SIZE=2><B>Reverse Stock Split Proposal</B></FONT><FONT SIZE=2>; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>FOR </B></FONT><FONT SIZE=2>the</FONT><FONT SIZE=2><B> Plan Amendment Proposal</B></FONT><FONT SIZE=2>. </FONT></P>

</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_notice_of_internet_availability_of_proxy_materials"> </A>
<A NAME="toc_cc48901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice of Internet Availability of Proxy Materials    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to rules adopted by the Securities and Exchange Commission (the "</FONT><FONT SIZE=2><B><I>SEC</I></B></FONT><FONT SIZE=2>"), we have elected
to provide access to our proxy materials via the internet. Accordingly, we are sending a notice of internet availability of proxy materials to our stockholders. All stockholders will have the ability
to access the proxy materials on the website referenced in the notice and to request to receive a printed set of the proxy materials by mail. Instructions on how to access the proxy materials over the
internet and how to request a printed copy may be found in the notice. In addition, stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing
basis. We encourage stockholders to take advantage of the availability of the proxy materials on the internet or through email to help reduce the environmental impact of our special and annual
meetings. The proxy materials, including the notice of the Special Meeting, this proxy statement and a proxy card or voting instruction card are also available for viewing, printing and downloading on
the internet at www.proxyvote.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_who_can_vote_at_the_special_meeting"> </A>
<A NAME="toc_cc48901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote at the Special Meeting    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date of October&nbsp;19, 2018 are entitled to receive notice of the Special
Meeting and to vote the shares of our common stock that they held on that date. As of October&nbsp;19, 2018, there were
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of common stock issued
and
outstanding. Each share of common stock is entitled to one vote on each matter properly brought before the Special Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=379416,FOLIO='2',FILE='DISK130:[18ZEO1.18ZEO48901]CC48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_cc48901_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_difference_between_a__stockhol__dif03838"> </A>
<A NAME="toc_cc48901_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Difference Between a "Stockholder of Record" and a Beneficial Owner of Shares Held in "Street  Name"</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you have shares registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp;
Trust
Company,&nbsp;LLC, then you are considered a "stockholder of record" of those shares. For these shares, your set of proxy materials has been made available to you directly by us. You may vote these
shares by proxy prior to the Special Meeting by following the instructions contained on the proxy card. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you hold shares in a brokerage account or by a bank, trust or other nominee or
custodian, then you
are considered the beneficial owner of those shares, which are held in "street name." For these shares, your set of proxy materials has been made available to you by that organization. The
organization holding your account is considered the stockholder of record for purposes of voting at the Special Meeting. As the beneficial owner, you have the right to instruct that organization as to
how to vote the shares held in your account by following the instructions contained on the voting instruction card provided to you by that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_how_to_vote"> </A>
<A NAME="toc_cc48901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How to Vote    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you can vote your shares in one of two ways: either by proxy or in
person at the Special
Meeting. If you choose to vote by proxy, you may do so by telephone, via the internet or by mail. Each of these methods is explained below.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail
and you live in the United States or Canada, you may vote by proxy by calling the toll free number found on the proxy card. You must have the control number that is on the proxy card when voting. If
you choose to vote by telephone, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may transmit your proxy voting instructions&nbsp;via the
internet by following the instructions provided on the notice of internet availability of proxy materials or the proxy card. You will need to have the control number that is on the proxy card when
voting. If you choose to vote via the internet, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail, you
may vote by proxy by completing, signing and dating the proxy card and returning it in the envelope provided.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Special Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote in person at the Special
Meeting. We will give you a ballot when you arrive. Even if you plan to attend the Special Meeting, we urge you to vote your shares by proxy in advance of the Special Meeting so that, if you should
become unable to attend the Special Meeting, your shares will be voted as directed by you. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone
and internet voting for stockholders of record will be available up until 11:59&nbsp;p.m. Eastern Time on December&nbsp;11, 2018, and mailed proxy cards must be received by
December&nbsp;11, 2018 in order to be counted at the Special Meeting. If the Special Meeting is adjourned or postponed, these deadlines may be extended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in street name: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone or Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions or a voting
instruction form from your broker or other nominee if you are permitted to vote by telephone or internet.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares by mail.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Special Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the Special Meeting, you
may vote in person. To do so, you will need to show a picture identification as well as an account statement or a letter from the record holder indicating that you owned the shares as of the record
date, and obtain </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=7,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=678324,FOLIO='3',FILE='DISK130:[18ZEO1.18ZEO48901]CC48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_cc48901_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>from
the broker or other nominee who holds your shares a legal proxy or broker's proxy card and bring it with you to the meeting. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
voting deadlines and availability of telephone and internet voting for beneficial owners of shares held in "street name" will depend on the voting processes of the organization that
holds your shares. Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


If you hold your shares of Catabasis common stock in multiple accounts, you should vote your shares as
described in each set of proxy materials you receive.  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_quorum"> </A>
<A NAME="toc_cc48901_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quorum    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. Our bylaws provide that a quorum will exist if stockholders holding a majority of
the shares of stock issued and outstanding and entitled to vote are present at the meeting in person or by proxy. Abstentions and broker non-votes count as present for establishing a quorum but will
not be counted as votes cast. Broker non-votes occur when your broker or other nominee submits a proxy for your shares (because the broker or other nominee has received instructions from you on one or
more proposals, but not all, or has not received instructions from you but is entitled to vote on a particular "discretionary" matter) but does not indicate a vote for a particular proposal because
the broker or other nominee either does not have the authority to vote on that proposal and has not received voting instructions from you or has discretionary authority but chooses not to exercise it.
If a quorum is not present, the meeting may be adjourned until a quorum is obtained. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_ballot_measures_consid__cc402174"> </A>
<A NAME="toc_cc48901_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ballot Measures Considered "Routine" and "Non-Routine"    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The </FONT><FONT SIZE=2><B>Reverse Stock Split Proposal</B></FONT><FONT SIZE=2> (Proposal No.&nbsp;1) is a matter considered routine under
applicable rules. A broker or other nominee may generally exercise discretionary authority and vote on routine matters. If they exercise this discretionary authority, no broker non-votes are expected
to exist in connection with Proposal No.&nbsp;1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
</FONT><FONT SIZE=2><B>Plan Amendment Proposal</B></FONT><FONT SIZE=2> (Proposal No.&nbsp;2) is a matter considered non-routine under applicable rules. A broker or other nominee
cannot vote without instructions on non-routine matters, and therefore there may be broker non-votes on Proposal No.&nbsp;2. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_votes_required_to_approve_reve__vot03448"> </A>
<A NAME="toc_cc48901_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Votes Required to Approve Reverse Stock Split Proposal and Plan Amendment Proposal    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The approval of the Reverse Stock Split Proposal requires the holders of a majority of our outstanding shares of common stock to vote "FOR" such
proposal (Proposal No.&nbsp;1), and
broker non-votes and abstentions (shares present at the meeting and voted "ABSTAIN") will have the effect of a vote "AGAINST" this proposal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
approval of the Plan Amendment Proposal requires the affirmative vote of a majority of the votes cast at the Special Meeting (Proposal No.&nbsp;2). Abstentions and broker non-votes
will have no effect on the outcome of the vote on this proposal. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_method_of_counting_votes"> </A>
<A NAME="toc_cc48901_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Method of Counting Votes    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote at the Special Meeting on each matter to come before the Special Meeting for each share held
by such stockholder as of the record date. Votes cast in person at the Special Meeting or by proxy by mail, via the internet or by telephone will be tabulated by the inspector of election appointed
for the Special Meeting, who will also determine whether a quorum is present. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=8,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=363434,FOLIO='4',FILE='DISK130:[18ZEO1.18ZEO48901]CC48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_cc48901_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_revoking_a_proxy;_changing_your_vote"> </A>
<A NAME="toc_cc48901_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revoking a Proxy; Changing Your Vote    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may revoke your proxy before the vote is taken at the
meeting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by submitting a new proxy with a later date before the applicable deadline either signed and returned by mail or transmitted using the
telephone or internet voting procedures described in the "How to Vote" section above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by voting in person at the meeting; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by filing a written revocation with our corporate secretary. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in street name, you may submit new voting instructions by contacting your broker or other organization holding your account. You may also vote in person at the
Special Meeting, which will have the effect of revoking any previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares as described in the "How
to Vote" section above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
attendance at the Special Meeting will not automatically revoke your proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_costs_of_proxy_solicitation"> </A>
<A NAME="toc_cc48901_12"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Costs of Proxy Solicitation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will bear the costs of soliciting proxies. In addition to solicitations by mail, our directors, officers and regular employees, without
additional remuneration, may solicit proxies by telephone, facsimile, email, personal interviews and other means. In addition, we have hired Morrow Sodali&nbsp;LLC, 470 West Ave., Stamford, CT 06902
to aid us in the solicitation of proxies for a fee of $7,500 plus out-of-pocket expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cc48901_voting_results"> </A>
<A NAME="toc_cc48901_13"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Results    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to announce preliminary voting results at the Special Meeting and to publish final results in a Current Report on Form&nbsp;8-K to be
filed with the SEC within four business days following the Special Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=9,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=581156,FOLIO='5',FILE='DISK130:[18ZEO1.18ZEO48901]CC48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ce48901_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_proposal_no._1"> </A>
<A NAME="toc_ce48901_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PROPOSAL NO. 1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ce48901_to_approve_an_amendment_to_our__to_03732"> </A>
<A NAME="toc_ce48901_2"> </A></FONT> <FONT SIZE=2><B>  TO APPROVE AN AMENDMENT TO OUR CERTIFICATE OF<BR>  INCORPORATION TO EFFECT A REVERSE STOCK SPLIT    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_general"> </A>
<A NAME="toc_ce48901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;21, 2018, our board of directors unanimously approved, subject to stockholder approval, an amendment to our certificate of
incorporation to effect a reverse stock split of our outstanding common stock by combining outstanding shares of common stock into a lesser number of outstanding shares of common stock by a ratio of
not less than 1-for-5 and not more than 1-for-15 at any time prior to June&nbsp;30, 2019, with the exact ratio to be set within this range by our board of directors at its sole discretion (the
"</FONT><FONT SIZE=2><B><I>Reverse Stock Split</I></B></FONT><FONT SIZE=2>"). The board of directors may alternatively elect to abandon such proposed amendment and not effect the Reverse Stock Split
authorized by stockholders, in its sole discretion. Upon the effectiveness of the amendment to our certificate of incorporation effecting the Reverse Stock Split, the outstanding shares of our common
stock will be reclassified and combined into a lesser number of shares such that one share of our common stock will be issued for a specified number of shares in accordance with the ratio for the
Reverse Stock Split selected by our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this Proposal No.&nbsp;1 is approved by our stockholders as proposed, our board of directors would have the sole discretion to effect the amendment and Reverse Stock Split at any
time prior to June&nbsp;30, 2019, and to fix the specific ratio for the Reverse Stock Split, provided that the ratio would be not less than 1-for-5 and not more than 1-for-15. We believe that
enabling our board of directors to fix the specific ratio of the Reverse Stock Split within the stated range will provide us with the flexibility to implement the split in a manner designed to
maximize the anticipated benefits for our stockholders. The determination of the ratio of the Reverse Stock Split will be based on a number of factors, described further below under the heading
"&#151;Criteria to be Used for Decision to Apply the Reverse Stock Split." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Reverse Stock Split, if approved by our stockholders, would become effective upon the filing of an amendment to our certificate of incorporation with the Secretary of State of the
State of Delaware. The exact timing of the amendment will be determined by our board of directors based on its evaluation as to when such action will be the most advantageous to us and our
stockholders, but the amendment will not occur after June&nbsp;30, 2019. In addition, our board of directors reserves the right, notwithstanding stockholder approval and without further action by
our stockholders, to abandon the amendment and the Reverse Stock Split if, at any time prior to the effectiveness of the filing of the certificate of amendment with the Secretary of State, our board
of directors, in its sole discretion, determines that it is no longer in our best interest and the best interests of our stockholders to proceed. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary purpose for effecting the Reverse Stock Split is to increase the per share trading price of our common stock so as to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain the listing of our common stock on The Nasdaq Stock Market ("</FONT><FONT SIZE=2><B><I>Nasdaq</I></B></FONT><FONT SIZE=2>") and avoid a
delisting of our common stock from Nasdaq in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> broaden the pool of investors that may be interested in investing in our company by attracting new investors who would prefer not to invest in
shares that trade at lower share prices; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> make our common stock a more attractive investment to institutional investors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
evaluating the Reverse Stock Split, our board of directors has taken, and will take, into consideration negative factors associated with reverse stock splits. These factors include
the negative perception of reverse stock splits held by many investors, analysts and other stock market participants, as well as the fact that the stock price of some companies that have effected
reverse stock splits has </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=27336,FOLIO='6',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>subsequently
declined back to pre-reverse stock split levels. In approving the amendment to our certificate of incorporation for the Reverse Stock Split, our board of directors determined that these
potential negative factors were significantly outweighed by the potential benefits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
form of the proposed amendment to our certificate of incorporation to effect the Reverse Stock Split is attached as </FONT><FONT SIZE=2><I>Appendix&nbsp;A</I></FONT><FONT SIZE=2>
to this proxy statement. Any amendment to our certificate of incorporation to effect the Reverse Stock Split will include the Reverse Stock Split ratio fixed by our board of directors, within the
range approved by our stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_criteria_to_be_used_for_decisi__cri02669"> </A>
<A NAME="toc_ce48901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Criteria to be Used for Decision to Apply the Reverse Stock Split    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our stockholders approve the Reverse Stock Split, our board of directors will be authorized to proceed with the Reverse Stock Split. The
exact ratio of the Reverse Stock Split, within the 1-for-5 to 1-for-15 range, would be determined by our board of directors and publicly announced by us prior to the effective time of the Reverse
Stock Split. In determining whether to proceed with the reverse split and setting the appropriate ratio for the Reverse Stock Split, our board of directors will consider, among other things, factors
such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Nasdaq's minimum price per share requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the historical trading prices and trading volume of our common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of our common stock outstanding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the then-prevailing and expected trading prices and trading volume of our common stock and the anticipated impact of the Reverse Stock Split on
the trading market for our common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the anticipated impact of a particular ratio on our ability to reduce administrative and transactional costs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> business developments affecting us; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prevailing general market and economic conditions. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_reasons_for_the_reverse_stock_split"> </A>
<A NAME="toc_ce48901_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reasons for the Reverse Stock Split    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors authorized the Reverse Stock Split with the primary intent of increasing the price of our common stock in order to meet
the price criteria for continued listing on Nasdaq. Our common stock is publicly traded and listed on the Nasdaq Global Market under the symbol "CATB." Our board of directors believes that, in
addition to increasing the price of our common stock to meet the price criteria for continued listing on Nasdaq, the Reverse Stock Split would also make our common stock more attractive to a broader
range of institutional and other investors. Accordingly, for these and other reasons discussed below, we believe that effecting the Reverse Stock Split is in our and our stockholders' best interests. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August&nbsp;3, 2018, we received a deficiency letter from the Listing Qualifications Department (the "</FONT><FONT SIZE=2><B><I>Staff</I></B></FONT><FONT SIZE=2>") of Nasdaq, notifying us
that, for the previous 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market
pursuant to Nasdaq Listing Rule&nbsp;5450(a)(1) (the "</FONT><FONT SIZE=2><B><I>Bid Price Rule</I></B></FONT><FONT SIZE=2>"). In accordance with Nasdaq Listing Rule&nbsp;5810(c)(3)(A) (the
"</FONT><FONT SIZE=2><B><I>Compliance Period Rule</I></B></FONT><FONT SIZE=2>"), we have been provided an initial period of 180 calendar days, or until January&nbsp;30, 2019 (the
"</FONT><FONT SIZE=2><B><I>Compliance Date</I></B></FONT><FONT SIZE=2>"), to regain compliance with the Bid Price Rule. If, at any time before the Compliance Date, the bid price for our common stock closes
at $1.00 or more for a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to us that it complies with the Bid Price Rule,
unless the Staff exercises its discretion to extend this 10&nbsp;day period pursuant to Nasdaq Listing Rule&nbsp;5810(c)(3)(F). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=456122,FOLIO='7',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not regain compliance with the Bid Price Rule by the Compliance Date, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to
transfer the listing of our common stock to the Nasdaq Capital Market, provided that we meet the continued listing requirement for the market value of publicly held shares and all other initial
listing standards, with the exception of the bid price requirement. To effect such a transfer, we would also need to pay an application fee to Nasdaq and provide written notice to the Staff of our
intention to cure the deficiency during the additional compliance period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not regain compliance with the Bid Price Rule by the Compliance Date and we are not eligible for an additional compliance period at that time, the Staff will provide written
notification to us that our common stock may be delisted. At that time, we may appeal the Staff's delisting determination to a Nasdaq Listing Qualifications Panel (the
"</FONT><FONT SIZE=2><B><I>Panel</I></B></FONT><FONT SIZE=2>"). We expect that our common stock would remain listed pending the Panel's decision. There can be no assurance that, if we do appeal the
delisting determination by the Staff to the Panel, such appeal would be successful. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event we are delisted from Nasdaq, the only established trading market for our common stock would be eliminated and we would be forced to list our shares on the OTC Markets or
another quotation medium, depending on our ability to meet the specific listing requirements of those quotation systems. As a result, an investor would likely find it more difficult to trade, or to
obtain accurate price quotations for, our shares. Delisting would likely also reduce the visibility, liquidity and value of our common stock, including as a result of reduced institutional investor
interest in our company, and may increase the volatility of our common stock. Delisting could also cause a loss of confidence of potential industry partners, lenders and employees, which could further
harm our business and our future prospects. We believe that effecting the Reverse Stock Split may help us avoid delisting from Nasdaq and any resulting consequences. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our board of directors believes that an increased stock price could encourage investor interest and improve the marketability of our common stock to a broader range of
investors, and thus enhance our liquidity. Because of the trading volatility often associated with low-priced stocks, many brokerage firms and institutional investors have internal policies and
practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Additionally, because brokers'
commissions on low-priced stocks generally represent a higher percentage of the stock price than commissions on higher-priced stock, the current share price of our common stock may result in an
investor paying transaction costs that represent a higher percentage of total share value than would be the case if our share price were higher. Our board of directors believes that the higher share
price that may result from the Reverse Stock Split could enable institutional investors and brokerage firms with such policies and practices to invest in our common stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we expect that the Reverse Stock Split will result in an increase in the market price of our common stock, the Reverse Stock Split may not result in a permanent increase in the
market price of our common stock, which would be dependent on many factors, including general economic, market and industry conditions and other factors detailed from time to time in the reports we
file with the SEC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<A NAME="CRA"></A>Certain Risks Associated with the Reverse Stock Split  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There can be no assurance that the total market capitalization of our common stock after the implementation of the Reverse Stock Split will be
equal to or greater than the total market capitalization before the Reverse Stock Split or that the per share market price of our common stock following the Reverse Stock Split will increase in
proportion to the reduction in the number of shares of our common stock outstanding in connection with the Reverse Stock Split. Also, we cannot assure you that the Reverse Stock Split would lead to a
sustained increase in the trading price of our common </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=177071,FOLIO='8',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>stock.
The trading price of our common stock may change due to a variety of other factors, including our ability to successfully accomplish our business goals, market conditions and the market
perception of our business. You should also keep in mind that the implementation of a reverse stock split does not have an effect on the actual or intrinsic value of our business or a stockholder's
proportional ownership in our company. However, should the overall value of our common stock decline after the proposed Reverse Stock Split, then the actual or intrinsic value of the shares of our
common stock held by you will also proportionately decrease as a result of the overall decline in value. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
the liquidity of our common stock may be harmed by the proposed Reverse Stock Split given the reduced number of shares that would be outstanding after the Reverse Stock Split,
particularly if the expected increase in stock price as a result of the Reverse Stock Split is not sustained. In addition, the proposed Reverse Stock Split may increase the number of stockholders who
own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders to experience an increase in the cost of selling their shares and greater difficulty effecting
sales. If we effect the Reverse Stock Split, the resulting per-share stock price may nevertheless fail to attract institutional investors and may not satisfy the investing guidelines of such investors
and, consequently, the trading liquidity of our common stock may not improve. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
our board of directors has proposed the Reverse Stock Split to bring the price of our common stock back above $1.00 per share in order to meet the requirements for the continued
listing of our common stock on Nasdaq, there is no guarantee that the price of our common stock will not decrease in the future, or that our common stock will remain in compliance with Nasdaq listing
standards. There can be no guarantee that the closing bid price of our common stock will remain at or above $1.00 for 10 consecutive trading days, whether following the Reverse Stock Split or
otherwise, which is required to cure our current Nasdaq listing standard deficiency. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<A NAME="ERS"></A>Effect of the Reverse Stock Split  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Reverse Split Proposal is approved and our board of directors elects to effect the Reverse Stock Split, the number of outstanding shares
of common stock will be reduced in proportion to the ratio of the split chosen by our board of directors. As of the effective time of the Reverse Stock Split, we would also adjust and proportionately
decrease the number of shares of our common stock reserved for issuance upon exercise of, and adjust and proportionately increase the exercise price of, all options and warrants and other rights to
acquire our common stock. In addition, as of the effective time of the Reverse Stock Split, we would adjust and proportionately decrease the total number of shares of our common stock that may be the
subject of the future grants under our stock plans. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Reverse Stock Split would be effected simultaneously for all outstanding shares of our common stock. The Reverse Stock Split would affect all of our stockholders uniformly and would
not change any stockholder's percentage ownership interest in our company, except to the extent that the Reverse Stock Split results in any of our stockholders owning fractional shares. We will not
issue any fractional shares as a result of the Reverse Stock Split and in lieu thereof any stockholders that would otherwise be entitled to receive a fractional share will be entitled to a cash
payment. The Reverse Stock Split would not change the terms of our common stock. The Reverse Stock Split is not intended as, and would not have the effect of, a "going private transaction" covered by
Rule&nbsp;13e-3 under the Securities Exchange Act of 1934 (the "</FONT><FONT SIZE=2><B><I>Exchange Act</I></B></FONT><FONT SIZE=2>"). Following the Reverse Stock Split, we would continue to be subject to
the periodic reporting requirements of the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
Reverse Stock Split ratios of 1-for-5, 1-for-10 and 1-for-15, which reflect the low end, middle and high end of the range that our stockholders are being asked to approve, the
following table sets forth (i)&nbsp;the number of shares of our common stock that would be issued and outstanding, (ii)&nbsp;the number of shares of our common stock that would be reserved for
issuance pursuant to outstanding </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=471249,FOLIO='9',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>warrants
and options, and (iii)&nbsp;the weighted-average exercise price of outstanding options and warrants, each giving effect to the Reverse Stock Split and based on securities outstanding as of
71,038,419. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Before Reverse<BR>
Stock Split </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Reverse Stock<BR>
Split Ratio of<BR>
1-for-5 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Reverse Stock<BR>
Split Ratio of<BR>
1-for-10 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Reverse Stock<BR>
Split Ratio of<BR>
1-for-15 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of Shares of Common Stock Issued and Outstanding</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,038,419</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,207,684</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,103,842</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,735,895</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Number of Shares of Common Stock Reserved for Issuance Pursuant to Outstanding Options and Warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46,637,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,327,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,663,725</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,109,150</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-Average Exercise Price of Outstanding Options and Warrants</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.91</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.82</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our board of directors does not implement the Reverse Stock Split by June&nbsp;30, 2019, the authority granted in this proposal to implement the Reverse Stock Split would terminate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in the Reverse Split Proposal, except to the extent of their
ownership in shares of our
common stock and securities convertible or exercisable for our common stock, which shares and securities would be subject to the same proportionate adjustment in accordance with the terms of the
Reverse Stock Split as all other outstanding shares of our common stock and securities convertible into or exercisable for our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_authorized_shares_of_common_stock"> </A>
<A NAME="toc_ce48901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized Shares of Common Stock    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently authorized under our certificate of incorporation to issue up to a total of 155,000,000 shares of capital stock, comprised of
150,000,000 shares of common stock and 5,000,000 shares of preferred stock. While the Reverse Stock Split would decrease the number of outstanding shares of our common stock, it would not change the
number of authorized shares under our certificate of incorporation. Consequently, the Reverse Stock Split would have the effect of increasing the number of shares of common stock available for
issuance under our certificate of incorporation. Our board of directors believes that such an increase is in our and our stockholders' best interests as it would provide us with greater flexibility to
issue shares of common stock in connection with possible future financings, joint ventures and acquisitions as well as under our equity incentive plans and for other general corporate purposes. We do
not currently have any plans, understandings, arrangements, commitments or agreements, written or oral, for the issuance of the additional shares of common stock that would become available for
issuance if the Reverse Stock Split is effected, however we desire to have the shares available to provide us with additional flexibility to use our common stock for these business and financial
purposes in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
increasing the number of authorized but unissued shares of common stock, the Reverse Stock Split could, under certain circumstances, have an anti-takeover effect, although this is not
the intent of our board of directors. For example, our board of directors might be able to delay or impede a takeover or transfer of control of our company by causing such additional authorized but
unissued shares to be issued to holders who might side with our board of directors in opposing a takeover bid that the board determines is not in the best interests of our company or our stockholders.
The Reverse Stock Split could therefore have the effect of discouraging unsolicited takeover attempts. By potentially discouraging initiation of any such unsolicited takeover attempts the Reverse
Stock Split could limit the opportunity for our stockholders to dispose of their shares at the higher price generally available in takeover attempts or that may be available under a merger proposal.
The Reverse Stock Split could have the effect of permitting our current management, including our current board of directors, to retain its position, and place it in a better position to resist
changes that stockholders may wish to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=14,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=481700,FOLIO='10',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>make
if they are dissatisfied with the conduct of our business. However, our board of directors is not aware of any attempt to take control of our company and the board did not authorize the Reverse
Stock Split with the intent that it be utilized as a type of anti-takeover device. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_procedure_for_effecting_the_reverse_stock_split"> </A>
<A NAME="toc_ce48901_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Procedure for Effecting the Reverse Stock Split    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If our stockholders approve the Reverse Split Proposal, and if our board of directors still believes that a Reverse Stock Split is in the best
interests of us and our stockholders, our board of directors will determine the ratio of the Reverse Stock Split to be implemented and we will publicly announce the ratio selected by our board of
directors and file the certificate of amendment effecting the Reverse Split with the Secretary of State of the State of Delaware. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owners of Common Stock.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the implementation of the Reverse Stock Split, we would treat shares held by
stockholders in street name in
the same manner as shares held directly by stockholders of record. Banks, brokers, custodians or other nominees would be instructed to effect the Reverse Stock Split for their beneficial holders
holding our common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than our procedures for stockholders of record for processing the
Reverse Stock Split and making payment for fractional shares. If a stockholder holds shares of our common stock with a bank, broker, custodian or other nominee and has any questions in this regard,
stockholders are encouraged to contact their bank, broker, custodian or other nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registered Holders of Common Stock.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All of our registered holders of common stock hold their shares electronically in book-entry
form with our
transfer agent, American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC. These stockholders do not hold physical stock certificates evidencing their ownership of our common stock. However, they are
provided with a statement reflecting the number of shares of our common stock registered in their accounts. If a stockholder holds registered shares in book-entry form with our transfer agent, no
action needs to be taken to receive post-Reverse Stock Split shares and any payment in lieu of fractional shares, if applicable, because the exchange and payment will be automatic. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_fractional_shares"> </A>
<A NAME="toc_ce48901_8"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fractional Shares    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We would not issue fractional shares in connection with the Reverse Stock Split. Instead, stockholders who otherwise would be entitled to
receive fractional shares because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio would be entitled to receive a cash payment in lieu thereof at a price equal to the
fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of our common stock as reported on the Nasdaq on the effective date of the Reverse Stock Split. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_no_appraisal_rights"> </A>
<A NAME="toc_ce48901_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Appraisal Rights    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No action is proposed herein for which the laws of the State of Delaware, or our certificate of incorporation or bylaws, provide a right to our
stockholders to dissent and obtain appraisal of, or payment for, such stockholders' capital stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_accounting_matters"> </A>
<A NAME="toc_ce48901_10"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accounting Matters    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Reverse Stock Split would not affect the par value of our common stock per share, which would remain $0.001 par value per share, while the
number of outstanding shares of common stock would decrease in accordance with the Reverse Stock Split ratio. As a result, as of the effective time of the Reverse Stock Split, the stated capital
attributable to common stock on our balance sheet would decrease and the additional paid-in capital account on our balance sheet would increase by an offsetting amount. Following the Reverse Stock
Split, reported per share net income or loss would be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=15,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=632752,FOLIO='11',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>higher
because there would be fewer shares of common stock outstanding and we would adjust historical per share amounts set forth in our future financial statements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_federal_income_tax_consequences"> </A>
<A NAME="toc_ce48901_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Income Tax Consequences    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion is a summary of the material U.S. federal income tax consequences of a reverse stock split to us and to U.S. Holders
(as defined below) that hold shares of our common stock as capital assets for U.S. federal income tax purposes. This discussion is based upon current U.S. tax law, which is subject to change, possibly
with retroactive effect, and differing interpretations. Any such change may cause the U.S. federal income tax consequences of a reverse stock split to vary substantially from the consequences
summarized below. We have not sought and will not seek any rulings from the Internal Revenue Service (the "</FONT><FONT SIZE=2><B><I>IRS</I></B></FONT><FONT SIZE=2>") regarding the matters discussed below
and there can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the proposed Reverse Stock Split. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this discussion, a "U.S. Holder" is a beneficial owner of our common stock that, for U.S. federal income tax purposes, is or is treated as (i)&nbsp;an individual who is
a citizen or resident of the United States; (ii)&nbsp;a corporation (or any other entity or arrangement treated as a corporation) created or organized under the laws of the United States, any state
thereof, or the District of Columbia; (iii)&nbsp;an estate, the income of which is subject to U.S. federal income tax regardless of its source; or (iv)&nbsp;a trust if (1)&nbsp;its
administration is subject to the primary supervision of a court within the United States and all of its substantial decisions are subject to the control of one or more "United States persons" (within
the meaning of Section&nbsp;7701(a)(30) of the Internal Revenue Code of 1986, as amended (the "</FONT><FONT SIZE=2><B><I>Code</I></B></FONT><FONT SIZE=2><I>"</I></FONT><FONT SIZE=2>)), or (2)&nbsp;it has a
valid election in effect under applicable U.S. Treasury regulations to be treated as a United States person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
summary does not address all aspects of U.S. federal income taxation that may be relevant to U.S. Holders in light of their particular circumstances or to stockholders who may be
subject to special tax treatment under the Code, including, without limitation, dealers in securities, commodities or foreign currency, persons who are treated as non-U.S. persons for U.S. federal
income tax purposes, certain former citizens or long-term residents of the United States, insurance companies, tax-exempt organizations, banks, financial institutions, small business investment
companies, regulated investment companies, real estate investment trusts, retirement plans, persons whose functional currency is not the U.S. dollar, traders that mark-to-market their securities or
persons who hold their shares of our common stock as part of a hedge, straddle, conversion or other risk reduction transaction. If a partnership (or other entity treated as a partnership for U.S.
federal income tax purposes is the beneficial owner of our common stock, the U.S. federal income tax treatment of a partner in the
partnership will generally depend on the status of the partner and the activities of the partnership. Accordingly, partnerships (and other entities treated as partnerships for U.S. federal income tax
purposes) holding our common stock and the partners in such entities should consult their own tax advisors regarding the U.S. federal income tax consequences of the proposed Reverse Stock Split to
them. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
state and local tax consequences, alternative minimum tax consequences, non-U.S. tax consequences and U.S. estate and gift tax consequences of a reverse stock split are not discussed
herein and may vary as to each U.S. Holder. Furthermore, the following discussion does not address any tax consequences of transactions effectuated before, after or at the same time as the proposed
Reverse Stock Split, whether or not they are in connection with the proposed Reverse Stock Split. This discussion should not be considered as tax or investment advice, and the tax consequences of a
reverse stock split may not be the same for all stockholders. U.S. Holders should consult their own tax advisors to understand their individual federal, state, local and foreign tax consequences. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=16,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=130552,FOLIO='12',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ce48901_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Consequences to the Company.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We believe that a reverse stock split will constitute a reorganization under Section&nbsp;368(a)
(1)(E) of the
Code. Accordingly, we should not recognize taxable income, gain or loss in connection with a reverse stock split. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Consequences to U.S. Holders.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A U.S. Holder generally should not recognize gain or loss upon the proposed Reverse Stock
Split for U.S. federal
income tax purposes, except with respect to cash received in lieu of a fractional share of our common stock, as discussed below. A U.S. Holder's aggregate adjusted tax basis in the shares of our
common stock received pursuant to the proposed Reverse Stock Split should equal the aggregate adjusted tax basis of the shares of our common stock exchanged therefor (reduced by the amount of such
basis that is allocated to any fractional share of our common stock). The U.S. Holder's holding period in the shares of our common stock received pursuant to the proposed Reverse Stock Split should
include the holding period in the shares of our common stock exchanged therefor. U.S. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of shares of common
stock surrendered in a recapitalization to shares received in the recapitalization. U.S. Holders of shares of our common stock acquired on different dates and at different prices should consult their
tax advisors regarding the allocation of the tax basis and holding period of such shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. Holder that, pursuant to the proposed Reverse Stock Split, receives cash in lieu of a fractional share of our common stock should recognize capital gain or loss in an amount equal
to the difference,
if any, between the amount of cash received and the portion of the U.S. Holder's aggregate adjusted tax basis in the shares of our common stock surrendered that is allocated to such fractional share.
Such capital gain or loss will be short term if the pre-Reverse Stock Split shares were held for one year or less at the effective time of the Reverse Stock Split and long term if held for more than
one year. No gain or loss will be recognized by us as a result of the proposed Reverse Stock Split. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
U.S. Holder of our common stock may be subject to information reporting and backup withholding on cash paid in lieu of a fractional share in connection with the proposed Reverse Stock
Split. A U.S. Holder of our common stock will be subject to backup withholding if such U.S. Holder is not otherwise exempt and such U.S. Holder does not provide its taxpayer identification number in
the manner required or otherwise fails to comply with applicable backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may
be refunded or allowed as a credit against a U.S. Holder's federal income tax liability, if any, provided the required information is timely furnished to the IRS. U.S. Holders of our common stock
should consult their own tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
U.S. federal income tax discussion set forth above does not discuss all aspects of U.S. federal income taxation that may be relevant to a particular stockholder in light of such
stockholder's circumstances and income tax situation. Accordingly, we urge you to consult with your own tax advisor with respect to all of the potential U.S. federal, state, local and foreign tax
consequences to you of the Reverse Stock Split. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ce48901_vote_required_and_board_of_directors_recommendation"> </A>
<A NAME="toc_ce48901_12"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required and Board of Directors Recommendation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Delaware General Corporation Law, this proposal must be approved by the affirmative vote of a majority of the outstanding shares
of our common stock. Abstentions and broker non-votes with respect to this proposal will be counted for purposes of establishing a quorum and, if a quorum is present, will have the same practical
effect as a vote against this proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" THE AMENDMENT TO THE CERTIFICATE OF INCORPORATION TO APPROVE THE REVERSE STOCK
SPLIT.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=17,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=729256,FOLIO='13',FILE='DISK130:[18ZEO1.18ZEO48901]CE48901A.;6',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cg48901_1_14"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg48901_proposal_no._2"> </A>
<A NAME="toc_cg48901_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PROPOSAL NO. 2    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cg48901_to_approve_an_amended___cg402218"> </A>
<A NAME="toc_cg48901_2"> </A></FONT> <FONT SIZE=2><B>  TO APPROVE AN AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;21, 2018, our board of directors unanimously approved, subject to stockholder approval, an amendment and restatement of our
2015 Stock Incentive Plan (the "</FONT><FONT SIZE=2><B><I>2015 Plan</I></B></FONT><FONT SIZE=2>"). We are asking our stockholders to approve the Amended and Restated 2015 Stock Incentive
Plan approved by our board of directors (the "</FONT><FONT SIZE=2><B><I>Amended and Restated 2015 Plan</I></B></FONT><FONT SIZE=2>"). If approved by stockholders, the Amended and Restated 2015 Plan
would:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> increase the number of shares of our common stock that may be issued under the 2015 Plan by 8,500,000, increasing the maximum number of shares
issuable under the 2015 Plan from 3,879,966 to 12,379,966, on a pre-Reverse Stock Split basis (the "</FONT><FONT SIZE=2><B><I>Plan Increase</I></B></FONT><FONT SIZE=2>"); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> eliminate the "evergreen" or automatic replenishment provision of the 2015 Plan pursuant to which the shares authorized for issuance under the
2015 Plan are automatically increased on an annual basis; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that shares tendered as payment for the exercise of an award or withheld to satisfy tax withholding obligations with respect to an
award and shares underlying stock appreciation rights ("</FONT><FONT SIZE=2><B><I>SARs</I></B></FONT><FONT SIZE=2>") settleable in either cash or in stock that are actually settled in cash will not be added
back to the number of shares available for future grant; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prohibit the payment of dividends or dividend equivalents with respect to unvested awards and the accrual of dividend equivalents with respect
to stock options and SARs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg48901_why_we_are_requesting_stockhol__why03012"> </A>
<A NAME="toc_cg48901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why We Are Requesting Stockholder Approval of the Amended and Restated 2015 Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that our future success depends, in large part, upon our ability to maintain a competitive position in attracting, retaining and
motivating persons who are expected to make important contributions to our company by providing such persons with equity ownership opportunities and performance-based incentives. The life sciences
industry in the Cambridge and Boston, Massachusetts market is highly competitive, and our results are largely attributable to the talents, expertise, efforts and dedication of our employees. Our
compensation program, including the
granting of equity compensation, is the primary means by which we attract and recruit new employees, as well as retain our most experienced and skilled employees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
compensation is also fundamental to our compensation philosophy and core objectives of paying for performance and aligning the interests of employees with those of stockholders. A
significant portion of our employees' compensation is provided in the form of equity. We believe that equity awards, and the potential they hold for appreciation through an increase in our stock
price, support our pay-for-performance philosophy, provide further incentive to our employees to focus on creating long-term stockholder value and create an ownership culture that links employees'
interests with those of our stockholders and our long-term results, performance, and financial condition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
outstanding incentive equity holdings of our employees were significantly diluted by our June 2018 financing, which resulted in the issuance of 42&nbsp;million units at a price of
$1.00 per unit, with each unit comprised of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.20 per share. Immediately prior to the
June&nbsp;2018 financing, the shares of common stock acquirable upon exercise of outstanding stock options held by our employees was approximately 9% of our fully diluted capitalization, based on
shares and equity instruments outstanding, whether or not vested. This percentage declined to 3.5% of our fully diluted capitalization, as of September&nbsp;30, 2018, primarily due to the
June&nbsp;2018 financing. In addition, as of September&nbsp;30, 2018, 72.1% of our outstanding stock options were underwater, with a weighted-average exercise price of $3.02 per share and
individual option exercise prices ranging up to $14.05 per share as compared to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=625076,FOLIO='14',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
$0.84 per share closing price of our common stock on the Nasdaq Global Market on October&nbsp;1, 2018. Accordingly, we believe that our employees currently have a very limited opportunity to
participate in any future appreciation in the value of our common stock. For example, if the value of our common stock tripled from its closing price on the Nasdaq Global Market of $0.84 on
October&nbsp;1, 2018 to $2.52 per share, our employees would be entitled to realize less than 2.2% of the increased equity value of our company on a fully diluted basis assuming full acceleration of
all vesting provisions. We believe that such a limited opportunity to participate in appreciation in the value of our common stock results in such outstanding options holding insufficient retention
value for our employees, puts us at risk of not being able to retain our most experienced and skilled employees and provides for insufficient alignment of our employees' interests with those of our
stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of September&nbsp;30, 2018, we had 123,227 shares available for grant under the 2015 Plan, representing 0.18% of the sum of (i)&nbsp;the total number of our shares of common stock
outstanding, plus (ii)&nbsp;the total number of shares of common stock issuable under outstanding equity incentive awards that were not underwater, plus (iii)&nbsp;the total number of shares
available for grant under the 2015 Plan. During the years ended December&nbsp;31, 2016 and 2017 and the nine months ended September&nbsp;30, 2018, we granted equity awards with respect to
1,068,845, 890,740 and 2,133,845 shares, respectively, to employees, non-employee directors and consultants. The grants made during the nine months ended September&nbsp;30,
2018 included grants approved by our board of directors in September 2018 that were intended to provide additional retentive value for our employees in light of the dilutive effect our June 2018
financing had on our employees' existing stock option and other equity holdings. A summary of outstanding stock options granted under our 2008 Equity Incentive Plan (the "2008 Plan") and 2015 Plan,
our shares available for grant under our 2015 Plan, and related information for employees and nonemployees as of September&nbsp;30, 2018 follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Options<BR>
Outstanding

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares<BR>
Available<BR>
for Grant </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise Price of<BR>
Options<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted Average<BR>
Remaining Contractual<BR>
Term of Options<BR>
Outstanding<BR>
(years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic Value<BR>
(in thousands) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 4,489,457</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123,227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.02</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>No
restricted stock or restricted stock unit awards (or other such "full-value" awards) were outstanding as of September&nbsp;30, 2018. Without the Plan Increase, we would not be able to adequately
complete our planned annual company-wide equity award grant for fiscal year 2018, and we believe that we would not have sufficient shares available for grant under the 2015 Plan to make meaningful
equity incentive grants to any potential new employees. Without the Plan Increase, we believe that we would be forced to rely on providing cash-settled awards for a portion of our incentive-based
compensation in order to retain our most experienced and skilled employees, which we believe would put us at a competitive disadvantage in our industry and would not be in our stockholders' best
interests as it would remove incentives aligning the interests of our employees and our senior leaders with those of our stockholders to drive company-wide performance and create long-term stockholder
value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the amount of the proposed Plan Increase amount, we considered several factors, including the number of options shares needed for annual employee option grants over the
next two to three years, which we estimated at 3% to 4% of our outstanding stock at the time of such grants, the number of option shares needed for new hires over the next two to three years,
including anticipated executive level hires in senior commercial, financial and clinical positions, and potential performance grants to employees to align employee interests with specified program,
strategic and financial priorities. If stockholders approve the Amended and Restated 2015 Plan, we will have 8,623,227 shares of common stock available for issuance pursuant to future awards under the
Amended and Restated 2015 Plan. Given our historical and projected utilization and assuming relative stock price stability, we expect that this number of shares available for issuance will meet our
grant needs for the next two to three years. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=190601,FOLIO='15',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the Plan Increase, the Amended and Restated 2015 Plan would implement several changes to the 2015 Plan designed to protect stockholder interests, promote effective
corporate governance and reflect use of corporate governance best practices, specifically: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> No Evergreen Provision.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended and Restated 2015 Plan would eliminate
the "evergreen" or automatic replenishment provision of the 2015 Plan pursuant to which the shares authorized for issuance under the 2015 Plan are automatically increased on an annual basis. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Restrictions on Share Recycling.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended and Restated 2015 Plan would
provide that shares tendered as payment for the exercise of an award or withheld to satisfy tax withholding obligations with respect to an award and shares underlying SARs settleable in either cash or
in stock that are actually settled in cash will no longer be added back to the number of shares available for the future grant under the plan.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Restrictions on Dividends and Dividend Equivalents.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The Amended and
Restated 2015 Plan would prohibit the payment of dividends or dividend equivalents with respect to unvested awards and the accrual of dividend equivalents with respect to stock options and SARs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg48901_vote_required_and_board_of_directors_recommendation"> </A>
<A NAME="toc_cg48901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required and Board of Directors Recommendation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be approved, this proposal requires the affirmative vote of the majority of the shares of our common stock cast at the Special Meeting for
the proposal. Abstentions and broker non-votes with respect to this proposal will be counted for purposes of establishing a quorum and, if a
quorum is present, abstentions and broker non-votes will have no effect on the outcome of the vote on this proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the Amended and Restated 2015 Plan and the Plan Increase will serve a critical role in attracting and retaining the high caliber employees and consultants essential to
our success and in motivating these individuals to strive to enhance our growth and profitability. Therefore, our board of directors urges you to vote to approve the Plan Amendment Proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
directors and executive officers have an interest in this proposal by virtue of their being eligible to receive equity awards under the Amended and Restated 2015 Plan. If the Plan
Amendment Proposal is approved, we plan to file&nbsp;a registration statement on Form&nbsp;S-8 with the SEC to register the additional shares of common stock authorized under the Amended and
Restated 2015 Plan by the Plan Increase. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" THE PLAN AMENDMENT PROPOSAL.</B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg48901_summary_of_the_amended_and_restated_2015_plan"> </A>
<A NAME="toc_cg48901_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of the Amended and Restated 2015 Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary of the Amended and Restated 2015 Plan assumes and gives effect to stockholder approval of the Plan Amendment Proposal and
is qualified in its entirety by the specific language of the Amended and Restated 2015 Plan, which is set forth in </FONT><FONT SIZE=2><I>Appendix&nbsp;B</I></FONT><FONT SIZE=2> to this proxy
statement, with the proposed new text underlined, bolded and italicized and the proposed deleted text marked as struck out. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Amended and Restated 2015 Plan is to advance the interests of our stockholders by enhancing our
ability to attract,
retain and motivate persons who are expected to make important contributions to our company and by providing such persons with equity ownership opportunities and performance-based incentives that are
intended to better align the interests of such persons with those of our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=700220,FOLIO='16',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All of our employees, officers and directors, as well as consultants and advisors to our company, are eligible to
be granted awards
under the Amended and Restated 2015 Plan; however, incentive stock options may only be granted to our employees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares Available for Awards.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An aggregate of 12,379,966 shares of our common stock will be authorized for issuance under the
Amended and Restated
2015 Plan, of which 2,917 shares were already issued, 3,753,822 shares were subject to outstanding awards and 8,623,227 were available for grant of future awards, in each case as of
September&nbsp;30, 2018 and after giving effect to the Plan Increase of 8,500,000 shares. To the extent awards outstanding as of September&nbsp;30, 2018 under our 2008 Equity Incentive Plan
expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by us at their original issuance price pursuant to a contractual repurchase right, they will increase the number of
shares authorized for issuance under the Amended and Restated 2015 Plan, subject to certain limitations specified in the Amended and Restated 2015 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
shares of our common stock covered by SARs are counted against the number of shares available for the grant of awards under the Amended and Restated 2015 Plan; provided, however,
that (i)&nbsp;SARs that may be settled only in cash will not be so counted and (ii)&nbsp;if we grant a SAR in tandem with an option for the same number of shares of common stock and provide that
only one such award may be exercised (a "</FONT><FONT SIZE=2><B><I>Tandem SAR</I></B></FONT><FONT SIZE=2>"), only the shares covered by the option, and not the shares covered by the Tandem SAR, will be so
counted, and the expiration of one in connection with the other's exercise will not restore shares to the Amended and Restated 2015 Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any award under the Amended and Restated 2015 Plan (i)&nbsp;expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part
(including as the result of shares of common stock subject to such award being repurchased by us at the original issuance price pursuant to a contractual repurchase right) or (ii)&nbsp;results in
any common stock not being issued, the unused common stock covered by such award shall again be available for the grant of awards under the Amended and Restated 2015 Plan, subject to specified
limitations. Shares of common stock delivered (by actual delivery, attestation, or net exercise) to us by a plan participant to (1)&nbsp;purchase shares of common stock upon the exercise of an award
or (2)&nbsp;satisfy tax withholding obligations (including shares retained from the award creating the tax obligation) will not be added back to the number of shares available for the future grant
of awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with a merger or consolidation of an entity with our company or the acquisition by us of property or stock of an entity, our board of directors may grant awards under the
Amended and Restated 2015 Plan in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Such substitute awards may be granted on such terms
as our board of directors deems appropriate in the circumstances, notwithstanding any limitations on awards contained in the Amended and Restated 2015 Plan. Such substitute awards will not count
against the overall share limit under the Amended and Restated 2015 Plan, except as may be required by reason of Section&nbsp;422 and related provisions of the Code and the regulations thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Administration.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors administers the Amended and Restated 2015 Plan and has authority to grant awards and
to adopt, amend and
repeal the administrative rules, guidelines and practices relating to the Amended and Restated 2015 Plan and to construe and interpret the terms of the plan and any award agreements entered into under
the plan. Our board of directors may correct any defect, supply any omission or reconcile any inconsistency in the Amended and Restated 2015 Plan or any award under the plan in the manner and to the
extent it deems expedient and it is the sole and final judge of such expediency. All decisions by our board of directors are made in the board's sole discretion and are final and binding on all
persons having or claiming any interest in the Amended and Restated 2015 Plan or in any award under the plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors may delegate any or all of its powers under the Amended and Restated 2015 Plan to one or more committees or subcommittees of the board. Our board of directors has </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=482978,FOLIO='17',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>authorized
its compensation committee to administer the Amended and Restated 2015 Plan, including delegation to the compensation committee of the authority to interpret the terms of the Amended and
Restated 2015 Plan, to grant options thereunder and to make stock awards thereunder; provided, however, that, the compensation committee is not authorized to amend the Amended and Restated 2015 Plan.
Our board of directors may also delegate authority to an executive officer to grant awards under the Amended and Restated 2015 Plan to employees other than executive officers, provided that the board
will fix the terms of the awards to be granted by such executive officer, including the exercise price of such awards (or a formula for establishing such price), and the maximum number of shares
subject to awards that such executive officer may make. All references that we make to our board of directors in this summary of the Amended and Restated 2015 Plan are also intended to include
reference to any committee or subcommittee of the board or officer to whom our board of directors has delegated authority under the Amended and Restated 2015 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Types of Awards.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended and Restated 2015 Plan authorizes the award of stock options, SARs, restricted stock awards,
restricted stock units and
other stock-based awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock options entitle the holder to purchase a specified number of shares of common stock at a specified exercise price,
subject to
such other terms and conditions as are specified in connection with the option grant. The Amended and Restated 2015 Plan allows for the grant of nonqualified stock options as well as incentive stock
options, which qualify under Section&nbsp;422 of the Code and may be granted only to our employees or employees of any parent or subsidiary of ours. The exercise price of incentive stock options and
nonqualified stock options granted under the Amended and Restated 2015 Plan will not be less than the fair market value of a share of our common stock on the date of grant. The maximum term of options
granted under Amended and Restated 2015 Plan is ten years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;SARs entitle the holder, upon exercise, to receive an amount of common stock or cash or a combination
thereof determined
by reference to appreciation, from and after the date of grant, in the fair market value of our common stock over the measurement price of the SAR. The per share measurement price of a SAR granted
under the Amended and Restated 2015 Plan may not be less than the fair market value of a share of our common stock on the date of grant. The maximum term of SARs granted under Amended and Restated
2015 Plan is ten years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards entitle the recipient to acquire shares of common stock subject to our right to
repurchase all or
part of such shares at their issue price or other stated or formula price (or to require forfeitures of such shares if issued at no cost) from the recipient in the event that conditions specified in
the applicable award are not satisfied prior to the end of the applicable restriction period or periods specified in the award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units entitle the recipient to receive such number of shares of common stock or (if so
provided in the
applicable award agreement) an amount of cash equal to the fair market value of such number of shares of common stock as are set forth in the applicable award agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Stock-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended and Restated 2015 Plan authorizes other awards of shares of common stock and other awards that are
valued in
whole or in part by reference to, or are otherwise based on, shares of common stock or other property, having such terms and conditions as our board of
directors may determine ("</FONT><FONT SIZE=2><B><I>Other Stock-Based Awards</I></B></FONT><FONT SIZE=2>"). Other Stock-Based Awards are available as a form of payment in the settlement of other awards
granted under the Amended and Restated 2015 Plan or as payment in lieu of compensation to which a participant under the plan is otherwise entitled. Other Stock-Based Awards may be paid in shares of
common stock or cash, as our board of directors may determine. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=22,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=568488,FOLIO='18',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation on Repricing of Stock Options and SARs.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;With respect to stock options and SARs, unless such action is approved by our
stockholders or
otherwise permitted under the terms of the Amended and Restated 2015 Plan as an equitable adjustment in connection with certain changes in capitalization and reorganization events as described below,
we may not (i)&nbsp;amend any outstanding stock option or SAR granted under the plan to provide an exercise or measurement price per share that is lower than the then-current exercise or measurement
price per share of such outstanding stock option or SAR, (ii)&nbsp;cancel any outstanding stock option or SAR (whether or not granted under the plan) and grant in substitution therefor new awards
under the plan (other than certain substitute awards described above) covering the same or a different number of shares of common stock and having an exercise or measurement price per share lower than
the then-current exercise or measurement price per share of the cancelled stock option or SAR, (iii)&nbsp;cancel in exchange for a cash payment any outstanding stock option or SAR with an exercise
or measurement price per share above the then-current fair market value of a share of our common stock or (iv)&nbsp;take any other action under the plan that constitutes a "repricing" within the
meaning of the rules of Nasdaq. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions on Dividends and Dividend Equivalents.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Amended and Restated 2015 Plan prohibits the payment of dividends or
dividend equivalents
with respect to unvested awards and the accrual of dividend equivalents with respect to stock options and SARs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equitable Adjustments.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares,
reclassification of shares, spin-off or other similar change in capitalization or event (including the Reverse Stock Split), or any dividend or distribution to holders of our common stock other than
an ordinary cash dividend, we are required by the Amended and Restated 2015 Plan to make equitable adjustments (or make substitute awards, if applicable), in a manner determined by our board of
directors, to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and class of securities available under the Amended and Restated 2015 Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the share counting rules under the Amended and Restated 2015 Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and class of securities and exercise price per share of each outstanding option; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the share and per-share provisions and measurement price of each outstanding SAR; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares and the repurchase price per share subject to each outstanding restricted stock award or restricted stock unit award; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the share and per-share related provisions and purchase price, if any, of any outstanding Other Stock-Based Award. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
a merger or other reorganization event (as defined in the Amended and Restated 2015 Plan), our board of directors, may, on such terms as our board determines (except to the extent
specifically provided otherwise in an applicable award agreement or other agreement between the plan participant and us), take any one or more of the following actions pursuant to the Amended and
Restated 2015 Plan, as to some or all outstanding awards, other than restricted stock awards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that all outstanding awards will be assumed or substantially equivalent awards will be substituted by the successor corporation (or an
affiliate thereof); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon written notice to a participant, provide that the participant's unexercised awards will terminate immediately prior to the consummation of
such transaction unless exercised by the participant within a specified period following the date of such notice; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that outstanding awards will become exercisable, realizable or deliverable, or restrictions applicable to outstanding awards will
lapse, in whole or in part, prior to or upon the reorganization event; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=23,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=257430,FOLIO='19',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the event of a reorganization event pursuant to which holders of our common stock will receive a cash payment for each share surrendered in
the reorganization event, make or provide for a cash payment to the participants with respect to each award held by a participant equal to (1)&nbsp;the number of shares of our common stock subject
to the vested portion of the award (after giving effect to any acceleration of vesting that occurs upon or immediately prior to such reorganization event) multiplied by (2)&nbsp;the excess, if any,
of the cash payment for each share surrendered in the reorganization event over the exercise, measurement or purchase price of such award and any applicable tax withholdings, in exchange for the
termination of such award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide that, in connection with a liquidation or dissolution, awards convert into the right to receive liquidation proceeds (if applicable,
net of the exercise, measurement or purchase price thereof and any applicable tax withholdings); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any combination of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors is not obligated by the Amended and Restated 2015 Plan to treat all awards, all awards held by a participant or all awards of the same type, identically. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of certain restricted stock units, no assumption or substitution is permitted, and the restricted stock units will instead be settled in accordance with the terms of the
applicable restricted stock unit agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of a reorganization event other than a liquidation or dissolution, the repurchase and other rights under each outstanding restricted stock award will continue for the
benefit of the successor company and will, unless our board of directors may otherwise determine, apply to the cash, securities or other property which our common stock is converted into or exchanged
for pursuant to the reorganization event, unless our board provided for the termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement or any
other agreement between the participant and us. Upon the occurrence of a reorganization event involving a liquidation or dissolution, all restrictions and conditions on each outstanding restricted
stock award will automatically be deemed terminated or satisfied, unless otherwise provided in the agreement evidencing the restricted stock award or in any other agreement between the participant and
us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to limited exceptions specified in the Amended and Restated 2015 Plan, awards under the Amended and
Restated 2015 Plan may
not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and
distribution or, other than in the case of an incentive stock option, pursuant to a qualified domestic relations order, and, during the life of the plan participant, are exercisable only by the plan
participant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acceleration.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may at any time provide that any award under the Amended and Restated 2015 Plan shall become
immediately
exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment, Term and Termination.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may amend, suspend or terminate the Amended and Restated 2015 Plan at
any time, except that
stockholder approval will be required to comply with applicable law or stock market requirements. No award may be granted under the Amended and Restated 2015 Plan after June&nbsp;23, 2025. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg48901_u.s._federal_income_tax_consequences"> </A>
<A NAME="toc_cg48901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S. Federal Income Tax Consequences    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary is intended only as a general guide to the U.S. federal income tax consequences of participation in the Amended and
Restated 2015 Plan and does not attempt to describe all possible federal or other tax consequences of such participation or tax consequences based on particular circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=24,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=644904,FOLIO='20',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive Stock Options.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An optionee who is granted an incentive stock option does not recognize taxable income at the time the
option is granted or
upon its exercise, although the exercise may subject the optionee to the alternative minimum tax. Upon a disposition of the shares more than two years after grant of the option and one year after
exercise of the option, any gain or loss is treated as long-term capital gain or loss. If these holding periods are not satisfied, the optionee recognizes ordinary income at the time of disposition
equal to the difference between the exercise price and the lower of (i)&nbsp;the fair market value of the shares at the date of the option exercise or (ii)&nbsp;the sale price of the shares. Any
gain or loss recognized on such a premature disposition of the shares to the extent not recognized as taxable income as provided above, will be long-term or short-term capital gain or loss, depending
on the holding period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonqualified Stock Options.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An optionee does not recognize taxable income at the time he or she is granted a nonqualified stock
option. Upon
exercise, the optionee recognizes taxable income generally measured by the excess of the then fair market value of the shares over the exercise price. Any taxable income recognized in connection with
an option exercise by our employee is subject to tax withholding by us. We are generally entitled to a deduction in the same amount as the ordinary income recognized by the optionee. Upon a
disposition of such shares by the optionee, any difference between the sale price and the optionee's exercise price, to the extent not recognized as taxable income as provided above, is treated as
long-term or short-term capital gain or loss, depending on the holding period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A holder of a SAR does not recognize taxable income at the time he or she is
granted a SAR. Upon exercise, the participant will recognize ordinary income in an amount equal to the amount of cash received and the fair market value of the shares received, and if granted to an
employee, tax withholding is generally due. Any additional gain or loss recognized upon any later disposition of the shares would be capital gain or loss, depending on the holding period. We generally
should be entitled to a deduction equal to the amount of ordinary income recognized by the participant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A participant acquiring restricted stock generally will recognize ordinary income equal to the fair market
value of the shares on
the date our right of repurchase lapses (i.e.&nbsp;the date the award vests). If the participant is an employee, such ordinary income generally is subject to withholding of income and employment
taxes. The participant may elect, pursuant to Section&nbsp;83(b) of the Code, to have the date of acquisition of the shares be a date earlier than the date our repurchase rights lapses, provided
such election is made no later than 30&nbsp;days after the participant acquires the shares. Upon the sale of shares acquired pursuant to a restricted stock award pursuant to which an election
pursuant to Section&nbsp;83(b) of the Code has been made, any gain or loss, based on the difference between the sale price and the fair market value on the determination date, will be taxed as short
term or long term capital gain or loss, depending on the holding period. Any taxable income recognized in connection with the grant of restricted stock by our employee is subject to tax withholding by
us. The Company generally should be entitled to a deduction equal to the amount of ordinary income recognized by the participant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A participant generally will recognize no income upon the grant of a restricted stock unit. Upon the
settlement and/or
payment of restricted stock units, participants normally will recognize ordinary income in the year of receipt in an amount equal to the cash received and the fair market value of any nonrestricted
shares received. If the participant is an employee, such ordinary income generally is subject to withholding taxes. Upon the sale of any shares received, any gain or loss, based on the difference
between the sale price and the fair market value will be taxed as capital gain or loss, depending on the holding period. We generally should be entitled to a deduction equal to the amount of ordinary
income recognized by the participant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>The foregoing is only a summary of the effect of federal income taxation upon award recipients and us with respect to the grant and exercise of options and SARs
and the grant and vesting of  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=25,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=234579,FOLIO='21',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<A NAME="page_cg48901_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> restricted stock and restricted stock units under the Amended and Restated 2015 Plan. Reference should be made to the applicable provisions of the Code. In addition, the summary does not purport to be
complete, and does not discuss the tax consequences of the Amended and Restated 2015 Plan
participant's death or the provisions of the income tax laws of any municipality, state or foreign country in which the Amended and Restated 2015 Plan participant may reside, nor does it discuss the
Medicare tax on net investment income.</B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="cg48901_plan_benefits"> </A>
<A NAME="toc_cg48901_7"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Plan Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;30, 2018, approximately 23 employees of ours and 5 non-employee directors of ours were eligible to participate in the
2015 Plan. On October&nbsp;1, 2018, the closing price of our common stock on the Nasdaq Global Market was $0.84 per share. No awards have been approved for grant under the Amended and Restated 2015
Plan contingent upon stockholder approval of the Plan Amendment Proposal. The granting of awards under the 2015 Plan is discretionary, and we cannot now determine with certainty the number or type of
awards to be granted in the future to any particular person or group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
the adoption of 2015 Plan through September&nbsp;30, 2018, we have granted the following stock options under the 2015 Plan to the individuals and groups listed below. In all
cases, the securities underlying such stock options were shares of our common stock. As of the date hereof we have granted only stock options and no other type of award under the 2015 Plan. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Subject to Stock<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer </I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>968,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.<BR></FONT> <FONT SIZE=2><I>Chief Medical Officer </I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>461,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph.D.<BR></FONT> <FONT SIZE=2><I>Chief Scientific Officer </I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>429,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All current executive officers as a group </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,323,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All current directors who are not executive officers, as a group </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>181,282</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Each associate of any such directors or executive officers </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Each person who received 5% of such awards</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(1)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>968,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.(1)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>461,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph.D.(1)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>429,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deirdre Cunnane<BR></FONT> <FONT SIZE=2><I>Chief Legal Officer </I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>465,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Angelika Fretzen, Ph.D.<BR></FONT> <FONT SIZE=2><I>SVP Product Development </I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>308,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All employees who are not executive officers, as a group(2) </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,850,275</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
awards reported on these lines are the same awards as shown with respect to Drs.&nbsp;Milne, Donovan and Nichols, as applicable, in the "Named Executive
Officers" section of this table, and represent all awards made to them under the 2015 Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
608,018 shares subject to stock options that have expired without being exercised.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=26,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=500607,FOLIO='22',FILE='DISK130:[18ZEO1.18ZEO48901]CG48901A.;16',USER='HYUNG',CD='12-OCT-2018;10:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ci48901_1_23"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ci48901_principal_stockholders"> </A>
<A NAME="toc_ci48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial
ownership of our common stock as of September&nbsp;30, 2018 by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers ("</FONT><FONT SIZE=2><B><I>NEOs</I></B></FONT><FONT SIZE=2>"); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities and include shares of common stock issuable upon the exercise of stock options that are immediately exercisable or
exercisable within 60&nbsp;days after September&nbsp;30, 2018. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have
sole voting and investment power with respect to the shares beneficially owned by them, subject to community property laws, where applicable. The information is not necessarily indicative of
beneficial ownership for any other purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage ownership calculations for beneficial ownership are based on 71,038,419 shares of common stock outstanding as of September&nbsp;30, 2018. Except as otherwise indicated
in the table below, addresses of named beneficial owners are in care of Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA&nbsp;02139. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to
options held by that person that are currently exercisable or exercisable within 60&nbsp;days after September&nbsp;30, 2018. We did not deem these shares outstanding, however, for the purpose of
computing the percentage ownership of any other person. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Stockholders</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Federated Investment Management Company(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,434,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Empery Asset Management(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Stonepine Capital Management,&nbsp;LLC(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,800,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Armistice Capital,&nbsp;LLC(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,634,316</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>NEOs and Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>813,221</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, Ph.D., M.D.(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>227,306</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph.D.(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157,572</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,977</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,914,946</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,167</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,881,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors as a group (9&nbsp;persons)(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,187,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of our outstanding stock. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=638128,FOLIO='23',FILE='DISK130:[18ZEO1.18ZEO48901]CI48901A.;4',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ci48901_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 10,434,000 shares of common stock beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated
Investors,&nbsp;Inc. ("</FONT><FONT SIZE=2><B><I>Federated</I></B></FONT><FONT SIZE=2>") that have been delegated the power to direct investment and power to vote the securities by the registered
investment companies' board of trustees or directors and by the separate accounts' principals. All of the voting securities of Federated are held in the Voting Shares Irrevocable Trust
("</FONT><FONT SIZE=2><B><I>Trust</I></B></FONT><FONT SIZE=2>"), the trustees of which are Thomas R. Donahue, Rhodora&nbsp;J. Donahue and J. Christopher Donahue (collectively, the
"</FONT><FONT SIZE=2><B><I>Trustees</I></B></FONT><FONT SIZE=2>"). Federated and the Trust each reported sole voting and dispositive power, and the Trustees reported shared voting and dispositive power,
with respect to the shares of common stock owned by the registered investment companies and separate accounts advised by subsidiaries of Federated, however they expressly disclaimed that they were the
beneficial owners of such shares. The address for each of the foregoing persons and entities is Federated Investors Tower, Pittsburgh, PA 15222-3779. The foregoing information is based on a
Schedule&nbsp;13G filed with the SEC on July&nbsp;10, 2018 that reported beneficial ownership as of June&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 5,000,000&nbsp;shares of common stock held by funds to which Empery Asset Management,&nbsp;LP ("</FONT><FONT SIZE=2><B><I>Investment
Manager</I></B></FONT><FONT SIZE=2>") serves as investment manager (the "</FONT><FONT SIZE=2><B><I>Empery Funds</I></B></FONT><FONT SIZE=2>"). Empery AM&nbsp;GP,&nbsp;LLC (the
"</FONT><FONT SIZE=2><B><I>GP</I></B></FONT><FONT SIZE=2>"), is the sole general partner of Investment Manager and each of Ryan&nbsp;M. Lane and Martin D. Hoe is a Managing Member of the&nbsp;GP. Each
of Investment Manager, Mr.&nbsp;Lane and Mr.&nbsp;Hoe (the "</FONT><FONT SIZE=2><B><I>Reporting Persons</I></B></FONT><FONT SIZE=2>") reported shared voting and dispositive power with respect to the
shares held by the Empery Funds. In addition, each of the Reporting Persons reported shared voting and dispositive power with respect to an additional 5,000,0000&nbsp;shares of common stock
acquirable upon exercise of warrants that were subject to limitations on exercise that do not permit the exercise of such warrants to the extent that the Reporting Persons would beneficially own after
any such exercise more than 4.99% of the outstanding shares of common stock, and accordingly the Reporting Persons reported that such warrants were not exercisable as of the date of such report. Each
of the Empery Funds and each of the Reporting Persons disclaimed any beneficial ownership of all such shares of common stock and all such shares of common stock underlying such warrants. The address
for each of the foregoing persons and entities is 1 Rockefeller Plaza, Suite&nbsp;1205, New York, NY&nbsp;10020. The foregoing information is based on a Schedule&nbsp;13G filed with the SEC on
June&nbsp;25, 2018 that reported beneficial ownership as of June&nbsp;20, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,400,000 shares of common stock and an additional 2,400,000 shares of common stock acquirable upon exercise of warrants with respect to which each of
Stonepine Capital,&nbsp;L.P. (the&nbsp;"</FONT><FONT SIZE=2><B><I>Partnership</I></B></FONT><FONT SIZE=2>"), Stonepine Capital Management,&nbsp;LLC (the "</FONT><FONT SIZE=2><B><I>General
Partner</I></B></FONT><FONT SIZE=2>"), Jon M. Plexico and Timothy P. Lynch reported sole voting and dispositive power. The warrants are subject to a limitation on exercise that does not permit the
exercise of such warrants to the extent that the Partnership and certain related persons and entities would beneficially own after any such exercise more than 9.99% of the outstanding shares of common
stock, which limitation did not limit the exercisability of such warrants as of the date of such report. The General Partner is the general partner and investment adviser the Partnership and
Mr.&nbsp;Plexico and Mr.&nbsp;Lynch are the control persons of the General Partner. Each of the foregoing persons and entities disclaimed membership in a group and disclaimed beneficial ownership
of the shares except to the extent of that entity's or person's pecuniary interest therein. The address for each of the foregoing persons and entities is 919 NW Bond Street, Suite&nbsp;204, Bend, OR
97703. The foregoing information is based, on part, on a Schedule&nbsp;13G filed with the SEC on June&nbsp;28, 2018 that reported beneficial ownership as of June&nbsp;20, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 3,634,316 shares of common stock with respect to which each of Armistice Capital,&nbsp;LLC
("</FONT><FONT SIZE=2><B><I>Armistice</I></B></FONT><FONT SIZE=2>"), Armistice Capital Master Fund&nbsp;Ltd. ("</FONT><FONT SIZE=2><B><I>Armistice Master Fund</I></B></FONT><FONT SIZE=2>") and Steven Boyd
reported shared voting and dispositive power. Steve Boyd is a managing member of </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=998903,FOLIO='24',FILE='DISK130:[18ZEO1.18ZEO48901]CI48901A.;4',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ci48901_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>Armistice
and a director of Armistice Master Fund. Each of Armistice and Mr.&nbsp;Boyd disclaimed beneficial ownership in such shares of common stock except to the extent of his or its pecuniary
interest therein. The address for Armistice and Steve Boyd is 510 Madison Avenue, 22<SUP>nd</SUP>&nbsp;Floor, New York, NY 10022. The address for Armistice Master Fund is 20&nbsp;Genesis Close,
P.O.&nbsp;Box&nbsp;314, Grand Cayman, KY1-1104, Cayman Islands. The foregoing information is based on a Schedule&nbsp;13G filed with the SEC on July&nbsp;2, 2018 that reported beneficial
ownership as of June&nbsp;20, 2018.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
550,596 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
226,897 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 157,572 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 25,050 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 33,977 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,133,943 shares held by Advanced Technology Ventures&nbsp;VIII,&nbsp;L.P. ("</FONT><FONT SIZE=2><B><I>ATV VIII</I></B></FONT><FONT SIZE=2>").
ATV&nbsp;Associates&nbsp;VIII,&nbsp;L.L.C. ("</FONT><FONT SIZE=2><B><I>ATV A VIII</I></B></FONT><FONT SIZE=2>") is the General Partner of ATV&nbsp;VIII and exercises voting and dispositive authority
over the shares held by ATV&nbsp;VIII. Voting and dispositive decisions of ATV&nbsp;A&nbsp;VIII are made collectively by Michael&nbsp;A. Carusi, Jean George, a member of our board of
directors, Steven&nbsp;N. Baloff, Robert C. Hower and William&nbsp;C. Wiberg (collectively, the "</FONT><FONT SIZE=2><B><I>ATV&nbsp;VIII&nbsp;Managing Directors</I></B></FONT><FONT SIZE=2>").
ATV&nbsp;A&nbsp;VIII and the ATV&nbsp;VIII Managing Directors disclaim beneficial ownership of the shares held by ATV&nbsp;VIII except to the extent of their pecuniary interest therein. The
address for each of the foregoing persons and entities is 500&nbsp;Boylston Street, Suite&nbsp;1380, Boston, MA&nbsp;02116. The information about ATV&nbsp;VIII share ownership is based on a
Schedule&nbsp;13G filed with the SEC on February&nbsp;14, 2018 that reported ownership as of December&nbsp;31, 2017. Also includes 666,145&nbsp;shares of common stock held by Lightstone
Ventures,&nbsp;L.P. and 90,764&nbsp;shares of common stock held by Lightstone Ventures&nbsp;(A),&nbsp;L.P. LSV&nbsp;Associates,&nbsp;LLC
("</FONT><FONT SIZE=2><B><I>LSV&nbsp;GP</I></B></FONT><FONT SIZE=2>") is the General Partner of Lightstone Ventures,&nbsp;L.P. and Lightstone Ventures&nbsp;(A),&nbsp;L.P. (collectively,
"</FONT><FONT SIZE=2><B><I>LSV</I></B></FONT><FONT SIZE=2>") and exercises voting and dispositive authority over the shares held by LSV. Voting and dispositive decisions of LSV&nbsp;GP are made
collectively by Michael&nbsp;A. Carusi, Jean George, a member of our board of directors, Ralph&nbsp;E. Christoffersen and Henry&nbsp;A. Plain,&nbsp;Jr. (collectively, the
"</FONT><FONT SIZE=2><B><I>LSV Managing Directors</I></B></FONT><FONT SIZE=2>"). LSV&nbsp;GP and the LSV Managing Directors disclaim beneficial ownership of the shares held by LSV except to the extent of
their pecuniary interest therein Ms.&nbsp;George disclaims beneficial ownership of the shares held by ATV&nbsp;VIII and LSV except to the extent of any pecuniary interest therein.
Ms.&nbsp;George's address and the address for the Lightstone Ventures members and entities is 500 Boylston Street, Suite&nbsp;1380, Boston, MA&nbsp;02116. Also includes 24,094 shares of common
stock issuable upon the exercise of options held by Ms.&nbsp;George exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 15,167 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,798,528 shares of record held by SV Life Sciences Fund&nbsp;V,&nbsp;L.P. ("</FONT><FONT SIZE=2><B><I>SVLS V&nbsp;LP</I></B></FONT><FONT SIZE=2>") and
59,139 shares of record held by SV Life Sciences Fund V Strategic Partners,&nbsp;L.P. ("</FONT><FONT SIZE=2><B><I>SVLS V SPP</I></B></FONT><FONT SIZE=2>"). SV Life Sciences Fund V (GP),&nbsp;LP
("</FONT><FONT SIZE=2><B><I>SVLS V&nbsp;GP</I></B></FONT><FONT SIZE=2>") is the general partner of SVLS V&nbsp;LP and SVLS V SPP. The general partner of SVLS&nbsp;V&nbsp;GP is SVLSF V,&nbsp;LLC.
The members of the investment committee of SVLSF&nbsp;V,&nbsp;LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=939631,FOLIO='25',FILE='DISK130:[18ZEO1.18ZEO48901]CI48901A.;4',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ci48901_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>David
Milne and Michael Ross, a member of our board of directors. SVLS V&nbsp;LP, SVLS&nbsp;V&nbsp;SPP, SVLS&nbsp;GP, SVLSF V,&nbsp;LLC and each of the individuals comprising the SVLSF
V,&nbsp;LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS&nbsp;V&nbsp;LP and SVLS V SPP. Each of SVLS V&nbsp;LP,
SVLS V SPP, SVLS V&nbsp;GP, SVLSF&nbsp;V,&nbsp;LLC and the individual members of the SVLSF V,&nbsp;LLC investment committee disclaim beneficial ownership of the shares owned directly by
SVLS&nbsp;V&nbsp;LP and SVLS V SPP except to the extent of any pecuniary interest therein. The address for each of the foregoing entities and individuals, with the exception of Kate Bingham, is
One Boston Place, Suite&nbsp;3900, 201&nbsp;Washington Street, Boston, Massachusetts 02108. The address for Kate Bingham is 71 Kingsway, London WC2B&nbsp;6ST, United Kingdom. Also includes
24,094&nbsp;shares of common stock issuable upon the exercise of options held by Mr.&nbsp;Ross exercisable within 60&nbsp;days after September&nbsp;30, 2018.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,175,802 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after September&nbsp;30, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=291371,FOLIO='26',FILE='DISK130:[18ZEO1.18ZEO48901]CI48901A.;4',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ck48901_1_27"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ck48901_executive_compensation"> </A>
<A NAME="toc_ck48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to Jill&nbsp;C.&nbsp;Milne, Joanne M. Donovan and
Andrew Nichols, who together constitute all of our NEOs. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our
executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_summary_compensation_table"> </A>
<A NAME="toc_ck48901_2"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation earned in 2017 and 2016 by our NEOs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>462,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>168,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>632,619</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>453,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163,152</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>431,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,049,404</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
389,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
475,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Medical Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>381,982</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>321,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>835,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
346,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
432,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>316,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,627</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>238,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>675,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Bonus" column represent discretionary annual cash bonuses awarded to our NEOs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share-based compensation awarded during the year computed in
accordance with the provisions of Financial Accounting Standards Board ("</FONT><FONT SIZE=2><B><I>FASB</I></B></FONT><FONT SIZE=2>") Accounting Standard Codification
("</FONT><FONT SIZE=2><B><I>ASC</I></B></FONT><FONT SIZE=2>") Topic 718. See Note&nbsp;13 to the consolidated financial statements included in our Annual Report on Form&nbsp;10-K for the fiscal year
ended December&nbsp;31, 2017 previously filed with the SEC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "All Other Compensation" column reflect, for each NEO, the cost to us of life insurance premiums paid for the NEO.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_overview/compensation_philosophy"> </A>
<A NAME="toc_ck48901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview/Compensation Philosophy    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We operate in the highly competitive biotechnology industry, which is characterized by frequent scientific and technological advances, rapidly
changing regulatory and market requirements, and the frequent emergence of new competitors. Our ability to attract and retain highly qualified managerial, scientific and medical personnel in this
environment is essential to the achievement of our strategic and financial goals. We have embraced a compensation philosophy of offering our employees competitive compensation and benefits packages
that are focused on long-term value creation and rewarding them for achieving our developmental, financial and strategic objectives, because we recognize the necessity of attracting and retaining
individuals in our industry with the breadth of skills and experience required to develop, gain marketing approval of and commercialize products successfully. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
compete with many other companies, universities and research institutions in seeking to attract and retain a skilled team. To meet this challenge, we observe the following core
principles in formulating our compensation policies and making compensation decisions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> creating a direct and meaningful link between strategic business objectives and rewarding individual performance in the achievement of key
goals and milestones to reach those objectives; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=504250,FOLIO='27',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> providing for a performance-driven culture by setting clear, aggressive goals, rewarding outstanding performers to the extent those goals are
achieved and making sure our best performers know clearly that we value their contributions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> providing equity awards that establish a clear alignment between the interests of our employees and our stockholders and enhance our employees'
sense of ownership; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fostering a collaborative team culture centered on our principles of patient-focused drug development and commercialization, reinforced through
our compensation and incentive programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ensuring that compensation plans and arrangements are simple to communicate and understand; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> offering total compensation that is competitive and fair. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_narrative_disclosure_to_summary_compensation_table"> </A>
<A NAME="toc_ck48901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative Disclosure to Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity
incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and
objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target
a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Chief Executive Officer typically proposes base salary, target bonuses, and equity incentive compensation for members of our executive team (excluding herself) to the compensation
committee. Her proposals are based on our company's pay philosophy and methodology and in-line with executive compensation for similarly situated executives at peer companies. Our compensation
committee then typically reviews and discusses the proposals with the Chief Executive Officer for all executives other than the Chief Executive Officer. The compensation committee, without the
applicable members of management present, further discusses the Chief Executive Officer's recommendations and ultimately recommends for our board of directors' approval the base salary, target bonuses
and equity incentive compensation of our executive officers for the current year, as well as the amount of executive officer cash bonuses for the prior year, based on the attainment of corporate and
individual goals. The Chief Executive Officer is not present during voting or deliberations regarding her compensation by the compensation committee or the board of directors. During 2017, our
compensation committee engaged Radford, an AON Hewitt company, as its independent compensation consultant, to review our executive compensation peer group and program design and assess our executives'
compensation relative to comparable companies. Our compensation committee considered the relationship that Radford has with us, the members of our board of directors and our executive officers. Based
on the committee's evaluation, the compensation committee has determined that no conflicts of interest existed between our company and Radford. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
assisted the committee in conducting a competitive compensation assessment for our executive officers for the fiscal year ended December&nbsp;31, 2017. In evaluating the total
compensation of our executive officers, the compensation committee, with the assistance of Radford, established a peer group of 19 publicly traded companies in the biopharmaceutical industry that was
selected based on companies whose market capitalization, number of employees, maturity of product development pipeline and area of therapeutic focus are similar to ours. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=32,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=834128,FOLIO='28',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
peer group for our executive benchmarking as approved by the compensation committee for 2017 was comprised of the following companies: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Akebia Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fate Therapeutics, Inc</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Proteon Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>aTyr Pharma,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Genocea Biosciences,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Regulus Therapeutics&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Capricor Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>GlycoMimetics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Stemline Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Cellular Biomedicine Group,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Immune Design Corp.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Trevena,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ChemoCentryx,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Kura Oncology,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Vital Therapies,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Concert Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Matinas BioPharma Holdings,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Endocyte,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Mirati Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
then supplemented the peer group information with published survey data, which provided a broader market representation of companies and deeper position reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2017, we paid annual base salaries to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols in the amounts of $462,264,
$389,621, and $346,800, respectively. These 2017 annual base salaries reflected a market-based merit increase from 2016 of 2%. These base salaries were determined using a competitive assessment of
similarly situated executives at our peer companies to make them competitive with the 50<SUP>th</SUP>&nbsp;percentile, as well as to address customary annual base salary increases and to
recognize their individual performance. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our NEOs. None of our NEOs is
currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual bonus.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may, in its discretion, award bonuses to our NEOs from time to time. We typically establish annual
bonus targets
based around a set of specified corporate goals for our NEOs, along with individual goals, and conduct an annual performance review to determine the attainment of such goals. Our compensation
committee recommends and our board of directors approves target percentages of annual base salary for our NEOs based on target percentages for similar executives at our peer companies to make these
percentages competitive with the 50<SUP>th</SUP>&nbsp;percentile, which for 2017 were 50%, 40% and 35% for Drs. Milne, Donovan and Nichols, respectively. Our management may propose bonus awards
to the compensation committee or the board of directors primarily based on such review process and such target percentages. Our compensation committee makes a recommendation to the board of directors
regarding eligibility requirements for and the amount of such bonus awards. With respect to 2017, we did not award or pay bonuses to Drs. Milne, Donovan or Nichols, as our board of directors, upon the
recommendation of the compensation committee, determined to grant increased equity incentive compensation to our executive officers in lieu of cash bonuses as a means of reducing our cash
expenditures. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity incentives.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any
formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to
align the interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes
our executive officers to remain in our employment during the vesting period. Accordingly, we typically grant stock option awards at the start of employment to each executive officer and our other
employees and our compensation committee and board of directors periodically review the equity incentive compensation of our NEOs and other employees and from time to time may grant equity incentive
awards to them in the form of stock options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, our board of directors granted options to purchase 200,000, 100,000 and 100,000 shares of our common stock to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols,
respectively, as part of a review of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=33,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=401843,FOLIO='29',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>their
overall compensation. For grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option grants to our executives and other employees
typically vest 25% on the first anniversary of grant or, in the case of new hire grants, the initial employment date, if earlier, and 2.0833% per month thereafter, through the fourth anniversary of
the vesting commencement date, and have a term of 10&nbsp;years from the grant date. The exercise price of all options is equal to the fair market value of our common stock on the date of grant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_outstanding_equity_awa__ck402048"> </A>
<A NAME="toc_ck48901_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at 2017 Fiscal Year End Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table set forth information regarding outstanding equity awards held by our NEOs as of December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,276</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,477</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,605</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,149</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,216</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,420</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,918</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,937</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
27,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/6/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,764</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>527</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,937</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
55,933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2,432</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,864</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,918</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/29/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.79</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10/2/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Became
fully vested on January&nbsp;1, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through March&nbsp;26, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through July&nbsp;8, 2019. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=34,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=742374,FOLIO='30',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through February&nbsp;11, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through September&nbsp;8, 2020
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards vested on February&nbsp;9, 2018. The remaining unvested awards are scheduled to vest in equal monthly installments through
February&nbsp;9, 2021.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Became
fully vested on February&nbsp;16, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through June&nbsp;1, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through October&nbsp;3, 2020.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_employment_agreements,_severan__emp02667"> </A>
<A NAME="toc_ck48901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements, Severance and Change in Control Arrangements    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements with Current NEOs  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into an employment agreement with Dr.&nbsp;Milne, dated as of April&nbsp;7, 2010. The employment agreement confirms
Dr.&nbsp;Milne's title, compensation arrangements and eligibility for benefits made available to employees generally. The employment agreement with Dr.&nbsp;Milne provides that she is eligible to
receive an annual cash bonus, as determined by our board of directors in its sole discretion, with a target of 40% of her annual base salary earned in such particular calendar year, which percentage
shall be subject to adjustment from time to time by the board of directors in its sole discretion. The board of directors has approved for 2018 a target cash bonus (expressed as a percentage of base
salary) of up to 50% for Dr.&nbsp;Milne based on its assessment of our company's performance against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has approved for 2018 a target cash bonus of up to 40% of annual base salary for Dr.&nbsp;Donovan and up to 35% of annual base salary for Dr.&nbsp;Nichols, as
determined in the sole discretion of the board of directors, based on its assessment of their respective performance and that of our company against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of Drs. Milne, Donovan and Nichols is an employee at will and is entitled to certain benefits upon termination pursuant to our Severance Benefits Plan (the
"</FONT><FONT SIZE=2><B><I>Severance Plan</I></B></FONT><FONT SIZE=2>"), which was adopted by our board of directors in April 2016, as further described below. In connection with the adoption of the
Severance Plan, each of Drs. Milne, Donovan and Nichols has acknowledged that their entitlement to severance benefits is governed by the terms of the Severance Plan and that any terms of their
employment agreement or offer letter, as applicable, relating to severance have been superseded in their entirety by the terms of the Severance Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_severance_plan"> </A>
<A NAME="toc_ck48901_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Severance Plan provides eligible full time executives holding the title of vice president or above ("</FONT><FONT SIZE=2><B><I>Covered
Employees</I></B></FONT><FONT SIZE=2>") certain severance benefits upon a termination without cause (as defined in the Severance Plan) or a resignation for good reason (as defined in the Severance Plan),
including in each case within one year following a change in control (as defined in the Severance Plan) (each, a "</FONT><FONT SIZE=2><B><I>Covered Termination</I></B></FONT><FONT SIZE=2>"). Pursuant to the
Severance Plan, each Covered Employee who is subject to a Covered Termination is entitled to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuation of such Covered Employee's monthly base salary (as defined in the Severance Plan) for a period ranging from six months to
18&nbsp;months (the "</FONT><FONT SIZE=2><B><I>Severance Period</I></B></FONT><FONT SIZE=2>") following such termination depending on the title/role of the Covered Employee and the type of Covered
Termination; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=35,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=135498,FOLIO='31',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment by us of a portion of the cost of COBRA continuation of benefits coverage for the Covered Employee and his or her applicable dependents
for no longer than the Covered Employee's applicable Severance Period or until the Covered Employee commences new employment and is eligible for new plan coverage, if sooner, subject to certain
conditions set forth in the Severance Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any unpaid annual bonus in respect to any completed bonus period which has ended prior to the date of the Covered Employee's Covered
Termination and which our board of directors deems granted to the Covered Employee in its discretion pursuant to our contingent compensation program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of our chief executive officer, a bonus amount equal to one-half of the average annual bonus paid to the chief executive officer
over the three calendar years preceding the calendar year in which the Covered Termination occurs, which bonus shall be prorated to reflect the number of days served in the calendar year in which such
Covered Termination occurs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a change in control termination, full vesting of any unvested equity awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
of any severance benefits under the Severance Plan requires that the Covered Employee: (a)&nbsp;comply with the provisions of any applicable noncompetition, nonsolicitation,
and other obligations to us; and (b)&nbsp;execute and deliver a suitable waiver and release under which the Covered Employee releases and discharges us and our affiliates from and on account of any
and all claims that relate to or arise out of the employment relationship between us and the Covered Employee, which release will become binding within 60&nbsp;days following the Covered Employee's
termination of employment. If a Covered Employee dies following a Covered Termination but before such Covered Employee has received all of the severance benefits to which such Covered Employee is
entitled under the Severance Plan, the remaining payments will be made to the Covered Employee's designated beneficiary or estate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides that the following employees will not be eligible for severance benefits, except to the extent specifically determined otherwise by the Severance Plan's
administrator:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is terminated for cause (as defined in the Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who retires, terminates employment as a result of an inability to perform his or her duties due to physical or mental disability or
dies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who voluntarily terminates his or her employment, except in the case of a Covered Termination for good reason (as defined in the
Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is employed for a specific period of time in accordance with the terms of a written employment agreement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who promptly becomes employed by another member of the controlled group of entities of which we (or our successor in the change in
control (as defined in the Severance Plan)) is a member as defined in Sections&nbsp;414(b) and (c)&nbsp;of the Code. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides for recoupment of severance benefits under specified circumstances if the Covered Employee fails to comply with the terms of the Severance Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan supersedes (i)&nbsp;existing severance plans and separation policies applying to Covered Employees with respect to any termination that would constitute a Covered
Termination and (ii)&nbsp;the provisions of any agreements between any Covered Employee and us that provide for severance benefits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=36,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=865830,FOLIO='32',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_33"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the schedule of severance payments our NEOs would have received, assuming a qualifying termination occurred on December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>COBRA<BR>
Continuation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Vesting of<BR>
Equity<BR>
Awards<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Jill C. Milne, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>462,264</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>538,746</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>693,396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,336</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>831,324</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Joanne M. Donovan, M.D., Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>389,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>412,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>389,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>437,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Andrew Nichols, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>346,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>369,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>346,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>394,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent, in the case of Dr.&nbsp;Milne, 12&nbsp;months' base salary for a termination without cause or resignation with good reason and
18&nbsp;months' base salary for a termination upon a change of control; and, in the case of Dr.&nbsp;Donovan and Dr.&nbsp;Nichols, 12&nbsp;months' base salary; each at the rate in effect
immediately prior to the executive's termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent 50% of the average performance bonus received by Dr.&nbsp;Milne for the three most recently completed years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent paid health coverage for 12&nbsp;months and, in the case of Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months' paid
health coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
values of accelerated vesting of equity awards included in the table above are based on the intrinsic values of such unvested awards on December&nbsp;31, 2017
(i.e.,&nbsp;the difference between the closing price of our common stock on the Nasdaq Global Market on that date and the exercise price multiplied by the number of shares for which vesting would
have been accelerated).  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into employee confidentiality, non-competition and proprietary information agreements with each of our NEOs. Under the employee confidentiality, non-competition and
proprietary information agreements, each NEO has agreed (1)&nbsp;not to compete with us during his or her employment and for a period of 18&nbsp;months after the termination of his or her
employment, (2)&nbsp;not to solicit our employees during his or her employment and for a period of 18&nbsp;months after the termination of his or her employment, (3)&nbsp;to protect our
confidential and proprietary information and (4)&nbsp;to assign to us related intellectual property developed during the course of his or her employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_401(k)_retirement_plan"> </A>
<A NAME="toc_ck48901_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) Retirement Plan    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of the Code.
In general, all of our employees are eligible to participate, beginning on the first day of the month following commencement of their employment. The 401(k) plan includes a salary deferral arrangement
pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $18,500 in 2018, and have the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=37,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=312940,FOLIO='33',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_34"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>amount
of the reduction contributed to the 401(k) plan. Participants over the age of 50 are entitled to an additional catch-up contribution up to the statutorily prescribed limit, equal to $6,000 in
2018. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_securities_authorized_for_issu__sec02789"> </A>
<A NAME="toc_ck48901_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Securities Authorized for Issuance under Equity Compensation Plans    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table contains information about our equity compensation plans as of December&nbsp;31, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan category


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
securities to<BR>
be issued<BR>
upon exercise<BR>
of outstanding<BR>
stock options,<BR>
warrants and<BR>
rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-average<BR>
exercise price<BR>
of outstanding<BR>
options, warrants<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
securities<BR>
remaining<BR>
available for<BR>
future issuance<BR>
under equity<BR>
compensation<BR>
plans (excluding<BR>
securities<BR>
reflected in<BR>
column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(a)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(b)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(c)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,845,626</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>824,165</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans not approved by security holders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,845,626</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>824,165 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of stock options outstanding as of December&nbsp;31, 2017 under the 2008 Plan and the 2015 Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of shares issuable under the 2015 Plan and our 2015 Employee Stock Purchase Plan, but does not reflect automatic increases that were effective as of
January&nbsp;1, 2018 of 945,810 shares and 236,452 shares under the respective plans. The 2015 Plan provides for further annual increases, to be added as of the first day of each fiscal year, from
January&nbsp;1, 2019 until, and including, January&nbsp;1, 2025, equal to the lowest of 1,297,334 shares of our common stock, 4% of the number of shares of our common stock outstanding on such
first day of the fiscal year in question and an amount determined by our board of directors. If the Amended and Restated 2015 Plan is approved by stockholders these annual increases will be eliminated
and the number of shares of common stock authorized for issuance under the 2015 Plan will be increased by 8,500,000 shares on a pre-Reverse Stock Split basis. Our 2015 Employee Stock Purchase Plan
provides for further annual increases, to be added as of the first day of each fiscal year, from January&nbsp;1, 2019 until, and including, January&nbsp;1, 2026, in an amount equal to the least of
364,705 shares of our common stock, 1% of the total number of shares of our common stock outstanding on the first day of the applicable year, and an amount determined by our board of directors. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ck48901_director_compensation"> </A>
<A NAME="toc_ck48901_10"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not provide any compensation to Dr.&nbsp;Milne, our President and Chief Executive Officer, for her service as a director.
Dr.&nbsp;Milne's compensation as an executive officer is set forth below under "Executive Compensation&#151;Summary Compensation Table." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, our board of directors adopted an amended director compensation program, which became effective as of January&nbsp;1, 2016. Under this director compensation program,
we pay our non-employee directors a cash retainer for service on our board of directors and for service on each committee on which the director is a member. The Co-Chairmen of the board of directors
and the chairman of each committee receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the
amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=38,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=907652,FOLIO='34',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>directors.
The fees paid to non-employee directors for service on the board of directors and for service on each committee of the board of directors on which the director is a member are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Member<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Chairman<BR>
Incremental<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Science and Technology Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event co-chairmen are appointed, the retainer for Chairman of the board will be divided equally between the co-chairmen.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our board of directors and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2018, our board of directors adopted an amended non-employee director equity compensation program, effective as of January&nbsp;1, 2018. Under the amended non-employee
director equity compensation program, each new non-employee director elected to our board of directors receives an option to purchase 28,000 shares of our common stock, which option vests in equal
annual installments over a three-year period measured from the date of grant, subject to the director's continued service as a director. Further, on the date of the first board of directors meeting
held after each annual meeting of stockholders, each non-employee director that has served on our board of directors for at least six months will receive an option to purchase 14,000 shares of our
common stock. Each of these options will vest in full after a one-year period measured from the date of grant, subject to the director's continued service as a director. The exercise price of all
options granted to directors will equal the fair market value of our common stock on the date of grant. Options granted to non-employee directors become exercisable in full upon a change in control of
our company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during 2017. Dr.&nbsp;Galakatos' term as a Class&nbsp;II director expired at
our 2017 annual meeting of stockholders in June 2017, and he did not stand for reelection. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned<BR>
or Paid<BR>
In Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,160</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,783</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,318</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,940</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts included in the "Option Awards" column reflect the aggregate grant date fair value of awards granted during 2017 calculated in accordance with FASB ASC
Topic 718. Assumptions used in the calculation of these amounts are included in Note&nbsp;13 to the consolidated financial </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=39,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=663551,FOLIO='35',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_ck48901_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>statements
included in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 previously filed with the SEC. As of December&nbsp;31,
2017:</FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Ross held stock options to purchase an aggregate of 24,094 shares of common stock, 13,896 shares of which were vested as of
December&nbsp;31, 2017; 3,698 of the shares are scheduled to vest on June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Ms.&nbsp;George held stock options to purchase an aggregate of 24,094 shares of common stock, 13,896 shares of which were vested as of
December&nbsp;31, 2016; 3,698 of the shares are scheduled to vest on June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Bate held stock options to purchase an aggregate of 33,977 shares of common stock, 23,573 shares of which were vested as of
December&nbsp;31, 2017; 206 of the shares vested on January&nbsp;1, 2018; 3,698 shares are scheduled to vest on June&nbsp;30, 2018; and 6,500 of the shares are scheduled to vest on
June&nbsp;7, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Adelman held stock options to purchase an aggregate of 19,500 shares of common stock, 4,333 of which were vested as of
December&nbsp;31, 2017; 4,333 of the shares vested on April&nbsp;5, 2018; 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; and 4,334 of the shares are scheduled to vest on
April&nbsp;5, 2019. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Kishbauch held stock options to purchase an aggregate of 19,500 shares of common stock, 4,333 of which were vested as of
December&nbsp;31, 2017; 4,333 of the shares vested on April&nbsp;5, 2018; 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; and 4,334 of the shares are scheduled to vest on
April&nbsp;5, 2019.  </FONT></DD></DL>
</UL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ck48901_compensation_committee__ck402488"> </A>
<A NAME="toc_ck48901_11"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2017, the members of our compensation committee were Mr.&nbsp;Bate and Dr.&nbsp;Nicholas Galakatos through June&nbsp;7, 2017, and
Mr.&nbsp;Kishbauch, Mr.&nbsp;Bate and Ms.&nbsp;George thereafter, each of whom is an independent director or, in the case of Dr.&nbsp;Galakatos, was an independent director prior to his
departure from our board. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of
whose executive officers served as a director or member of our compensation committee during the fiscal year ended December&nbsp;31, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=40,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=22370,FOLIO='36',FILE='DISK130:[18ZEO1.18ZEO48901]CK48901A.;13',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cm48901_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cm48901_householding"> </A>
<A NAME="toc_cm48901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  HOUSEHOLDING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers and other nominee record holders may be participating in the practice of "householding" proxy statements and annual reports.
This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been made available to multiple stockholders in your household. We will
promptly deliver a separate copy of either document to you upon written or oral request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building&nbsp;1400E, Suite B14202, Cambridge,
MA 02139, Attention: Corporate Secretary, or telephone: (617)&nbsp;349-1971. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or if you
are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and
phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cm48901_stockholder_proposals"> </A>
<A NAME="toc_cm48901_2"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder who would like to have a proposal considered for inclusion in our proxy statement for our 2019 Annual Meeting must submit the
proposal in accordance with the procedures outlined in Rule&nbsp;14a-8 of the Exchange Act so that it is received by us no later than December&nbsp;27, 2018, which is 120&nbsp;days prior to the
first anniversary of the mailing date of the proxy statement for our 2018 Annual Meeting of Stockholders. However, if the date of our 2019 Annual Meeting is changed by more than 30&nbsp;days from
the date of our 2018 Annual Meeting of Stockholders, then the deadline is a reasonable time before we begin to print and send our proxy statement for our 2019 Annual Meeting. SEC rules set standards
for eligibility and specify the types of stockholder proposals that may be excluded from a proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stockholder wishes to propose a nomination of persons for election to our board of directors or present a proposal at an annual meeting but does not wish to have the proposal
considered for inclusion in our proxy statement and proxy card, our amended and restated bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual
meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on
the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder's intention to bring such
business before the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the
first anniversary of the preceding year's annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30&nbsp;days, or delayed by more than 60&nbsp;days,
from the first anniversary of the preceding year's annual meeting, a stockholder's notice must be so received no earlier than the 120th&nbsp;day prior to such annual meeting and not later than the
close of business on the later of (A)&nbsp;the 90th&nbsp;day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was
mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before our 2019 Annual Meeting, the required notice must be
received by our corporate secretary at our principal executive offices no earlier than February&nbsp;7, 2019 and no later than March&nbsp;9, 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
proposals should be addressed to Catabasis Pharmaceuticals,&nbsp;Inc., Attention: Secretary, One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139,
Attention: Corporate Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cm48901_other_matters"> </A>
<A NAME="toc_cm48901_3"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors does not know of any other matters to be brought before the Special Meeting. If any other matters not mentioned in this
proxy statement are properly brought before the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=125620,FOLIO='37',FILE='DISK130:[18ZEO1.18ZEO48901]CM48901A.;8',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_cm48901_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>meeting,
the individuals named in the proxy made available to stockholders intend to use their discretionary voting authority under the proxy to vote the proxy in accordance with their best judgment
on those matters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g111573.jpg" ALT="GRAPHIC" WIDTH="159" HEIGHT="73">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=42,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=982825,FOLIO='38',FILE='DISK130:[18ZEO1.18ZEO48901]CM48901A.;8',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_la48901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="la48901_appendix_a"> </A>
<A NAME="toc_la48901_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>Appendix&nbsp;A    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="la48901_certificate_of_amendment_to_re__cer03882"> </A>
<A NAME="toc_la48901_2"> </A></FONT> <FONT SIZE=2><B>  CERTIFICATE OF AMENDMENT    <BR>    <BR>    TO    <BR>    <BR>    RESTATED CERTIFICATE OF INCORPORATION    <BR>    <BR>    OF    <BR>    <BR>    CATABASIS PHARMACEUTICALS,&nbsp;INC.    <BR>
</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="la48901_pursuant_to_section_242_of_the__pur03055"> </A>
<A NAME="toc_la48901_3"> </A></FONT> <FONT SIZE=2><B>  Pursuant to Section&nbsp;242 of the<BR>  <U>General Corporation Law of the State of Delaware</U>  <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Catabasis Pharmaceuticals,&nbsp;Inc.</B></FONT><FONT SIZE=2> (hereinafter called the "Corporation"), a corporation
organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section&nbsp;242 of the General Corporation Law of the State of Delaware setting forth an
amendment to the Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable. The stockholders of the Corporation duly approved and adopted said proposed
amendment at a special meeting of stockholders in accordance with Section&nbsp;242 of the General Corporation Law of the State of Delaware. The resolution setting forth the amendment is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><U>RESOLVED</U>:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>That the first sentence of Article FOURTH of the Restated Certificate of Incorporation of the Corporation be and hereby is deleted in its entirety and the following three paragraphs are inserted in lieu
thereof:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"FOURTH: That, effective on the filing of this Certificate of Amendment to Restated Certificate of Incorporation with the Secretary of State
of the State of Delaware (the "Effective Time"), a one-for-[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;](1) reverse stock split of the Corporation's common stock, $0.001 par value per share (the "Common Stock"), shall
become effective, pursuant to which each [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;](1) shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares)
immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall
represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the "Reverse Stock Split"). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.001 per share.
No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Effective Time of a certificate or book entry position which formerly represented shares of Common Stock that
were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a
cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the closing price per share of the Common Stock on the Nasdaq Global Market at the close of business on the date of the
Effective Time.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Shall
be a number greater than five and equal to or lesser than fifteen and shall include not more than four decimal digits. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=467138,FOLIO='A-1',FILE='DISK130:[18ZEO1.18ZEO48901]LA48901A.;7',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<A NAME="page_la48901_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Each stock certificate or book entry position that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and
after the Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time into which the shares formerly represented by such certificate or
book entry position have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Effective Time); provided, however, that each person of record holding a certificate or book entry position that
represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall receive, upon surrender of such certificate or book entry position, a new certificate or book entry position evidencing and representing
the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate or book entry position shall have been reclassified.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The total number of shares of all classes of stock which the Corporation shall have authority to issue is 155,000,000 shares, consisting of
(i)&nbsp;150,000,000 shares of Common Stock and (ii)&nbsp;5,000,000 shares of Preferred Stock, $0.001 par value per share ("Preferred Stock")."</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN
WITNESS WHEREOF, the Corporation has caused its corporate seal to be affixed hereto and this Certificate of Amendment to be signed by its President this&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 201&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> CATABASIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jill C. Milne, </FONT><FONT SIZE=2><I>President</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=949149,FOLIO='A-2',FILE='DISK130:[18ZEO1.18ZEO48901]LA48901A.;7',USER='CHE109865',CD='11-OCT-2018;17:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_lc48901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lc48901_appendix_b"> </A>
<A NAME="toc_lc48901_1"> </A>
<BR></FONT><FONT SIZE=2><B><I>Appendix&nbsp;B    <BR>    </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lc48901_catabasis_pharmaceuticals,_inc__cat02743"> </A>
<A NAME="toc_lc48901_2"> </A></FONT> <FONT SIZE=2><B>  CATABASIS PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    </B></FONT><FONT SIZE=2><B><I><U>AMENDED AND RESTATED</U></I></B></FONT><FONT SIZE=2>    <BR>    <BR>    <U>2015 STOCK INCENTIVE PLAN</U>
 <BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Purpose</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of this 2015 Stock Incentive Plan (the "</FONT><FONT SIZE=2><B><I>Plan</I></B></FONT><FONT SIZE=2>") of Catabasis Pharmaceuticals,&nbsp;Inc., a Delaware corporation (the
"</FONT><FONT SIZE=2><B><I>Company</I></B></FONT><FONT SIZE=2>"), is to advance the interests of the Company's stockholders by enhancing the Company's ability to attract, retain and motivate persons who are
expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the
interests of such persons with those of the Company's stockholders. Except where the context otherwise requires, the term "</FONT><FONT SIZE=2><B><I>Company</I></B></FONT><FONT SIZE=2>" shall include any of
the Company's present or future parent or subsidiary corporations as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Internal Revenue Code of 1986, as amended, and any regulations thereunder
(the "</FONT><FONT SIZE=2><B><I>Code</I></B></FONT><FONT SIZE=2>") and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a
controlling interest, as determined by the Board of Directors of the Company (the "</FONT><FONT SIZE=2><B><I>Board</I></B></FONT><FONT SIZE=2>"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Eligibility</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the Company's employees, officers and directors, as well as consultants and advisors to the Company (as such terms are defined and interpreted for purposes of Form&nbsp;S-8
under the Securities Act of 1933, as amended (the "</FONT><FONT SIZE=2><B><I>Securities Act</I></B></FONT><FONT SIZE=2>"), or any successor form) are eligible to be granted Awards under the Plan. Each
person who is granted an Award under the Plan is deemed a "</FONT><FONT SIZE=2><B><I>Participant</I></B></FONT><FONT SIZE=2>." "</FONT><FONT SIZE=2><B><I>Award</I></B></FONT><FONT SIZE=2>" means Options (as
defined in Section&nbsp;5), SARs (as defined in Section&nbsp;6), Restricted Stock (as defined in Section&nbsp;7), Restricted Stock Units (as defined in Section&nbsp;7) and Other Stock-Based
Awards (as defined in Section&nbsp;8). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Administration and Delegation</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Administration by Board of Directors</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Plan will be administered by the
Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may
construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or
any Award in the manner and to the extent it shall deem expedient and it shall be the sole and final judge of such expediency. All decisions by the Board shall be made in the Board's sole discretion
and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Appointment of Committees</U>.&nbsp;&nbsp;&nbsp;&nbsp;To the extent permitted by applicable law, the Board
may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a "</FONT><FONT SIZE=2><B><I>Committee</I></B></FONT><FONT SIZE=2>"). All references in the Plan
to the "</FONT><FONT SIZE=2><B><I>Board</I></B></FONT><FONT SIZE=2>" shall mean the Board or a Committee of the Board or the officers referred to in Section&nbsp;3(c) to the extent that the Board's powers
or authority under the Plan have been delegated to such Committee or officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Delegation to Officers</U>.&nbsp;&nbsp;&nbsp;&nbsp;To the extent permitted by applicable law, the Board
may delegate to one or more officers of the Company the power to grant Options and other Awards that constitute rights under Delaware law (subject to any limitations under the Plan) to employees or
officers of the Company and to exercise such other powers under the Plan as the Board may determine, </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that the Board shall fix the terms of such
Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the exercise price will be determined) and the maximum number of shares subject
to such Awards that the officers may grant; </FONT><FONT SIZE=2><I>provided further</I></FONT><FONT SIZE=2>, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=45,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=612945,FOLIO='B-1',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>however,
that no officer shall be authorized to grant such Awards to any "executive officer" of the Company (as defined by Rule&nbsp;3b-7 under the Securities Exchange Act of 1934, as amended (the
"</FONT><FONT SIZE=2><B><I>Exchange Act</I></B></FONT><FONT SIZE=2>")) or to any "officer" of the Company (as defined by Rule&nbsp;16a-1 under the Exchange Act). The Board may not delegate authority under
this Section&nbsp;3(c) to grant Restricted Stock, unless Delaware law then permits such delegation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Stock Available for Awards</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Number of Shares; Share Counting</U>.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Authorized Number of Shares</U>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment under Section&nbsp;9,
Awards may be made under the Plan (any or all of which Awards may be in the form of Incentive Stock Options, as defined in
Section&nbsp;5(b)) for up to such number of shares of common stock, $0.001 par value per share, of the Company (the "</FONT><FONT SIZE=2><B><I>Common Stock</I></B></FONT><FONT SIZE=2>") as is equal to the
sum of: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;&nbsp;<STRIKE>13,727,495</STRIKE></FONT><FONT
SIZE=2><B><I><U>11,879,330</U></I></B></FONT><FONT SIZE=2> shares of Common Stock; plus </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;&nbsp;such
additional number of shares of Common Stock (up to
<STRIKE>19,334,779</STRIKE></FONT><FONT SIZE=2><B><I><U>1,504,652</U></I></B></FONT><FONT SIZE=2> shares) as is equal to the sum of
(x)&nbsp;<STRIKE>the number of</STRIKE></FONT><FONT SIZE=2><B><I><U>25,942</U></I></B></FONT><FONT SIZE=2> shares of Common Stock reserved for issuance under
the Company's 2008 Equity Incentive Plan (the "</FONT><FONT SIZE=2><B><I>Existing Plan</I></B></FONT><FONT SIZE=2>") that
remain</FONT><FONT SIZE=2><B><I><U>ed</U></I></B></FONT><FONT SIZE=2> available for grant under the Existing Plan immediately prior to the closing of the Company's initial public
offering and (y)&nbsp;the number of shares of Common Stock subject to awards granted under the Existing Plan which awards expire, terminate or are otherwise surrendered, canceled, forfeited or
repurchased by the Company at their original issuance price pursuant to a contractual repurchase right (subject, however, in the case of Incentive Stock Options to any limitations of the
Code<STRIKE>); plus</STRIKE><U>).</U> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<STRIKE>(C)</STRIKE>&nbsp;&nbsp;<STRIKE>an
annual increase to be added on the first day of each fiscal year, beginning with the fiscal year ending
December&nbsp;31, 2016 and continuing for each fiscal year until, and including, the fiscal year ending December&nbsp;31, 2025, equal to the least of (i)&nbsp;16,670,752 shares of Common Stock,
(ii)&nbsp;4% of the outstanding shares on such date and (iii)&nbsp;an amount determined by the Board.</STRIKE> </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>Shares
issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Share Counting</U>.&nbsp;&nbsp;&nbsp;&nbsp;For purposes of counting the number of shares available for the
grant of Awards under the Plan: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;&nbsp;all
shares of Common Stock covered by SARs shall be counted against the number of shares available for the grant of Awards under the Plan; </FONT> <FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that (i)&nbsp;SARs that may be settled only in
cash shall not be so counted and (ii)&nbsp;if the Company grants an SAR in tandem
with an Option for the same number of shares of Common Stock and provides that only one such Award may be exercised (a "</FONT><FONT SIZE=2><B><I>Tandem SAR</I></B></FONT><FONT SIZE=2>"), only the shares
covered by the Option, and not the shares covered by the Tandem SAR, shall be so counted, and the expiration of one in connection with the other's exercise will not restore shares to the Plan; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;&nbsp;if
any Award (i)&nbsp;expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the
result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or (ii)&nbsp;results in any Common
Stock not being issued<STRIKE> (including as a result of an SAR that was settleable either in cash or in stock actually being settled in
cash),</STRIKE><U>,</U> the unused Common Stock covered by such Award shall again be available for the grant of Awards; </FONT><FONT SIZE=2><I>provided,
however</I></FONT><FONT SIZE=2>, that (1)&nbsp;in the case of Incentive Stock Options, the foregoing shall be subject to any limitations under the Code, (2)&nbsp;in the case of </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=46,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=315659,FOLIO='B-2',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_3"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>the
exercise of an SAR, the number of shares counted against the shares available under the Plan shall be the full number of shares subject to the SAR multiplied by the percentage of the SAR actually
exercised, regardless of the number of shares actually used to settle such SAR upon exercise and (3)&nbsp;the shares covered by a Tandem SAR shall not again become available for grant upon the
expiration or termination of such Tandem SAR; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;&nbsp;shares
of Common Stock delivered (by actual delivery, attestation, or net exercise) to the Company by a Participant to (i)&nbsp;purchase shares of Common Stock upon
the exercise of an Award or (ii)&nbsp;satisfy tax withholding obligations (including shares retained from the Award creating the tax obligation) shall </FONT><FONT SIZE=2><B><I><U>not
</U></I></B></FONT><FONT SIZE=2>be added back to the number of shares available for the future grant of Awards. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Substitute Awards</U>.&nbsp;&nbsp;&nbsp;&nbsp;In connection with a merger or consolidation of an entity
with the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such
entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan.
Substitute Awards shall not count against the overall share limit set forth in Section&nbsp;4(a)(1), except as may be required by reason of Section&nbsp;422 and related provisions of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Stock Options</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>General</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board may grant options to purchase Common Stock (each, an
"</FONT><FONT SIZE=2><B><I>Option</I></B></FONT><FONT SIZE=2>") and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and
limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Incentive Stock Options</U>.&nbsp;&nbsp;&nbsp;&nbsp;An Option that the Board intends to be an "incentive
stock option" as defined in Section&nbsp;422 of the Code (an "</FONT><FONT SIZE=2><B><I>Incentive Stock Option</I></B></FONT><FONT SIZE=2>") shall only be granted to employees of Catabasis
Pharmaceuticals,&nbsp;Inc., any of Catabasis Pharmaceuticals,&nbsp;Inc.'s present or future parent or
subsidiary corporations as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code,
and shall be subject to and shall be construed consistently with the requirements of Section&nbsp;422 of the Code. An Option that is not intended to be an Incentive Stock Option shall be designated
a "</FONT><FONT SIZE=2><B><I>Nonstatutory Stock Option</I></B></FONT><FONT SIZE=2>." The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is
intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Exercise Price</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board shall establish the exercise price of each Option and
specify the exercise price in the applicable Option agreement. The exercise price shall be not less than 100% of the fair market value per share of Common Stock as determined by (or in a manner
approved by) the Board ("</FONT><FONT SIZE=2><B><I>Fair Market Value</I></B></FONT><FONT SIZE=2>") on the date the Option is granted; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that if the
Board approves the grant of an Option with an exercise price to be determined on a future date, the exercise price shall be not less than 100% of the Fair Market Value on such future date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Duration of Options</U>.&nbsp;&nbsp;&nbsp;&nbsp;Each Option shall be exercisable at such times and subject
to such terms and conditions as the Board may specify in the applicable option agreement; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that no Option will be granted with a term
in excess of 10&nbsp;years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Exercise of Options</U>.&nbsp;&nbsp;&nbsp;&nbsp;Options may be exercised by delivery to the Company of a
notice of exercise in a form (which may be electronic) approved by the Company, together with payment in full (in the manner specified in Section&nbsp;5(f)) of the exercise price for the number of
shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as soon as practicable following exercise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=47,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=726064,FOLIO='B-3',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Payment Upon Exercise</U>.&nbsp;&nbsp;&nbsp;&nbsp;Common Stock purchased upon the exercise of an Option
granted under the Plan shall be paid for as follows: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;in
cash or by check, payable to the order of the Company; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;except
as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i)&nbsp;delivery of an irrevocable and
unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii)&nbsp;delivery by the
Participant to the Company of a copy of irrevocable and
unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;to
the extent provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of
shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (i)&nbsp;such method of payment is then permitted under applicable law, (ii)&nbsp;such Common Stock, if
acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii)&nbsp;such Common Stock is not
subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;to
the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its sole discretion, by delivery of a notice of "net
exercise" to the Company, as a result of which the Participant would receive (i)&nbsp;the number of shares underlying the portion of the Option being exercised, less (ii)&nbsp;such number of
shares as is equal to (A)&nbsp;the aggregate exercise price for the portion of the Option being exercised divided by (B)&nbsp;the Fair Market Value on the date of exercise; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;&nbsp;&nbsp;to
the extent permitted by applicable law and provided for in the applicable Option agreement or approved by the Board, in its sole discretion, by payment of such other
lawful consideration as the Board may determine; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;&nbsp;&nbsp;by
any combination of the above permitted forms of payment. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Limitation on Repricing</U>.&nbsp;&nbsp;&nbsp;&nbsp;Unless such action is approved by the Company's
stockholders, the Company may not (except as provided for under Section&nbsp;9): (1)&nbsp;amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower
than the then-current exercise price per share of such outstanding Option, (2)&nbsp;cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new
Awards under the Plan (other than Awards granted pursuant to Section&nbsp;4(b)) covering the same or a different number of shares of Common Stock and having an exercise price per share lower than
the then-current exercise price per share of the cancelled option, (3)&nbsp;cancel in exchange for a cash payment any outstanding Option with an exercise price per share above the then-current Fair
Market Value, or (4)&nbsp;take any other action under the Plan that constitutes a "repricing" within the meaning of the rules of the NASDAQ Stock Market
("</FONT><FONT SIZE=2><B><I>NASDAQ</I></B></FONT><FONT SIZE=2>"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>(h)</U></FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I><U>No Dividend
Equivalents.</U></I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I><U>No Option shall provide for the payment or accrual of dividend
equivalents.</U></I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Stock Appreciation Rights</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>General</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board may grant Awards consisting of stock appreciation rights
("</FONT><FONT SIZE=2><B><I>SARs</I></B></FONT><FONT SIZE=2>") entitling the holder, upon exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the
Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock over the measurement price established pursuant to
Section&nbsp;6(b). The date as of which such appreciation is determined shall be the exercise date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=48,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=614318,FOLIO='B-4',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Measurement Price</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board shall establish the measurement price of each SAR
and specify it in the applicable SAR agreement. The measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that if the Board approves the grant
of an SAR effective as of a future date, the measurement price shall be not less than 100% of the Fair
Market Value on such future date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Duration of SARs</U>.&nbsp;&nbsp;&nbsp;&nbsp;Each SAR shall be exercisable at such times and subject to
such terms and conditions as the Board may specify in the applicable SAR agreement; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that no SAR will be granted with a term in excess
of 10&nbsp;years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Exercise of SARs</U>.&nbsp;&nbsp;&nbsp;&nbsp;SARs may be exercised by delivery to the Company of a notice
of exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Limitation on Repricing</U>.&nbsp;&nbsp;&nbsp;&nbsp;Unless such action is approved by the Company's
stockholders, the Company may not (except as provided for under Section&nbsp;9): (1)&nbsp;amend any outstanding SAR granted under the Plan to provide a measurement price per share that is lower
than the then-current measurement price per share of such outstanding SAR, (2)&nbsp;cancel any outstanding SAR (whether or not granted under the Plan) and grant in substitution therefor new Awards
under the Plan (other than Awards granted pursuant to Section&nbsp;4(b)) covering the same or a different number of shares of Common Stock and having an exercise or measurement price per share lower
than the then-current measurement price per share of the cancelled SAR, (3)&nbsp;cancel in exchange for a cash payment any outstanding SAR with a measurement price per share above the then-current
Fair Market Value, or (4)&nbsp;take any other action under the Plan that constitutes a "repricing" within the meaning of the rules of NASDAQ. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>(f)</U></FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><B><I><U>No Dividend
Equivalents.</U></I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B><I><U>No SAR shall provide for the payment or accrual of dividend
equivalents.</U></I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Restricted Stock; Restricted Stock Units</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>General</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board may grant Awards entitling recipients to acquire shares of
Common Stock ("</FONT><FONT SIZE=2><B><I>Restricted Stock</I></B></FONT><FONT SIZE=2>"), subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or
formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the applicable Award are not satisfied prior to
the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of Common Stock or cash to be
delivered at the time such Award vests ("</FONT><FONT SIZE=2><B><I>Restricted Stock Units</I></B></FONT><FONT SIZE=2>") (Restricted Stock and Restricted Stock Units are each referred to herein as a
"</FONT><FONT SIZE=2><B><I>Restricted Stock Award</I></B></FONT><FONT SIZE=2>"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Terms and Conditions for All Restricted Stock Awards</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board shall determine
the terms and conditions of a Restricted Stock Award, including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Additional Provisions Relating to Restricted Stock</U>.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Dividends</U>.&nbsp;&nbsp;&nbsp;&nbsp;<STRIKE>Unless otherwise provided in the applicable Award
agreement, any</STRIKE></FONT><FONT SIZE=2><B><I><U>Any</U></I></B></FONT><FONT SIZE=2> dividends (whether paid in cash, stock or property) declared and paid by the Company
with respect to shares of Restricted Stock ("</FONT><FONT SIZE=2><B><I>Accrued Dividends</I></B></FONT><FONT SIZE=2>") shall be paid to the Participant only if and when such shares become free from the
restrictions on transferability and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid
to stockholders of that class of stock or, if later, the 15th&nbsp;day of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to
the underlying shares of Restricted Stock. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=49,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=924637,FOLIO='B-5',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Stock Certificates</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Company may require that any stock certificates issued
in respect of shares of Restricted Stock, as well as dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in
blank, with the Company (or its designee). At the expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions
to the Participant or if the Participant has died, to his or her Designated Beneficiary. "</FONT><FONT SIZE=2><B><I>Designated Beneficiary</I></B></FONT><FONT SIZE=2>" means (i)&nbsp;the beneficiary
designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant's death or (ii)&nbsp;in the absence of
an effective designation by a Participant, the Participant's estate. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Additional Provisions Relating to Restricted Stock Units</U>.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Settlement</U>.&nbsp;&nbsp;&nbsp;&nbsp;Upon the vesting of and/or lapsing of any other restrictions
(i.e.,&nbsp;settlement) with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the Company such number of shares of Common Stock or (if so provided in the
applicable Award agreement) an amount of cash equal to the Fair Market Value of such number of shares of Common Stock as are set forth in the applicable Restricted Stock Unit agreement. The Board may,
in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with Section&nbsp;409A of
the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Voting Rights</U>.&nbsp;&nbsp;&nbsp;&nbsp;A Participant shall have no voting rights with respect to any
Restricted Stock Units. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Dividend Equivalents</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Award agreement for Restricted Stock Units may
provide Participants with the right to receive an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock
("</FONT><FONT SIZE=2><B><I>Dividend Equivalents</I></B></FONT><FONT SIZE=2>"). Dividend Equivalents may be settled in cash and/or shares of Common Stock and shall be subject to the same restrictions on
transfer and forfeitability as</FONT><FONT SIZE=2><B><I><U>, and the payment of such Dividend Equivalents shall be subject to the vesting of,</U></I></B></FONT><FONT SIZE=2> the
Restricted Stock Units with respect to which paid<STRIKE>, in each case to the extent provided in the Award agreement</STRIKE>. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Other Stock-Based Awards</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>General</U>.&nbsp;&nbsp;&nbsp;&nbsp;Other Awards of shares of Common Stock, and other Awards that are
valued in whole or in part by reference to, or are otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants ("</FONT><FONT SIZE=2><B><I>Other
Stock-Based-Awards</I></B></FONT><FONT SIZE=2>"). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu
of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall
determine.</FONT><FONT SIZE=2><B><I><U> Any Dividend Equivalents awarded with respect to Other Stock-Based Awards shall be subject to the same restrictions on transfer and forfeitability as,
and the payment of such Dividend Equivalents shall be subject to the vesting of, the Award with respect to which granted.</U></I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Terms and Conditions</U>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of the Plan, the Board shall
determine the terms and conditions of each Other Stock-Based Award, including any purchase price applicable thereto. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>9.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Adjustments for Changes in Common Stock and Certain Other Events</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Changes in Capitalization</U>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of any stock split, reverse stock
split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of
Common Stock other than an ordinary cash dividend, (i)&nbsp;the number and class of securities available under the Plan, (ii)&nbsp;the share </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=50,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=954687,FOLIO='B-6',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>counting
rules set forth in Section&nbsp;4(a), (iii)&nbsp;the number and class of securities and exercise price per share of each outstanding Option, (iv)&nbsp;the share and per-share provisions
and the measurement price of each outstanding SAR, (v)&nbsp;the number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (vi)&nbsp;the
share and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if
applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common Stock by means of a stock dividend and the
exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then
an optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to
the shares of Common Stock acquired upon such Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Reorganization Events</U>.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Definition</U>.&nbsp;&nbsp;&nbsp;&nbsp;A "</FONT><FONT SIZE=2><B><I>Reorganization
Event</I></B></FONT><FONT SIZE=2>" shall mean: (a)&nbsp;any merger or consolidation of the Company with or into another entity as a result of which all of the Common Stock of the Company is converted
into or exchanged for the right to receive cash, securities or other property or is cancelled, (b)&nbsp;any transfer or disposition of all of the Common Stock of the Company for cash, securities or
other property pursuant to a share exchange or other transaction or (c)&nbsp;any liquidation or dissolution of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Consequences of a Reorganization Event on Awards Other than Restricted Stock</U>.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;&nbsp;In
connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than
Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the
Participant): (i)&nbsp;provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof),
(ii)&nbsp;upon written notice to a Participant, provide that all of the Participant's unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless
exercised by the Participant (to the extent then exercisable) within a
specified period following the date of such notice, (iii)&nbsp;provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall
lapse, in whole or in part prior to or upon such Reorganization Event, (iv)&nbsp;in the event of a Reorganization Event under the terms of which holders of Common Stock will receive upon
consummation thereof a cash payment for each share surrendered in the Reorganization Event (the "</FONT><FONT SIZE=2><B><I>Acquisition Price</I></B></FONT><FONT SIZE=2>"), make or provide for a cash payment
to Participants with respect to each Award held by a Participant equal to (A)&nbsp;the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any
acceleration of vesting that occurs upon or immediately prior to such Reorganization Event) multiplied by (B)&nbsp;the excess, if any, of (I)&nbsp;the Acquisition Price over (II)&nbsp;the
exercise, measurement or purchase price of such Award and any applicable tax withholdings, in exchange for the termination of such Award, (v)&nbsp;provide that, in connection with a liquidation or
dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise, measurement or purchase price thereof and any applicable tax
withholdings) and (vi)&nbsp;any combination of the foregoing. In taking any of the actions permitted under this Section&nbsp;9(b)(2), the Board shall not be obligated by the Plan to treat all
Awards, all Awards held by a Participant, or all Awards of the same type, identically. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=51,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=850586,FOLIO='B-7',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_8"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;&nbsp;Notwithstanding
the terms of Section&nbsp;9(b)(2)(A), in the case of outstanding Restricted Stock Units that are subject to Section&nbsp;409A of the Code:
(i)&nbsp;if the applicable Restricted Stock Unit agreement provides that the Restricted Stock Units shall be settled upon a "change in control event" within the meaning of Treasury Regulation
Section&nbsp;1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a "change in control event", then no assumption or substitution shall be permitted pursuant to
Section&nbsp;9(b)(2)(A)(i) and the Restricted Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii)&nbsp;the Board may only
undertake the actions set forth in clauses&nbsp;(iii), (iv)&nbsp;or (v)&nbsp;of Section&nbsp;9(b)(2)(A) if the Reorganization Event constitutes a "change in control event" as defined under
Treasury Regulation Section&nbsp;1.409A-3(i)(5)(i) and such action is permitted or required by Section&nbsp;409A of the Code; if the Reorganization Event is not a "change in control event" as so
defined or such action is not permitted or required by Section&nbsp;409A of the Code, and the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to
clause&nbsp;(i) of Section&nbsp;9(b)(2)(A), then the unvested Restricted Stock Units shall terminate immediately prior to the consummation of the Reorganization Event without any payment in
exchange therefor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;&nbsp;For
purposes of Section&nbsp;9(b)(2)(A)(i), an Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event,
such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject to the Award immediately prior to the consummation of the Reorganization
Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior
to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of
Common Stock); </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring
or succeeding corporation (or an affiliate thereof), the Company
may, with the consent of the acquiring or succeeding corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares
of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board determined to be equivalent in value (as of the date of such determination or another date specified
by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Consequences of a Reorganization Event on Restricted Stock</U>.&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence
of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit
of the Company's successor and shall, unless the Board determines otherwise, apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such
Reorganization Event in the same manner and to the same extent as they applied to such Restricted Stock; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that the Board may provide for
termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any
Restricted Stock or any other agreement between a Participant and the Company, either initially or by amendment. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution
of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, all
restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=52,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=114183,FOLIO='B-8',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>10.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>General Provisions Applicable to Awards</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Transferability of Awards</U>.&nbsp;&nbsp;&nbsp;&nbsp;Awards shall not be sold, assigned, transferred,
pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of
an Incentive Stock Option, pursuant to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant; </FONT><FONT SIZE=2><I>provided,
however</I></FONT><FONT SIZE=2>, that the Board may permit or provide in an Award for the gratuitous transfer of the Award by the Participant to or for the benefit of any immediate family member,
family trust or other entity established for the benefit of the Participant and/or an immediate family member thereof if the Company would be eligible to use a Form&nbsp;S-8 under the Securities Act
for the registration of the sale of the Common Stock subject to such Award to such proposed transferee; </FONT><FONT SIZE=2><I>provided further</I></FONT><FONT SIZE=2>, that the Company shall not be
required to recognize any such permitted transfer until such time as such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument in form and substance
satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent relevant in the context, shall
include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section&nbsp;10(a) shall be deemed to restrict a transfer to the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Documentation</U>.&nbsp;&nbsp;&nbsp;&nbsp;Each Award shall be evidenced in such form (written, electronic
or otherwise) as the Board shall determine. Each Award may contain terms and conditions in addition to those set forth in the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Board Discretion</U>.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided by the Plan, each Award may be
made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Termination of Status</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board shall determine the effect on an Award of the
disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period
during which, the Participant, or the Participant's legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Withholding</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Participant must satisfy all applicable federal, state, and
local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may
decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the
Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company
will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of the exercise or purchase price, unless the Company determines otherwise. If provided
for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of shares of
Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2>, except as
otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company's minimum statutory withholding obligations (based
on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax withholding
requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Amendment of Award</U>.&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in Sections&nbsp;5(g) and
6(e) with respect to repricings and Section&nbsp;11(d) with respect to actions requiring stockholder approval, the Board may </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=53,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=935324,FOLIO='B-9',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>amend,
modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and
converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant's consent to such action shall be required unless (i)&nbsp;the Board determines that the action, taking into
account any related action, does not materially and adversely affect the Participant's rights under the Plan or (ii)&nbsp;the change is permitted under Section&nbsp;9. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Conditions on Delivery of Stock</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Company will not be obligated to deliver
any shares of Common Stock pursuant to the Plan or to remove restrictions from shares previously issued or delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or
removed to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company's counsel, all other legal matters in connection with the issuance and delivery of such shares have been
satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered
to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Acceleration</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time provide that any Award shall become
immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>11.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Miscellaneous</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>No Right To Employment or Other Status</U>.&nbsp;&nbsp;&nbsp;&nbsp;No person shall have any claim or right
to be granted an Award by virtue of the adoption of the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with
the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as
expressly provided in the applicable Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>No Rights As Stockholder</U>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of the applicable Award, no
Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of
such shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Effective Date and Term of Plan</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall become effective immediately
prior to the effectiveness of the Company's initial public offering (the "</FONT><FONT SIZE=2><B><I>Effective Date</I></B></FONT><FONT SIZE=2>"). No Awards shall be granted under the Plan after the
expiration of 10&nbsp;years from the Effective Date, but Awards previously granted may extend beyond that date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Amendment of Plan</U>.&nbsp;&nbsp;&nbsp;&nbsp;The Board may amend, suspend or terminate the Plan or any
portion thereof at any time provided that (i)&nbsp;to the extent required by Section&nbsp;162(m) of the Code, no Award granted to a Participant that is intended to comply with
Section&nbsp;162(m) of the Code after the date of such
amendment shall become exercisable, realizable or vested, as applicable to such Award, unless and until the Company's stockholders approve such amendment in the manner required by
Section&nbsp;162(m) of the Code; and (ii)&nbsp;no amendment that would require stockholder approval under the rules of NASDAQ may be made effective unless and until the Company's stockholders
approve such amendment;. In addition, if at any time the approval of the Company's stockholders is required as to any other modification or amendment under Section&nbsp;422 of the Code or any
successor provision with respect to Incentive Stock Options, the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment
to the Plan adopted in accordance with this Section&nbsp;11(d) shall apply to, and be binding on the holders of, all Awards outstanding under the Plan at the time the amendment is adopted, provided
the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under the Plan. No Award shall be made that is
conditioned upon stockholder </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=54,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=100628,FOLIO='B-10',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<A NAME="page_lc48901_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg48901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>approval
of any amendment to the Plan unless the Award provides that (i)&nbsp;it will terminate or be forfeited if stockholder approval of such amendment is not obtained within no more than
12&nbsp;months from the date of grant and (2)&nbsp;it may not be exercised or settled (or otherwise result in the issuance of Common Stock) prior to such stockholder approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Authorization of Sub-Plans (including for Grants to non-U.S. Employees)</U>.&nbsp;&nbsp;&nbsp;&nbsp;The
Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of various jurisdictions. The Board shall establish such
sub-plans by adopting supplements to the Plan containing (i)&nbsp;such limitations on the Board's discretion under the Plan as the Board deems necessary or desirable or (ii)&nbsp;such additional
terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each
supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not
the subject of such supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Compliance with Section&nbsp;409A of the Code</U>.&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in
individual Award agreements initially or by amendment, if and to the extent (i)&nbsp;any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in
connection with his or her employment termination constitutes "nonqualified deferred compensation" within the meaning of Section&nbsp;409A of the Code and (ii)&nbsp;the Participant is a specified
employee as defined in Section&nbsp;409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which determinations the Participant (through
accepting the Award) agrees that he or she is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of
"separation from service" (as determined under Section&nbsp;409A of the Code) (the "</FONT><FONT SIZE=2><B><I>New Payment Date</I></B></FONT><FONT SIZE=2>"), except as Section&nbsp;409A of the Code may
then permit. The aggregate of any payments that otherwise would have been paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid
to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original schedule. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
Company makes no representations or warranty and shall have no liability to the Participant or any other person if any provisions of or payments, compensation or other benefits under the Plan are
determined to constitute nonqualified deferred compensation subject to Section&nbsp;409A of the Code but do not to satisfy the conditions of that section. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Limitations on Liability</U>.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provisions of the Plan, no
individual acting as a director, officer, employee or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss,
liability, or expense incurred in connection with the Plan, nor will such individual be personally liable with respect to the Plan because of any contract or other instrument he or she executes in his
or her capacity as a director, officer, employee or agent of the Company. The Company will indemnify and hold harmless each director, officer, employee or agent of the Company to whom any duty or
power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys' fees) or liability (including any sum paid in
settlement of a claim with the Board's approval) arising out of any act or omission to act concerning the Plan unless arising out of such person's own fraud or bad faith. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT SIZE=2><U>Governing Law</U>.&nbsp;&nbsp;&nbsp;&nbsp;The provisions of the Plan and all Awards made hereunder shall
be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a
jurisdiction other than the State of Delaware. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=55,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=531232,FOLIO='B-11',FILE='DISK130:[18ZEO1.18ZEO48901]LC48901A.;14',USER='HYUNG',CD='12-OCT-2018;10:58' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information. Vote by 11:59 p.m.   Eastern Time on December 11, 2018. Have your proxy card in hand when you   access the web site and follow the instructions to obtain your records and to   create an electronic voting instruction form. CATABASIS PHARMACEUTICALS, INC.   ONE KENDALL SQUARE BLDG. 1400E, SUITE B14202 CAMBRIDGE, MA 02139 ELECTRONIC   DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs   incurred by our company in mailing proxy materials, you can consent to   receiving all future proxy statements, proxy cards and annual reports   electronically via e-mail or the Internet. To sign up for electronic   delivery, please follow the instructions above to vote using the Internet   and, when prompted, indicate that you agree to receive or access proxy   materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use   any touch-tone telephone to transmit your voting instructions. Vote by 11:59   p.m. Eastern Time on December 11, 2018. Have your proxy card in hand when you   call and then follow the instructions. VOTE BY MAIL Mark, sign and date your   proxy card and return it in the postage-paid envelope we have provided or   return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY   11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:   E52203-S77320 KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS   PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. CATABASIS   PHARMACEUTICALS, INC. The Board of Directors recommends you vote FOR   proposals 1 and 2. For Against Abstain ! ! ! 1. To approve an amendment to   our certificate of incorporation to effect a reverse stock split at a ratio   not less than 1-for-5 and not greater than 1-for-15, with the exact ratio to   be set within that range at the discretion of our board of directors before   June 30, 2019 without further approval or authorization of our stockholders   and with our board of directors able to elect to abandon such proposed   amendment and not effect the reverse stock split authorized by stockholders,   in its sole discretion. ! ! ! 2. To approve an amendment and restatement of   our 2015 Stock Incentive Plan to increase the number of shares available for   issuance thereunder by 8,500,000 shares on a pre-split basis and to provide   for certain other amendments. NOTE: Such other business as may properly come   before the meeting or any adjournment or postponement thereof. ! For address   changes and/or comments, please check this box and write them on the back   where indicated. ! Yes ! No Please indicate if you plan to attend this   meeting. Please sign exactly as your name(s) appear(s) hereon. When signing   as attorney, executor, administrator, or other fiduciary, please give full   title as such. Joint owners should each sign personally. All holders must   sign. If a corporation or partnership, please sign in full corporate or   partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX]   Date Signature (Joint Owners) Date </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1009" height="1304" src="g365892bci001.jpg"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=56,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=430048,FOLIO='',FILE="DISK131:[18ZEO2.18ZEO48902]36589-2-BC_ZEO48902.CHC",USER="HYUNG",CD='Oct 11 02:18 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Special Meeting:   The Notice and Proxy Statement is available at www.proxyvote.com.   E52204-S77320 CATABASIS PHARMACEUTICALS, INC. Special Meeting of Stockholders   December 12, 2018 10:00 AM This proxy is solicited by the Board of Directors   The stockholder(s) hereby appoint(s) Jill C. Milne, Ph.D. and Deirdre A.   Cunnane, or either of them, as proxies, each with the power to appoint her   substitute, and hereby authorize(s) them to represent and to vote, as   designated on the reverse side of this proxy, all of the shares of common   stock of CATABASIS PHARMACEUTICALS, INC. that the stockholder(s) is/are   entitled to vote at the Special Meeting of Stockholders to be held at 10:00   AM, EST on December 12, 2018, at the offices of WilmerHale, located at 60   State Street, Boston, Masschusetts 02109, and any adjournment or postponement   thereof. This proxy, when properly executed, will be voted in the manner directed   herein. If no such direction is made, this proxy will be voted in accordance   with the Board of Directors' recommendations. In their discretion, the   proxies are authorized to vote upon such other business as may properly come   before the meeting or any adjournment or postponement thereof. (If you noted   any Address Changes/Comments above, please mark corresponding box on the   reverse side.) Continued and to be signed on reverse side Address   Changes/Comments: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1009" height="1304" src="g365892bci002.jpg"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=57,EFW="2236896",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=355009,FOLIO='',FILE="DISK131:[18ZEO2.18ZEO48902]36589-2-BC_ZEO48902.CHC",USER="HYUNG",CD='Oct 11 02:18 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g365892bci001.jpg
<DESCRIPTION>G365892BCI001.JPG
<TEXT>
begin 644 g365892bci001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 48 _$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-UZ^W6K7]AP_9+>W\V3; 7*GC)W*P.?^^C1)HD,D4D9ED >W2W)XZ+G!^O-
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M41:85MW:,E7#/+O VC)7'7H*Z;6IK;5/&OAN/5"ATR6U>XA23_5R3\8SG@D
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M/4]JZ%'61 Z,&5AD$'((IM6T)3N.HHHI#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L+5KV[35A;6]Y';(MF]P=R!BQ5@._;GFMVJ-SI
M-I=WR75U$DK*GEJLBAE'.<\CK0-&*NKZC.QD\]((Y7@B5/+!\HR(&+$GJ<G
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M#*8EB&'+$[@3V&!QBNEMK.ULU<6MO#"KG+>6@4,??%17?V&PLY))XHUA 56
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MO;Q6EM';V\:QPQ*$1%Z*!P *EHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUJD-W/X@@:*S \J:(B98,LR9^;]YD;1R1MP<TNA:6]C)IT@MFB=H)1<MW)W
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MX:\2\N)I"'DN74Y^8GUJ23P?;2>-$\1_:)!*L>SR,#86P5#?7!JFGB?4I_\
MA%XC;);76J%GN8G4DI&JY./3/'7UJQXCU;5$U_2]'T66VAGNDEEDDGB,@5%
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M<&"W@"MYR+@E9"V<'..F.AH6H'<T5R5WK>N:3XFTVUO#83VVHSM$D,"L)8E
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MU&=+EI44^7&R$;% ZE1C'XTVW\/ZO?>*K+6-4TK3K>:RC?=+!+N:Y?;M7MD
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MC7;T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,9R*$#-N1["UNIKE_*2XV(DCX^;:20H/?&2<5,UK UTERT2&=%*+(1\P4XR
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MUM%<GK4:S:[>IY%S+<?8X_LQC#%8Y-SX/'"GIR>PH&FO'YDUW;SR1R7TAN5
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M (6D&<LP3J!P.3UKO**=P>H4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M(L<LNV!)$VE5ZM@>A<L:8&W1112 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/NKVX_M%
M;.SBB:01B61I6( 7.,# Y/!_*M"J%]:6DMS!+/,T$^=D;)+Y;/WV^XXZ4 9=
MQXH>">[BC2WN&BC:2,12-SAE7#$C&?F'3/0T:CJNI"*18XX8Q!-#%-(DASN9
MDSM!'3#8Y]:O)X<L$W?+*5*E%5I6(120Q"C/ RHJ2[T.SO;GSIA)DLKLJR,J
MLRD%20."1@4+H FE:E+?R7*SI'$\3X\K)WJ.?O COV(XJM>:_P#9-72TS;R*
M^5"JS;U;:6YXP!QZYYJ]:V-O9W<CB1WN)AUED+-M!Z#/8$_K4;Z%9O=M<,)=
MQ<R;/,;8'*E2VWIG!- &?'XAO/+B$UI"LUS'');JLI(&]@N&..V<\5=T2YNK
M@WPO,"2*Y* *<J!M7I[<]ZDDT:RE14*-^[B$*D.05 ((P?4$ YJ6PTZ#38Y$
MM]_[US([.Y8LQQDDGZ4",FZ\3M;7=U"J6\YCB>2,1.V?EQPQ(QW[9Q4CZU?1
MR&V:U@-V9HXQB0[,.K$$G&>-IR*G;0--C+&3>%;<BJTQVKO(R%&>,D"K;:9;
M/=?:&0^;N5\[CU4$#]&- S.@U^5UF$EN@D@MY)'VOD%D8J0..AQG-1W'B!DN
MX[<&#]_'P$9C)&Q0MSQCMZYZ5;NM"TZ5<3;XPY=6VS%?,WG)4\\@GM2MH>GQ
MRB9RZJ&#!3*0@<C;G&<9(.* &IJ,MMX434&'G3):"4ACC>VW/7WJF_B6:"_2
MUFAB\U"@F1"['YSQM^7!P#DYQ6N+.UGTH6:X>U,7E *V<KC&,TCZ9"]XMTK3
M1R#&[RY"H?'3<.AIO<.ACIXFN4MH;BZLXUCN0XA6.7+;E. &XP ?TJ:?6K^W
MF6T:UMVO&EC08E/E[7#?-G&>-AXJ33O#-K:68BN-TYVLI#.VQ=QRVT9^7/M5
MJ'1;6(JQ\V219!+YDDA9BP! R3V )XH&S)36]3@6Y:Z2U*+>-")<L$B4 'YL
M#/?&?SK7U;4UTO3_ +0P5BS*BY)VY8X!. 3CZ"HKC1K.1Y0\L\:W3[GC6<JL
MAQ@C&>X'(JY<64%S:_9Y%(C&-NTE2I'0@CH12![G.OXH=&CN)!M78T>SY@CO
MO5589&<<^E7+/7KG466WM8(3<#<TC.66/:"!E<C)SGT[&KS:+:R1JLQFE94*
MB1Y6+C)#9SZ@@8/:D;18'2+=-=>9%G;-Y[>9@]06[C@<4(1G)JVJ)//&T5K*
MS7WV>+#LH1=F[)XY_P#KU*-?N!$MTUM']DFWK"0YWY4,?F&,8.T_3BKBV%B=
M2D99,W =9VB$OW6V[0VW/&1^>*C?2=-AG9I&*[@Q$;S$*F[ABJYX)W8R/7WH
MZ 4EUVY/DK=P)$S^3,OE2$X1R1@\=1C\:L'5[L:8;Z1;."*7:8!)(V<'^]@=
M<=A5PZ1:-)&YC.Z)41?F/ 0Y7]34(\/VBKM1[E%5MT869@(CS]WT')H8&2-;
MN;V2&:"0QI(ML0@/&3*RMVS@X_*M;2M8.IR[5B"A(@TOS9V2$D%/PVG]*='H
M=A J".,C9L"Y<G[K%QW]231HM@EG#/*&B>6[F:>1HONECQQ^ %,&4[_7I(4N
MH!!^^B:0$"3!$:IN#YQWR!4BZ[C6H+$F!UF^4;&8NK!2WS<8[>N>E7)]'L[B
MZGN)(R99X/L\A#$93T_7K4<&C6(NUNH2[%)"ZJ)245R"K$#.,\G-) ROK>O_
M -EW$<$:HTK1F4A]W*@XP-H/)S1<^(HS$@L566Y:6.-HI,IY>\]^.WI5Z]TZ
M&\=)7>6*2,$"2*0HV.X)';BI9[2*Z6)906$3K(O)^\.AH0&/;Z]=&51=6]O%
M&TDL&\2GAXP26.1PIVGWJ!/$4EW&Z*4\V.1D+PLVTYB9@?F )Z5K2Z)8SQ&.
M2(LADDD(W'[S@AOYFHUT;3X&)D9VDD<9>68EF;:5')/]TFACTN"ZB]MX=M[N
M0&:5HHN"<;G; &3VY-5I=9OH9DLS:V[7AF2,D2'R]K*S;LXSQM(Q6HUA;OIX
MLF3-N$"!23T'3GKVZU##HUK"R/\ O))%D\WS))"S%@"HR3UP"1BGU%T(M;N;
MVU@M39& .]Q'&_F9Q@L <8K/M]=NK-)9;Z-6MO.G17#9?Y-S=,8QA2/7I6Y>
M6<5]!Y4VX ,'!1BK*P.0014']F6)VP,H8HSR[&;))?(8D>AW&D!7T36FU5I5
M>-0457#1[MN#GC+ <C'/U%5SJ=\FHSVMND<SR7+HAE<JL:K&K=AD\D_G6K96
M"6",D<L[J>@EE+[1Z#/04BZ;;)=_:0A\W>TF=QZE0I_0"@#"/B6ZC=[N2.$6
M0M$D$>3O#LY7KCIG]*L6OB"ZNY;>"&WA9WD=7DW,J;54-E<KD]<?45>.@6)5
M5V.%6,Q;1(<%<Y&?<'D'M4MOIL,1B?S)IGBW;'EE+GYL9Y/TH8D9"^*9H;-;
MJ\M8XXY8#+"$D)/#*N&X[[ATSWHAUR^O+BR6W6V"FY,4S$/M<;"PV9 /_P!<
M5JG1+(PQ1&(E(HFB4;CPI()_'*CF@:1#Y42/+<NT,OFI(\S%P>G7TQQB@?0N
MNN]&7++N&,J<$?2N;L9Y['[21<7%U,]Z;2!+B7*#@')X[ 'WKHH8UAC$:LS!
M>[-N/KUJL^DVKPRQE& EE\XLK$,'_O ]CQ0 NG7DETDR3QJD\$ACD"'*DX!R
M#Z8(K)_X2"7<K7,:Q;)RK0JQ#HH1V^8$<YV\8X]ZVK.RBL83'"&Y8LS,Q9F8
M]22>IJHFC61N&D+//.C9)EE+E>#A?IASQ[T C/D\0W]N&\ZR@):W2>(),>=S
MA=IR.V<YK5TV]FNC<Q7,:)/;R>6_EL2IRH8$9YZ&LZP\-!)I);U@VZ-8EC21
MV555MPP6.1R!Q6S%;16\D\J#:T[!Y"3U. O\@*>@&7+K[QVZ2_9P=TL\>-W_
M #S#G/3OL_6I=+U.YNIUAO+>.)Y(%N$\MRPVG@J>!R/RIDV@6-P\\D3-YO[S
M \TE(W=2&.W. 3NY^M6-+T>#2XUV%WD$:QEW<MA1T49Z#VI(&:%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<]KL,@UJTN+<S&>*UN&C17.TL N,CH>M=#5"[U:"P
MNC'=$1Q+"9FE8\*-P7'ZT#1STMU*T#1Z?J5S+'(L/FR[]S1NTB@@'^$D$Y7M
M[5LZ]+<6.C(+5F.'1))&D*E4S@L7P<?7%.?Q#8(UN$:1_M$QA&V)LJV,_,,9
M';KZ^E2G7-."3NUT@2 9D8@@ 9QD'N,\9&:!+<YJXN;V**WGCECF<0RJLL<W
MF;8C)&"3)MY(&><=N]6+:[<M#'?ZDL=@Q<QS0W>[+#;A&EP,]6.._OBMQ-=T
MYIT@6X D;: I1AC=]T'CC/;/6HKOQ%IUI:7,WF&06PRRHA)/....1GC(X%,-
MS&,134;BWAOKJ-YM23S )B6\LQYXST!(ZCT]J)K^X2*1X[R8ZAF99K?=D1(J
MOM;;VQA,-WSWS72SZC;6UJES*S+&^,$1L3Z] ,BH6UO3EN$A-RGF.%Q@$C#?
M=R<8&>V:7D._4Q/,N[0Q1"ZN)M_V20F5MQW,^&QZ XZ=JTO#\Z7$9DDO));U
ME_TB%I/]4V>1L_A]/>IFUVT_M."QB?S)9)&C.,@*54D\XP<8P<=,U=DN889D
MBD=5DD#%0>X7K^6:=Q>1RNISE]3C6:ZE^U+J4:QVN[Y3&.5.WT/7=Z\5#;7-
MY=VNZXGC?<\)FA^T>8Z2>:O\&T;!U&/I]:Z&Y\0V$.G1WT4J312 ,C*< H6"
MEL^@S4IUO3UMQ.9P$9BGW&W9'7*XR,#GI26@/70Y^VOK_;:VZRS,]ZN^,_W?
M+9BX]LC;^=0P7NH7&FS/]MV.XA$HCN?,EBD:10?EVC9P2,5U!UK3Q=K;?:4,
MI*C !(R1E<GH,CIZT7>L6%A<>1<W"QRE0Y7:3A2<;C@<#/<T^HVS*AN+BUUQ
M]/EN)OLUL#=M-(V<Q%<!2WLVX_A5[Q#=-#X>N+BWG>(X4B6,9(!8<C\#4;W6
MC"2_$LHE9B([@,&?GL@'X_='K3[S5=(DM(TN;A3%,-RJ V<*1DX R,'&<].]
M(1B75S,"6L)I+R.&X8VTC-ORWDN2 W?!_P *2+4)18L);L212NH1DU Y1L$M
MODVC:#QA<=:Z#_A(-,$1D^U($#A!\IY+9VX&.<X.".M-/B"P-U9P(S/]K#%&
M6-MHV]=W'!^O3O0!@#5;T6UI<^>T]U):_N[9)2'5\-\S)CYU.!R1QCWK6\-3
MSSK.SW44\6%( N?.96YW9.T8[<=N:NKKFG-#).+A2D9"D[3DYZ8&,G/;&<T_
M2]2BU2"6:%<(DSQ _P![:<9]OI3 P&3[)?Z@YNKB&WFOU6XE,I^1/*!&#_"-
MV!GTJK=2/<>66=YHQN6*5N2\8N(L'/?Z]\9KI)M<LK9W2ZF1&#L@5<N3M )X
M [;A3+_Q#8V,0/FK*Y5&55S@AB .<8&<\9ZT+2S!ZF/]HN[C"6]]/_:4IE6>
M -D0@!MIV_P\A0#WSWI+75KR^U"+9+,L.J!6@&,>2(V_>#VR*WO[8M%8+)(H
MD:1HU6,%R=K;23@<<_@/6F76OV-I%=.TCLULA=T$;9(''''//<4M@>I!K\49
MN])EEFEB1+K!*R%%Y5L9_' _'WK%ADO=,TB![.6>22:WF8HQ^52K#&T8XP">
MW/O73)K%C)+#%YV))E#*K*1UY /'!/H>:JZAXDM;">[A99#):Q)*^5*KAFQ]
M[&.*/(/,/#LLTMO.7N8IX=X\HI<>>5XY!? []NV:QWFO)A=M]LN8Q;V\\R+&
M=H+K(VW/KP,8KH?[9L1:M.)6\M7V-B)MP;KRN,].>E)!K-K=:D;*%G=Q"LP<
M(=A4],-C%'4#G=0F>ZBU2"2ZEF>2U:0>1.1Y( 'R,@^Z>>O<9JQ)/*B7MU!?
MW#P0-;K&1)N41G:7;/?C.36ZVKV"1+*US&$<,P/J%.#^IQ3K?4[.Y$8AF!,C
M%%4@@Y R00>0<<\TQ'/?VJMWJ,PFU!XM-,[A9TDV*6"1X4/V'+'W--=FL]4N
MA;7$SS27L)\MY2V5,?!P>@)&,^U=&VHV@L1=>9NMSP&1"V><< #/6H)]?TRV
MACFEND$<B;PP4G"^IP.!]<4BCGWOK@V:_9-1N))I80;KG)@DW(.!_">6&WTJ
M6^GELC<1M?2F"VN 1&]P4EF!0':K]2022!WZ5NMK>G)).AN%W08\P!2<$XP.
M!R3D<=:5M:T]5A9KE,3<H<'UQD\?+SQSCF@1#KEXL&FQEC(GG.JAO.\G;D9^
M9_X1Q_2N9COFF\JXN[Z:WG-@_EE6P9'65@HS@;CP.,<YZ5UEQJ]M;:E%8S%Q
M)+&T@8H=@ ZY;&!4EGJ5IJ&[[-*'*8)!4@X/0X(Z>_2@#GTO+J691+=31ZDU
MPL1M5; $1QEMOTR=WK^55I-3U"6!&>5TBBD6SN&:7R1O4,6;?@[<G:,_A71#
MQ!IC0B=;I3&6*A@C'..O;H.YZ"IGU2S2X,#3+O"[FP"548SRW0<<\F@"O:K/
M<^'-MQ,))7B8>9!)G(YQA@!DXQSBN=M+H0Z3 G]HSQ>391M:!9<F67!W*?[Q
M! &WMZ5TAUZQ\I)5G3RMQ5BV5*X4MT(ST&?IS4EQJ]C:EA-.H9<94*6/()'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=H#<= *OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?\)/9>9=G9<?9K17,MWY7[G*_>4-W(]A35\56+6LDK1W,<D;I']G>+$K,_W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>"1S5*'7W:6YCEL9A(ER8(45D)EPH8G[V!QSSCM5M]&M9KN>:YBCN!*4(25
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MZ8/49QS2Z)IIL[B_N9$,<EW.9!&S!MB]AQQR=Q_X%20&M1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !61XC@CEM+>209:*ZB9.3@'>!G%:],<QD$2%,+@G=V]Z Z&7
M?01CQ+ID^/WI65,DGIMSTJMK%JDHM[AKBQG$'FG;> %6SC@8Z$8QGFM:YO;6
MVN($G=5=]VQCT7 R<GMQ2RP63^4DT5NV6+1AE4\]21[T <KJQD>W>[CMHFFN
MH83:AG >V;T Z]3VZ]ZV=9NI(]2T^V%_]CBG64NP"Y)4 C!8$#O6D$M)+OS
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MC::WBS'&N0I5R0./;CTJI+K&I65H+C[2UR[FYC",B@#RR0K< <\<]OI75,8
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MKC= $.$&%7.,<8#9XZ9KH(8=/B@D,$=JD+\.450I]CBI%-HD,<2F!8G&(T&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+&T'DA. ,!,G XS^=8T%MY^LWOD6<GVE=2#BZQ\JH%3<,]N,C;WS0!UP8$D
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M(M9DEATV6SA^QQQ,74*&<,V>._7KWIV Z2BBBD 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0TY&?G(&,G\*FAA2WA2&)=L<:A57T I S/L?.77-2C>XED3;&Z*QXCSNX _
M57TM#+8:A%>W=Q(L5W(#*92C!1@]5Q@?2M=;>)+B2=4 ED #-Z@9Q_,U&=/M
MFM[B Q#RK@LTJY/S$]?SH P0ER/!US<)=W<32;KB,F4LZ)U5=S9/0#\S5O7X
MO,LX/+FN$NYV6"(Q3N@!/); (!P,GGTK7EMHIK9K>1 86784Z#'I2/:0R3PS
M,@,D&?+.?NY&#^E'4"55VJ%R3@8R>II:C2%$DDD7.Z3&[+$]!CIV_"I* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF3[\:N"R_4=J07]H;AH!=0&902T?F#< .N1UH L45%]I@! \Z/)3S/O#[O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445GZWJDFD:<;J*PN[]@P7R;5-SG/?'H*
M -"BN-_X3Z]_Z$[Q%_X#C_&I['QK=WE_!;/X5UVW660(9I8 $CSW8YZ"@#JZ
M*R=?UN71((9(=*O]2,C[2EG'N*<9R?:L/_A/KW_H3O$7_@./\: .RHKFM'\6
MW.JZG':2^&]9L4<$F>YA"QK@9Y.>_2KWB#79M#C@>'2-0U(RL05LXPQ3'<T
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MQWQZ&@#1HKD[SQM=VE[/;KX4UZ=8I&02Q0 H^#C<#GH:A_X3Z]_Z$[Q%_P"
MX_QH [*BJ&C:E)JVFI=RV%U8NQ8>1<KMD&#C)'O7.'Q[> D?\(=XA.#U^SC_
M !H [*BN-_X3Z]_Z$[Q%_P" X_QKJ+&\>\TR&[>UGMWDCWF"5<2(?[I'K0!:
MHKC?^$^O?^A.\1?^ X_QH_X3Z]_Z$[Q%_P" X_QH [*BJ']I2?V%_:/V&Z\S
MR/.^R;?WV<9V8_O=JYS_ (3Z]_Z$[Q%_X#C_ !H [*BN-_X3Z]_Z$[Q%_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKAO&/A_3;CQ+H<LMMN>^O#'<'S&'F*(VP#@^
MP_*@#N:*X(-J=AXQUJWT2RMYX8[.V0K/=-&(P%;&/E;/_P!:J/ADS2R>&T2=
MHY'TBYPY8G:V\8/OBC^OS_R#^OR_S/2Z*XGP9$NCZJ^E7]DT6K-;"5[I;@RI
M=J#@OR?E.>Q%97B+3;K5?&VKPV-E+-=BU@\BY6Y\H6C'=\QYR?P!Z4!W/2Z*
M\BU&-U\0ZH[0S+<C4+>%=668JEN2J9!0')!Y[8^:NHCL+7Q%XHUR/6Y)&^PM
M&MO#YS1B*,IGS  1R3GGVH [6BO,I+VZ;P=I>I0SRW&KVU\\.G$DEKQ-Y4*W
MJ"@R3[9JY:V O? \>LV-RS:M;S/?R2.2,S#/F1,.PP"N/84>86Z'H-%<[X.@
MEGT]]:O#F[U4B=E#9$4>/D0?0?J369I>GVGB76M9EUIY)KBSO#%#;F9E$$:@
M;6"@CKG.:=M;!TN=K17EWC+7E/B::>&:Y#Z&(S!'%%(R2R$@RABHP/DP.32^
M,;B&]\0F]2PGU" :*+B,PS[/(RYQ)P1G&>V32Z7';6QZA17GMOI%MJWB73X-
M6F-ZL6A1R>>)60,V_P"^"".W>MWP+=RW.A3J]S)=0P7<T-O<2'+21*V%)/?T
MSWQ0]/Z\["_K\+G2T5Y?::==WW@_1[KR?[0LK87#7-BUR8C)\YPX;N5P>">]
M=B\-MXH\"^78^9'!=VG[C<2&3CY<GKP0*.EQVUL;]%>>:;KXUFYT^^NG*PZ+
MI[W%X,])SE-I]QM8_B*I^!]<$7B:,337+/K4333K-$Z+'."6"J6 !&PXX_NT
M[:V%TN>GT5Y_8N__  J;6&+MN O,-DY^^_>H[+2;#5_$ET=3W[(-)M&243,A
MB)5LL"",'CK2';^OF>B45S'A'4+RZ\#K<R2/<S(LHAE<<S*I8(Q]<@"N9-M;
M1> 8?$L5[.=<94D^T>>Q9YBPS$5SC&25VXHZB/3:*\VGN9]-\8:YJSRN+5/)
MM[N,GY45XN']L-C/L34GA5W;4/"(9V(;2I\Y8G/S+0M0/1:*\_72;I?$I\+^
M:?['+_VE]\[_ "]W^I_W=_/TXK<\5@6-SI.L;BB65SLF.>/*D&TY^AVT>8=;
M'245Y!9W%Q%IMY;^=)YWB6..:'+'(9YBC8],(1TKI#)JEGXVUB'1[2WN8TLK
M966>Y,00 -C&%.?THZ!U.[HKR6.UFU/2O!MN+2.^=X;DM!/<-$C8(Y+ $\?2
MM/6+6ZL?%&E26*&"73=+,_V6.0LC*' =,GK\I.">X% =#T>BN5\!7<=_9:K<
MPR&2&74IGC;.?E."*R;& Z'XA>/5[9IKV_,_V74DN"P<8+;&3/RX'' (XH>@
MST"BO,-'_P")I;>'M+OI9FL_[,>X6W68I]KE#8V%LC.!SC/>FZCY.K:%I^G6
M%M<Z0T6MBV:-IM[1R!"<A@3QG'&:=M?Z[V$OZ^ZYZC17E=UJTNI_\)++*S1W
M,6C)%<1@D>7*KN&Q_/Z$5/>:0VG^ ;HRZ9;V)N9+8'R+MY?-7>O)) V]>WK2
M!Z'IM%<;96T.A>/+;3=(ED%K/:/)<VAD9UA*D;'&2=I.2/>JGQ%OX+FYL]$E
MGN(8W1[F9[>-W9=H(C'R G!?G_@-#&EJ=[17F6I7T_BS1/"4D%P]O>R7+*S*
M2"LR1MU'IN7H>QJM>ZJ=7L/%MSET<VEHDL>XCRY 2'7VYS3:W$>K45Q4%I;^
M'_&6D6>CRR)'=PR&ZL_-9T557*R8).TYX]\T_7]-M-6^(.FVU_&9(!I\TFW>
MR@,'7!X(]318#LJ*\RFU^73_  9JUK%=S7,9U!M/L9R3(YC.-V".6VC=S[4F
MG+IFJ>$M:TJ3SKA='626S>;S(W",A*'!P>#D<^E+I<=M;'IU%>6ZAHEO#X<\
M+16%DDKWT\;S123NBSMY)^\W)'KQ6I?Z';OJ7A32[VQCA@(N6DM8IW= =H/#
M<$\\TVM1([ZBN4\(3"#4=<L(;M[C3[2X1;=Y)-^PLN6C#'J ?RS75T@"BBB@
M HHHH **** "J6LW,MGHUY<0$++'$S(2,@''I5VJ]]:+?V$]K(S*LR%"R]1G
MTH&MS$U+4-0T>TG62[68M:O-%,T0!1EQG('!&&S^%%S<W3:9!<6.LF4-<)$T
MGD)SN<*>,=LU=DT%;B"=;J[GFFEB,(E(4%%Z_* ,#D#MV%6#IK36J0W=U+.5
ME24.553\K!@.!C&13%T,Y]5N;?68(#*LEG&5M[B0H QE<94\< = 1_MBK5G)
M>:C*;I;H0VRS,BPK&#O"L5)8GD$D'I3)?"VFS13>9"K7$KF0W)4>:&SD$''&
M.,?2K$>F/!=&2WO)HHG?S)(0JE68]3R,C/M2 RD\3*\5O$+F(WCWWD-'MYV^
M85Q]<"K^OW]U:PQ0Z=L-W(2ZAAD;$&YOSX7ZL*G&D0BUBM_,DVQW'V@'(R6W
ME\?3)I+K1;*^OOM5Y"EPRQ^6BRJ&5!G)('J>/R%'0;M<H2:]+_:]DT91M-GM
MED<X^92[ *V?3L?K4-C>ZGJDL8CO%@*V_F$>2&#MYCKSWQA1TK0MO#MG:JR+
MO:$PM (SC:J%BV!QVS@>U0V_AH6<<,=OJ%W&J0"!C\I9UR3DMC(/S'D4]!#;
MS693X6CU".1;9W,89]NX)EPK$ ]>]4'URX-O9E]26&":>5%N_*&945<@X/ Y
MR.G:N@ETR!["*S3='#$R%0AY&Q@1_*JLN@@S":VNY[>03/,I4*P!<888(/!Z
M_4T: 02/?C6HHDU)C;O;M/M\E.<%1C..AR:<-4N3INDSY7?<C]Y\O!_=LW'I
MR!6B+%3>1W3NSR)"8><88$@DD>O%5(=!2)HU:YGD@A!$$38Q%D$=<9. 2!G-
M)[!U,2WUW4)])GDL[V*ZE$<)$C1!525V *$#J,'\*V]/U1K^_*K\L7V=7*$?
M,C[F5@?IC%*= MR$ EE 6*.(X(^81L&4GCKU_.IK;28;35+J^B9P]RJAT)^4
M$9Y ]3GF@70R+BZU&R;59&U$R)9QAU5H4 .5)Y(':ENO$@DFG&GW$4B16OFG
M"YPV\#^1-:T^E17 O0SR#[8JJ^".,#'%)>Z1#?2.\CR M#Y)VD=-P;/UXH&B
MOIUW/+JEQ%=W!252VVU,8 V9X=6ZMQU]">U4KO6;B#7IX4N0PB=!]E$624*Y
M9MW48Y]N*UH]-;^T!=3W4LQCW>4C!0(]W7H,GIWJ:*S2*XN9068W!!93T&!C
MC\J ,F*]U".WL]0FG1X;ID#6X0 1A_ND-U)&1G/OTJKH.J7NKJT:Z@)"T >2
M185'V=]W"CL<C/7TK4AT-(GA5KJ>2V@;=#;MC:A[<XR<9X!-26>CPV,EN\4D
MFZ&#R.2/G7.1GZ<X^II@8D6M7]EIMG=W-P+GSXY9&4QA?NKP!CWJY>76I:5$
M'GN8Y_.BDQ^["^5(J%AC'5>#UYZ5<&@VIMK6!S(\=NCH 2/F##!S3/[!612M
MU>7%P!$T46_:/+##!/ Y..YS0QZ%;3-9NKF738+C8L[*ZW2@<%@JD$>@(.?Q
MJ>2:_O;R\6SN$MTM&"!3&&\UMH8[O0<@<<]:F71+=-3M;Y7D$MO"80 1M<<8
M)'J,?J:6YTCSKB66"[GMO/ $ZQ[<28&,\@X..,CVH?D(RK?Q%=274C2*BVTE
MLC1<<QRE6;!/<'''T]ZGMM1U&[LKB2$HTT(AD";?O@QJS+]3DX_"K4WAZTFM
M;JW_ 'B1W$21X4X,8084J?44ZUT9K*Y$D%[,(BJ*\15"&VJ%'.,] *.X#M(O
MI=322\'RV<A MU*X8@=6/U/;V]ZT:KV-HEA9Q6T;,R1C +=35BDP"BBB@ HH
MHH **** "BBH+V\@TZRFN[N01P0H7=ST % $]%>7I\0?%/B2>1O"FA(UE&Q4
M33@G=^.0 ?;FI?[8^)W_ $!;#]/_ (N@#TNBO-/[8^)W_0%L/T_^+H_MCXG?
M] 6P_3_XN@#TNBO-/[8^)W_0%L/T_P#BZ/[8^)W_ $!;#]/_ (N@#TNBO-/[
M8^)W_0%L/T_^+H_MCXG?] 6P_3_XN@#TNBO-/[8^)W_0%L/T_P#BZ/[8^)W_
M $!;#]/_ (N@#TNBO-/[8^)W_0%L/T_^+H_MCXG?] 6P_3_XN@#TNBO-/[8^
M)W_0%L/T_P#BZ/[8^)W_ $!;#]/_ (N@#TNBO-/[8^)W_0%L/T_^+H_MCXG?
M] 6P_3_XN@#TNBO-/[8^)W_0%L/T_P#BZ/[8^)W_ $!;#]/_ (N@#TNBO-/[
M8^)W_0%L/T_^+H_MCXG?] 6P_3_XN@#TNBO-/[8^)W_0%L/T_P#BZ/[8^)W_
M $!;#]/_ (N@#TNBO-/[8^)W_0%L/T_^+H_MCXG?] 6P_3_XN@#TNBO-/[8^
M)W_0%L/T_P#BZ/[8^)W_ $!;#]/_ (N@#TNBO-/[8^)W_0%L/T_^+H_MCXG?
M] 6P_3_XN@#TNBO-/[8^)W_0%L/T_P#BZ/[8^)W_ $!;#]/_ (N@#TNBO-/[
M8^)W_0%L/T_^+H_MCXG?] 6P_3_XN@#TNBO-/[8^)W_0%L/T_P#BZ/[8^)W_
M $!;#]/_ (N@#TNJ]S86UY-;S7$*R26S^9"QZHV",C\":\\_MCXG?] 6P_3_
M .+H_MCXG?\ 0%L/T_\ BZ /0DTZUCO+B[2!1<7"JDK]W"YP#],FJ\&@:9;>
M1Y-G$GV>)H8L9^5&.64>QKA?[8^)W_0%L/T_^+H_MCXG?] 6P_3_ .+H [K2
M_#^EZ*9&TVQAMVD^^R#D^V3V]JLQV%M%?37L<*K<S*J22#JP7H/PR:\\_MCX
MG?\ 0%L/T_\ BZ/[8^)W_0%L/T_^+H [N;0M-GBO(I;.-DO6#W /_+0C !/Y
M#\J9J/AO2-6>-]0L()WC&U6=><>F>X]C7#_VQ\3O^@+8?I_\71_;'Q._Z MA
M^G_Q= '?_P!D6/VFUN!:Q"6T0I 0,"('@A1T'%)#I%C MXL5LB+>L6N .DA(
MP21[BN!_MCXG?] 6P_3_ .+H_MCXG?\ 0%L/T_\ BZ /1K6VALK6*VMHQ'#$
MH1$'10.@JCJ'AO2-4NDN;[3X)ITQB0KAN.F2.OXUP_\ ;'Q._P"@+8?I_P#%
MT?VQ\3O^@+8?I_\ %T >@6VF6=G!-#;VZ)'.[22J/XV;[Q/UJ&UT#3++;]FL
MXTV0?9EQDXBSG9],FN%_MCXG?] 6P_3_ .+H_MCXG?\ 0%L/T_\ BZ .OF\&
M:!<"V$VF0N+:/RH0<_(F<[>O3FMB"WAM8$@MXDBB0;51%PJCV%><?VQ\3O\
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M=']L?$[_ * MA^G_ ,70!Z717FG]L?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T
M>ET5YI_;'Q._Z MA^G_Q=']L?$[_ * MA^G_ ,70!Z717FG]L?$[_H"V'Z?_
M !=']L?$[_H"V'Z?_%T >ET5YI_;'Q._Z MA^G_Q=']L?$[_ * MA^G_ ,70
M!Z717FG]L?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T >ET5YI_;'Q._Z MA^G_Q
M=']L?$[_ * MA^G_ ,70!Z717FG]L?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T
M>ET5YI_;'Q._Z MA^G_Q=']L?$[_ * MA^G_ ,70!Z717FG]L?$[_H"V'Z?_
M !=']L?$[_H"V'Z?_%T >ET5YI_;'Q._Z MA^G_Q=']L?$[_ * MA^G_ ,70
M!Z717FG]L?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T >ET5YI_;'Q._Z MA^G_Q
M=']L?$[_ * MA^G_ ,70!Z717FG]L?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&1@]*6B
M@#S#X9*+/QMXKL8,K;I-E4SP,.P_K7I]>9?#S_DH_BW_ *Z'_P!#->FT %%%
M% !1110 4444 %<;\6/^2?WO^_'_ .A"NRKC?BQ_R3^]_P!^/_T(4 ;'@W_D
M2]&_Z\HO_016U6+X-_Y$O1O^O*+_ -!%;5 !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%9OB#2WUO0;O3XKEK5[A-@F4$E.>O4?SKS[_A3NH?
M]#7=?]\/_P#%T >IT5Y9_P *=U#_ *&NZ_[X?_XNC_A3NH?]#7=?]\/_ /%T
M >IT5Y9_PIW4/^AKNO\ OA__ (NC_A3NH?\ 0UW7_?#_ /Q= 'J=%>$6VFWG
MAKXK:7I,FJ7-VJ3Q,69V ;<,XVY->[T %%%% 'F7P\_Y*/XM_P"NA_\ 0S7I
MM>9?#S_DH_BW_KH?_0S7IM !1110 4444 %%%% !7&_%C_DG][_OQ_\ H0KL
MJXWXL?\ )/[W_?C_ /0A0!L>#?\ D2]&_P"O*+_T$5M5B^#?^1+T;_KRB_\
M016U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'C?B+_DO6G_]=;?_ -!KV2O&_$7_ "7K3_\
MKK;_ /H->R4 %%%% 'F7P\_Y*/XM_P"NA_\ 0S7IM>9?#S_DH_BW_KH?_0S7
MIM !1110 4444 %%%% !7&_%C_DG][_OQ_\ H0KLJXWXL?\ )/[W_?C_ /0A
M0!L>#?\ D2]&_P"O*+_T$5M5B^#?^1+T;_KRB_\ 016U0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C?B-A_POO3QD9\V
MWX_X#7LE5GT^SDNA<O:0-<+C$IC!<8Z<XS5F@ HHHH \R^'G_)1_%O\ UT/_
M *&:]-KS+X>?\E'\6_\ 70_^AFO3: "BBB@ HHHH **** "N-^+'_)/[W_?C
M_P#0A795QOQ8_P"2?WO^_'_Z$* -CP;_ ,B7HW_7E%_Z"*VJQ?!O_(EZ-_UY
M1?\ H(K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /,OAY_P E'\6_]=#_ .AFO3:\R^'G_)1_%O\ UT/_
M *&:]-H **** "BBB@ HHHH *XWXL?\ )/[W_?C_ /0A795QOQ8_Y)_>_P"_
M'_Z$* -CP;_R)>C?]>47_H(K:K%\&_\ (EZ-_P!>47_H(K:H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,
MOAY_R4?Q;_UT/_H9KTVO,OAY_P E'\6_]=#_ .AFO3: "BBB@ HHHH ****
M"N-^+'_)/[W_ 'X__0A795QOQ8_Y)_>_[\?_ *$* -CP;_R)>C?]>47_ *"*
MVJQ?!O\ R)>C?]>47_H(K:H ***YGQP+J#1Q>6>HW=I)')&F(2N&#R*ISD'L
M3B@:U.FHKB;O6]0\.ZKJ*;I=0L[&SAE<SR@/RS!B,+RV/H.*T'\91C7FL$A5
MD2X6V8ACYFY@#NVXQM&0#S0(Z:BN*\97]]!K<$%I=:C$GV&:8)9(K$R*RA2P
M(/R\\U87QA<1V,DPMXKJ.QMX9+V9)<;BZ@GRQCG YY(]*.@VCK:*YV[\5"UU
MN"S*6\D<\GE+LF)D4[2P++C '&,9SWJI9>+[^_BL!'I<:2W\;S1!KCCRT W$
MG'7)P!^)Q0(ZVBN8TGQ!):_#ZWUB_,EQ*(MS#(#.Q;:!GIU(&:I>(/$NK0Z9
M?6T4,-KJ$#09=9-Z^7*^W*G'4'(Y'O1UL"U5SM**YWQ-)>6VA6445U+!/+<P
M022Q,"V&8!L$C^E9<VJW^F7USIDU]-=+!=6GES_*L@65L%'(&#T] 2#0A-V5
MSMJ*Y"7QM-%YADLH8HS=O9PRR3':S(6R2 I(&![\_G5NP\53:M<6<%C9*))8
MFFF,LA41J'V<<9;)!(Z<4+4;T.DHKCK'Q1J@>ZBNK>VFGDU-[&U5'*@8&3N.
M.@ SGJ:L#Q==2RVUM;Z<KWDEQ-;21M-A4>, DAL<@@^E '4T5B>']?;6I;M)
M84MI8'VFW9CYJC) + @=<9!&16;)XUEBCN)9+**.)+UK&*1YN&<,020!D+@9
M[^E '6T5S-EXKFU.6SM[&R0W$PD>4R2%4148*2#C+9)XXI8/%DDLT$C606PN
M;I[2&7S,OO7=R5QP"5/?- '2T5Q<'CB_FM(IAI,0\VQ>]4?:>B(<,#\O4\8_
M6I9?&UP)96ATU9+>.6VCW&;:Q,R@KQCL6&>:=F%SKZ*Y*7QN88ECFMH8KPW4
MUL0\I\H&, D[@N><C''>FS^-[CRFFMM-#11V"WTGF2[&4;B"N,=>#BD!U]%<
M;K/B>]F23^SXC#;PWMM;O/Y@WDL5+#;CIA@.N>:U](U]M3U6^LY84MWMF(6)
MV/FLH. ^",;3V()H VZ*YE/%S?;7LY+55N(;F5)U#YV0HF_S.G.05P/4U%_P
MF4\=F+BXT]8UN+&2^M0)MVY4 .U^.#A@>,T>8[:V.KHK(T_6VO=7:R, 0+9Q
M7.X-GER?EQCMBL]/%["4PS6H66&6X6Y4/GRXXEW;QQSN!7'UH$M3IZ*Y*;Q9
M?_893]BA@N)M/>^M"9=Z[5 R&XX(# ^AJ#_A.9K*UM$NX(9+HV<=S.$<@L'Z
M!!MY; )P<#M3M_7]>@':45RWC.^N+>/25M9KV-+BZV2"R4&5EV,< $>H%1VY
MO]9U.XLH]4O;&*QMX2ORIYTCNI.Z3(/3&,#'.:0'6T5YCJ/BC4I[.PN7NKZ$
M_89I'-C&I4R))L#N&!PG&3]:[/4M9N=&\,07TL4=U<XA1U1]JNS%5)!],F@#
M;HKE9_%M[#<&R_LV-[\78M?+$_R'=&75MV.G'/%21>+)7FBD>R5;*2]-B)1+
ME_,!(SMQ]W<".N>] '345R%EXXD>TM;N_P!/$-M=032QM'+O;,6201@=0.*D
ME\7W=K _VC2B9VM1=P1PR%\H6 .[C(*[@3@'CI0!U=%<Q?\ B_[%HT&H1FPG
M5XFE94N#\P'4)\N3^.,'BJ3>*KJR?5+@HT\ O(HT,F0EM&T2MN8J"0N?;J:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M))^;.>YJ*P\,6.FP1PV\EX(HI$D16NI&"[00 ,G[O/3H:V** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH RET&#[9JDTS&1=155="N-H";>#[BLR7P4+BS>"YU&:4BT^QP.8U'
ME1Y!/3[Q^4#/M7444 -5=J*O7 Q7/7_@NRU75[O4+^:XDDFB$,8CD:/RDQRO
MRGG).3FNCHH!:'#ZIX3U&*Q6WTV::>:6P%A-,Q15903M+ \@@$\C.:T)/!23
M7<%Q)>,6B>&0 QABIC &U2>0IQT'<UU%%%P.:MO!L=LH O)&Q9SVGW!TE??N
M_#I3[?PC%%?V=S)<EOLEO]G0+$J,PV!3N8<L.X'8UT5% &?H6EMHNDPV!N#.
MD V1LR!2$'0''4CUJGJGA:VUG68;Z]GG*P1&.&**1H]A)^9MRD')&!6Y10]=
M0.4M_!+V(LOL6K31&Q$Z0$Q*^$D(.TYZ[<<&K$'@VW@N-+9+AA'IH'E@1J)&
M.#G+]<$DDKTKHZ* .6;P0K6L5JVH2-;0O*8XWB5@%<Y((/!8'.&[4ZW\%16[
M0$7LA\DVI&4'/D@@?GFNGHH H:5I:Z6+L+*9/M-R]P<C&TMCC]*OT44 >9?#
MS_DH_BW_ *Z'_P!#->FUYE\//^2C^+?^NA_]#->FT %%%% !1110 4444 %<
M;\6/^2?WO^_'_P"A"NRKC?BQ_P D_O?]^/\ ]"% &QX-_P"1+T;_ *\HO_01
M6U6+X-_Y$O1O^O*+_P!!%;5 !116?K5]/IVF27-M"DKH1D.VT 9Y- &A124M
M !116'=:I>V>K/%.]HMFD8F)$;ERI;:%'/7/_P"J@#<HJK9:A%?+)L62.2(X
M>.1=KKQD9'N*J2>(;6%6\Z*ZC<2)&(VA.]BQ(4@>A(- &K160WB6S78HCNFD
M979HUA)9 I ;<.V,C^E.;Q%9":2-?.DV*C;DC)4EP"@![DYZ4 :M%9L>O6;[
M@QDC9$=W21""NW&X'WP0?I3K?6K:YN5A02C?PKLA",V,E0?4#/Y'TH T**I3
M:G%;WBV\L4Z[N%E*?(3C.,^N :CTW6[;5&"P+,NZ,2H9(RN]#_$,T :-%9UQ
MK=O:23K<QSQ+#&TF]HSM<*,MM/?%11^)+-YO+,=RC!E5R\) 3=PA8]@>W]*
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M,5S-?PSRPF,J84P-BMGGD\DCKTXZ4L?AUAK(OI;A'*M(0=AWD,"-I8G&!GC
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M<P#,(AE 0J"=QVE23QUQ@YK*74+A+M;2:68737ZDQC)Q$4S_ -\YS4<T4B^
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M<0W,-PAVW$LQRF0RR=0.>O3G]*S[29IO#>K1!Y+ADB<?: [N)B4/(#=#ZJ.
M>E9_VJ=+5/[/GN)++RX?M+S2R+L;G<-V"R\8SCI[4Q]#7U#2$EURWN;B]A4F
M='A61<OE1RBG.,'KTSS5R/2IDTBXL1=;=[/Y<B*05!.<'GGJ1QBL,073O974
M<K3W26ET8'BE=DZKL!SC<>V2.<4K2-.T<.GWE\UL[0B>3S'W*Y?Y@">02,Y
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M]!%;58O@W_D2]&_Z\HO_ $$5M4 %%%% !1110 5G2:U!'=-#Y<Q59!$TP7Y
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MFQC(X&*.@$H\00#;YD%P@ 3SFV@K"6Q@,<^XZ9Z\TR[U]8X'EAB?R4E5#<2
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MKYAD\F,)O(P6P.M %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /,OAY_R4?Q;_P!=#_Z&:]-KS+X>?\E'\6_]=#_Z&:]-H **** "BBB@
M HHHH *XWXL?\D_O?]^/_P!"%=E7&_%C_DG][_OQ_P#H0H V/!O_ ")>C?\
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M $(4 ;'@W_D2]&_Z\HO_ $$5M5B^#?\ D2]&_P"O*+_T$5M4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'9")8]LV%8,A-Q)E#C'RG=D#!(P.*(]#L(O*"P'9$-J1F1B@Z_PDXSR><9H
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M_P#H)JS3719(V1P"K @@]Q2:NK#3LS&\&_\ (FZ1_P!>L?\ *J_@G_D%WO\
MV$;G_P!#-,B\)7EG$L&G^)-2MK2,;8H0D+B->P!9"2/J:V=)TN'1[!+6W9W
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MP>>J;_N.#G!.X9(P3SS4-[I>I-8QVL-H $W&-E2-B/WA(!9C\HQC&/TKL:*
M9R5SH=P@,T=N>;V>658XXW:0,3L;#<'^F:M:;ILUCJEMY,$[)Y06>6Y5.R\;
M2#D'H".E='10#.<U'3IY;R\5;0RRW#QM!=97$ 7'7)R,$$\=<TNGZ/):W5A,
MMLL;K+<-.XQDAB2N3WSQ7144(#G+^SO[GQ!!(EOB**>-A(J)@H!R2Y.[/)&
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M22!6F>-(_-1%(5=H;=R1NR>>*KV2WQMRTTLFW,?VZ*-9M_7YCEOR.WM7;44
M<K!8I<WMC*L5PUM%>,;=G+@JGE^_.-W3-=-#,D\2R1YVMTW*0?R-244 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >9?#S_DH_BW_
M *Z'_P!#->FUYE\//^2C^+?^NA_]#->FT %%%% !1110 4444 %<;\6/^2?W
MO^_'_P"A"NRKC?BQ_P D_O?]^/\ ]"% &QX-_P"1+T;_ *\HO_016U6+X-_Y
M$O1O^O*+_P!!%;5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!YE\//^2C^+?^NA_P#0S7IM>9?#S_DH_BW_
M *Z'_P!#->FT %%%% !1110 4444 %<;\6/^2?WO^_'_ .A"NRKC?BQ_R3^]
M_P!^/_T(4 ;'@W_D2]&_Z\HO_016U6+X-_Y$O1O^O*+_ -!%;5 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!YE\//\ DH_BW_KH?_0S7IM>9?#S_DH_BW_KH?\ T,UZ;0 4444 %%%% !11
M10 5QOQ8_P"2?WO^_'_Z$*[*N-^+'_)/[W_?C_\ 0A0!L>#?^1+T;_KRB_\
M016U6+X-_P"1+T;_ *\HO_016U0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >9?#S_DH_BW_KH?_0S7IM>9
M?#S_ )*/XM_ZZ'_T,UZ;0 4444 %%%% !1110 5QOQ8_Y)_>_P"_'_Z$*[*N
M-^+'_)/[W_?C_P#0A0!L>#?^1+T;_KRB_P#016U6+X-_Y$O1O^O*+_T$5M4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'F7P\_Y*/XM_P"NA_\ 0S7IM>9?#S_DH_BW_KH?_0S7IM !1110
M 4444 %%%% !7&_%C_DG][_OQ_\ H0KLJXWXL?\ )/[W_?C_ /0A0!L>#?\
MD2]&_P"O*+_T$5M5B^#?^1+T;_KRB_\ 016U0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >9?#S_DH_BW_ *Z'_P!#->FUYE\//^2C^+?^NA_]
M#->FT %%%% !1110 4444 %<;\6/^2?WO^_'_P"A"NRKC?BQ_P D_O?]^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!YE\//^2C^+?^NA_]#->FUYE\//\
MDH_BW_KH?_0S7IM !1110 4444 %%%% !7&_%C_DG][_ +\?_H0KLJXWXL?\
MD_O?]^/_ -"% &QX-_Y$O1O^O*+_ -!%;58O@W_D2]&_Z\HO_016U0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,OAY_R4?Q;_UT/_H9
MKTVO,OAY_P E'\6_]=#_ .AFO3: "BBB@ HHHH **** "N-^+'_)/[W_ 'X_
M_0A795QOQ8_Y)_>_[\?_ *$* -CP;_R)>C?]>47_ *"*VJQ?!O\ R)>C?]>4
M7_H(K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8!YZ=:1M:L%O1:-<*)RVP+@X+8SC.,9QVH OT5F1Z_87$1>UN(Y<;#SE00Q
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M8!B1D;>.>O:IAK5@3;@7"EK@D1*%.6(Z\8R,9YSTH O45'//';0M+*2$49)
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M%%5$U.T>]-HLP,X_AP?3.,],X[=:9=:S865P(+BX5)#M&,$@%C@9(&!D],T
M7J*HQ:O:/#*[S1KY7WP"3@%BH[=R#4EMJ5I>3216\P=X_O  COC(]1GN* +5
M%95GKT%W?7$ &Q8IA K,&!=\9( (] >YZ4EUK\4$I6./SE";MRMCGS!&1^!/
MZ4+4#6HK/O=9M[&_@LY _FSH[J=AV@+ZG''6JI\36QDDBCC=Y8UA9L A2)"
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M_P E'\6_]=#_ .AFO3:\R^'G_)1_%O\ UT/_ *&:]-H **** "BBB@ HHHH
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M&R6,D<3QF, S;@N3GM][C'I185Q3X?N/LUE&)(@;>WCA;K@E71CCCI\IHN=
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M8+YIWVPVUV9+?RP/-,;  GDX/TZ<^M:5AJ>H+87D]W!(RQ1>;&[QK'O."2H
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M]9"2,R6_D>5;P;8X6SRX"C)QV]/PKG;/1=0O=&C@F6&!8UG$>=P8ERP&X8X
M!]\\=*!KVIVUC;2S/'.]Y DB".''E,S*O SR/F[GJ*LPW^L37%O;G$+;97)F
MB :4+MV\ D+G<0?I3%L*OAZZBN)VBD&2\DL$S7$A\MV!_P"6?W>,GG]*B7P]
M?*MS)^[,\SHT;M=R,T!"D;@Y7)Z], 8XIJ7%_>7EC$;MH;M&F6??"/W9V*0
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M-KS+X>?\E'\6_P#70_\ H9KTV@ HHHH **** "BBB@ KC?BQ_P D_O?]^/\
M]"%=E7&_%C_DG][_ +\?_H0H V/!O_(EZ-_UY1?^@BMJL7P;_P B7HW_ %Y1
M?^@BMJ@ K-N=1NEU"2UM+$3F.-)'9I@@&XL .A_NFM*LZW_Y&*^_Z]X/_0I:
M &_;=5_Z!,?_ (%C_P")H^VZK_T"8_\ P+'_ ,36G10!F?;=5_Z!,?\ X%C_
M .)H^VZK_P! F/\ \"Q_\36G10!F?;=5_P"@3'_X%C_XFC[;JO\ T"8__ L?
M_$UIT4 9GVW5?^@3'_X%C_XFC[;JO_0)C_\  L?_ !-:=% &9]MU7_H$Q_\
M@6/_ (FC[;JO_0)C_P# L?\ Q-:=% &9]MU7_H$Q_P#@6/\ XFC[;JO_ $"8
M_P#P+'_Q-:=% &9]MU7_ *!,?_@6/_B:/MNJ_P#0)C_\"Q_\36G10!F?;=5_
MZ!,?_@6/_B:/MNJ_] F/_P "Q_\ $UIT4 9GVW5?^@3'_P"!8_\ B:/MNJ_]
M F/_ ,"Q_P#$UIT4 9GVW5?^@3'_ .!8_P#B:/MNJ_\ 0)C_ / L?_$UIT4
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M[H:C+:V=B)_)1&=VF"#YLX &#Z5IUF6G_(PZE_UR@_\ 9Z #[;JO_0)C_P#
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M_$T?;=5_Z!,?_@6/_B:TZ* ,S[;JO_0)C_\  L?_ !-'VW5?^@3'_P"!8_\
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M4]SBH[72?"4VG?:IO#UI"5MEN7C:V7*J<_GT- RW_P +(\)_]!NV_)O\*/\
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M (61X3_Z#=M^3?X4?\+(\)_]!NV_)O\ "J</AG1+N1)X]%T.&S:4H@E@!>4
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MAK_H!:?_ -^%H J_\+(\)_\ 0;MOR;_"C_A9'A/_ *#=M^3?X5:_X0CPU_T
MM/\ ^_"T?\(1X:_Z 6G_ /?A: *O_"R/"?\ T&[;\F_PH_X61X3_ .@W;?DW
M^%6O^$(\-?\ 0"T__OPM'_"$>&O^@%I__?A: *O_  LCPG_T&[;\F_PH_P"%
MD>$_^@W;?DW^%6O^$(\-?] +3_\ OPM'_"$>&O\ H!:?_P!^%H J_P#"R/"?
M_0;MOR;_  H_X61X3_Z#=M^3?X5:_P"$(\-?] +3_P#OPM'_  A'AK_H!:?_
M -^%H J_\+(\)_\ 0;MOR;_"C_A9'A/_ *#=M^3?X5:_X0CPU_T M/\ ^_"T
M?\(1X:_Z 6G_ /?A: *O_"R/"?\ T&[;\F_PJC>_$#PQ+J6G2IK%N4BD<N<-
MP"C =O4UL?\ "$>&O^@%I_\ WX6J6L>%/#]CISS6^@Z69=Z(OF6XV_,P7)Q]
M: '_ /"R/"?_ $&[;\F_PH_X61X3_P"@W;?DW^%58O#6AP336]]X<TZ2:.,2
MJ;:V!\Q2<<*>A!]Z9_97A0W5O&/#5MY4L<CO*UJH$6PX8-Z$<YH N_\ "R/"
M?_0;MOR;_"C_ (61X3_Z#=M^3?X4ECX:\*W^\)X?M(W3!*2VH5MIZ-CT.#^5
M6_\ A"/#7_0"T_\ [\+0!5_X61X3_P"@W;?DW^%'_"R/"?\ T&[;\F_PJU_P
MA'AK_H!:?_WX6C_A"/#7_0"T_P#[\+0!1G^(WA1K>11K5ODJ0.&]/I6WH$B2
M^'M.>-U=#;1X93D'Y15+_A"/#7_0"T__ +\+6Q:VL%E;1VUK$D,$2A4C0851
MZ 4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YE\//\
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M$UU<PE85;84A(<DH5.3N/'.< #M7!_\ "OO''_0XO_W^EH_X5]XX_P"AQ?\
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M^_TM'_"OO''_ $.+_P#?Z6@#U.BO+/\ A7WCC_H<7_[_ $M'_"OO''_0XO\
M]_I: /4Z*\L_X5]XX_Z'%_\ O]+1_P *^\<?]#B__?Z6@#U.BO+/^%?>./\
MH<7_ ._TM'_"OO''_0XO_P!_I: /4Z*\L_X5]XX_Z'%_^_TM'_"OO''_ $.+
M_P#?Z6@#U.BO+/\ A7WCC_H<7_[_ $M'_"OO''_0XO\ ]_I: /4Z*\L_X5]X
MX_Z'%_\ O]+1_P *^\<?]#B__?Z6@#U.BO+/^%?>./\ H<7_ ._TM'_"OO''
M_0XO_P!_I: /4Z*\L_X5]XX_Z'%_^_TM'_"OO''_ $.+_P#?Z6@#U.BO+/\
MA7WCC_H<7_[_ $M'_"OO''_0XO\ ]_I: /4ZS]6L+C48&MDEA2WD4K)OB+-]
M5.0 ?J#7GG_"OO''_0XO_P!_I:/^%?>./^AQ?_O]+0!V-[IUS8.9K$RRSRM*
M,B(. KX/.6'.1U^O%2VOAYTTYX99QOEA@C;Y<X,8Y^N:XG_A7WCC_H<7_P"_
MTM'_  K[QQ_T.+_]_I: .QC\+'[1/++=*S2PRP[Q'\[!R#EB3R1CM@5++H-U
M*6_TV)1-Y1GVPGDQD8V_-P#CG.:XG_A7WCC_ *'%_P#O]+1_PK[QQ_T.+_\
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M_P"%?>./^AQ?_O\ 2T?\*^\<?]#B_P#W^EH#S/1M-M9(%GDFP)9Y3(P!S@<
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MG17EG_"OO''_ $.+_P#?Z6C_ (5]XX_Z'%_^_P!+0!ZG37=8T9Y&"HHRS,<
M#U->7?\ "OO''_0XO_W^EIP^&'B/4%\G6O%D\ML3\T:L[Y'T8XH =\+W6_\
M&/BG4K?+6LLN$?L<LQ_ES^->GUF>'_#]CX:TM+#3HRL:G<S,<L[=V)]:TZ "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g365892bci002.jpg
<DESCRIPTION>G365892BCI002.JPG
<TEXT>
begin 644 g365892bci002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 48 _$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M- &S15#1-9M]?TB#4;,2""<$J)%PW!QR/PJ>_O[;3+&:\O)1%;PJ7D<]A0]
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M6]A0 ^BJNFW<M]IT%S/:RVDDB[F@EQNC/H:H>*->?P]IL-TD"SF2YB@VEMN
M[8ST[4>0&S1535-1ATC3+F_N0YAMXS(X09.!Z"J.C>*M/US0Y=6M3*EM%O\
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MU;:CJE[;S&T#BW@M;40QAFX+D9.6Q26XGLRO\4M/M[KP9<7$T DEM2K1MSE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (0&!# $'
M@@]Z;'&D,:QQ(J(HP%48 _"GT4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3617QN4-M.1D9P?6G44 %%%
M% !3&AC:596C0R*"%<J,C/7!I]% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*DFX-VDF".@VCGF@#I**QO$&J:MIHMSI&BMJAD+>8%N%B\O&,=>N<G\JQO\
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MN?"$EO \BK),;Z-O+4GEL <X]*V]<O;_ $_3C-IFFG4;C>!Y E$?!ZG)XXH
MT:*XW_A*?%G_ $),G_@PC_PJ>P\1^)KB_@ANO",EM!(X628WL;>6O=L 9- '
M5T5D>(-2U33886TG1VU1W8AT$ZQ;!CKD]:Q/^$I\6?\ 0DR?^#"/_"@#LJ*Y
MK1]>\07VIQP:CX8>PMF#%K@W:2;2!P-HYY/%7?$&IZKIJ0'2=%;5&<D2!9UB
M\L#H>>N: -BBN-_X2GQ9_P!"3)_X,(_\*O:+KNOW^I+!J7AE]/MBI)G-VDF"
M.@VCGF@#I**P=?UC6M-NHH])\/OJ<3)N>07*Q;#GI@]:R_\ A*?%G_0DR?\
M@PC_ ,* .RHK!T#6-:U*YE35O#[:9&B!DD-RLN\YZ8'2DU[6=;TZ\CBTKP\^
MIPM'N:4721;6R?EP?;!S[T ;]%<;_P )3XL_Z$F3_P &$?\ A6MX?U?6=2FG
M75M!;2T104<W*R[SSD8'3% &Y17-:QKWB&QU.6#3O"[W]LH7;<"\2/=D9/RG
MD8/%4O\ A*?%G_0DR?\ @PC_ ,* .RHK)T#4M3U*WF?5M';3)$?:B&=9=XQU
MR.GI65?>(_$UO?W$-KX1DN8(Y"L<POHU\Q>S8(XS0!U=%<;_ ,)3XL_Z$F3_
M ,&$?^%=%HE[?7^G+-J>G'3K@L08#*), '@Y''- &A17)7?B3Q/#>3Q6_@^2
M>%)&6.47T:^8H/#8QQGKBHO^$I\6?]"3)_X,(_\ "@#LJ*H:/>7M]IB3ZCIY
ML+DEMUN91)MP>/F''(YKG/\ A*/%F?\ D29/_!A'_A0!V5%<;_PE/BS_ *$F
M3_P81_X5U%E<7,^F13W-H;>Y>,,]N7#;&Q]W<.#]: +5%<8/%/BW'_(DR?\
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MYYJ?7]7UK3;B%-)T!M3C="7<7*Q;#GI@]: -VBN-_P"$I\6?]"3)_P"#"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !15/5[B2TTB[N(6"R11,RL1G! ]*QY+
M^Y;3[62UU&YN(WF(FGBM0[(NPG&T+TSCG'>@#I**PK^]N([&TNK&_$WF,B1Q
M^6N+@D\Y[CC)XQC%/O[RZL=6B"W'G1NDDCV_E@>6BJ3NR.?O8'/7/M0!M45@
M0:K<66Q]0F$R3VWVA55 "K9 V+CKG< ,\U/I.IR>1-_:UQ;QS_:7C49"CL0H
MSU(SCWH%<V**Q-/GN[N2Y@N;V2WO #^Y\I<1C/#(2/F!'?G\*BM9[R72KN[F
MU218(I7,<PACW-&HP>,8Y(./PH&=!17-75_?6.B6=S=:@8[MT&(O(!$KDY"M
MQQP0,C'K5RYN[NTUBW7[1YL<JN\EOL'[I%7[P8<_>P.>N:'H!LT5BZ9>WC7-
MH+J99%O8#,JA /*(P=H/<8;OSQ6U0%[A1110 4444 %%%% !1110 4444 %%
M%07MY!IUE-=W<@C@A0N[GH * )Z*\O3X@^*?$D\C>%-"1K*-BHFG!.[\<@ ^
MW-2_VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!
MZ717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 70!Z717FG]L?$[_H"V'Z?
M_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_ ,71_;'Q._Z MA^G_P 7
M0!Z717FG]L?$[_H"V'Z?_%T?VQ\3O^@+8?I_\70!Z717FG]L?$[_ * MA^G_
M ,71_;'Q._Z MA^G_P 70!Z)>6JWMG-;2,RK*A0E>HSZ57%A="V$7]J7.\-G
MS?+CSC'3&W'Z9K@_[8^)W_0%L/T_^+H_MCXG?] 6P_3_ .+H [,>'UBN;>6V
MO+B(6\>Q$PC#DY8_,I.3W-2Q:,8]1N+HWDSK<']Y$ZH1MQ@*#MR /3/<UP_]
ML?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T =O!X?M4&VY+7B*@CC2X566- <@ 8
MY[<G)X%266A:?8"406L($DIE(\M>#[<>U<)_;'Q._P"@+8?I_P#%T?VQ\3O^
M@+8?I_\ %T =T-))GDFFO+B60QM'&QVCRE;&<8 YX')STI[Z1;OI46GY=;>,
M(, \L%(.#]<<UP7]L?$[_H"V'Z?_ !=']L?$[_H"V'Z?_%T =[?Z<U_E&NYH
M[=EVR0H%PX^I&1^!J*#1C;ZE/=K>3,)C\\3*A&T# 4';D >F?6N'_MCXG?\
M0%L/T_\ BZ/[8^)W_0%L/T_^+H [NQT>.QF$@FFE$:>5"LA&(D]!@<]!R<GB
MM"O-/[8^)W_0%L/T_P#BZ/[8^)W_ $!;#]/_ (N@#TNBO-/[8^)W_0%L/T_^
M+J.X\4_$72XC=WV@VLEM'S((QDX[GAB1^5 'I]%8GA3Q1:>+='6^M 48'9+$
MQR8V]/\  UMT %%%% !1110 4444 %<=\5W9?A_?;3C<T8/N-PKL:XWXL?\
M)/[W_?C_ /0A0!J^"(8X/!.CK$@4&TC8@#J2,D_F:W:Q?!O_ ")>C?\ 7E%_
MZ"*VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \R^'G_)1_%O\ UT/_ *&:]-KS+X>?\E'\6_\ 70_^AFO3: "BBB@ HHHH
M **** "N-^+'_)/[W_?C_P#0A795QOQ8_P"2?WO^_'_Z$* -CP;_ ,B7HW_7
ME%_Z"*VJQ?!O_(EZ-_UY1?\ H(K:H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHJCK=U)9:%?W, )EAMW=,>H4D4F[*XTKNQ1U7QIX?T2Y-OJ.JV\,PZQY+,
M/J!G'XUH)JUE)I/]II<QM8^69?.!^7:.]<E\+M'L?^$0@U%XHY[R^+27$T@#
M,S;B,9/TJ/XHWZ6?A^TT2TV0OJ<ZPX7"A8\@L?8=*;36G42L_0ZBR\3:3J&C
M2ZM:7J26,.[S)0K#;MY.01G]*R/^%H>$,9_MJ+'KY4G_ ,36-X4:T\/^/=1T
M&VDBDT^_A6YM@C!E# 89>/H3^%2SV\/_  NJVC\F/9_9A.W8,?>/:CL!U-QX
MIT>TT.+6)[Y$T^;'ES%6PV>F!C/Z5HVMW!>6D5U;2"2"5 Z..A4\@UY_XMDM
M-<\>:5X>N'BCT^SC:YN59@JDD85?U_6K7PPU$G1;[1)I%>;2IWB4A@=T9)VD
M'TZT=&P[&HOQ)\*//Y/]LPA\[<,CJ,_4C%=')=0Q6C73RJ(%0R&3.1MQG/Y5
MXCI<VH-\/=3M8M#2>R>XE\V_+*QA&1DA/O''6NE\8:I;Z7\+=,TW3+SSQJ$<
M=M%,>"R8&YO;T_&CI]WXCMJ=]HVO:=XALVNM*NEN858H64$8/I@@'O4.L^*-
M&\/;!JVH0VS.,JK$EB/7 R:X_P +_9?"_CR32+2:%['4[5)8A&X8+,@PPX]1
MDTOB33=4T/QO)XGM]*76+*2W$4D0/[R''4J#_GDT/H)'73>*M&@T:'59+^/[
M!,X2.90S!F)P!P,]JDUCQ'I.@0I+JM]#;+)]S>>6^@')K@O&VMV'B#X:VE[I
M:>7 ;^)3&5"E&!.00*O^+-(U6T\5V/B6PTU-6@@MO)DM2?F3K\R@_6C^OP [
M72]6L=;LEO--N4N+=B5#ITR.HJEK?BW1?#D\4.KWZ6TDJED#(QR,XSP#3/"7
MB'3_ !'I37.G0FWV2%)H&0*T;]P0/YUR7CC4;?2?B5H%Y=PRS0QVLNZ.*+S&
M.<CA>]#W2#H=G'XIT:;1Y]5AU&&2Q@&994);9]0.?TJT=5LQI']J&<?8O*\[
MS<'&S&<XQGI7E$UC<2:/XVUI-/ET[3KV!5@AE386((RVWM_]>KK^*[T_#LV'
M_",ZL(O[/\K[7L7R\;,;\Y^[WH>UQVU7]=CTVQU"VU'3XKZTE$EM*F]),$ K
MZ\U5T;Q'I7B%9VTF\2Y$#;9-H(VG\0*X>YUS^PO@A921MB>XM5MXL=<MG)_
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MH **** "BBB@ HHHH \R^'G_ "4?Q;_UT/\ Z&:]-KS+X>?\E'\6_P#70_\
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M+F+;!9FWDC"G+,<\@^G-5;7P;<V.K^();6[B6QU>)OW!4YCE(QN],<FNOHH
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M^?):8\QE4[.>.&Z'IVJE>_$/P[87\EI/?'?$VV5TB9DC/HS 8%8?@FTM]/\
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M^DZK<W5W(3UP?NC\OYU5O>L3TN>S4444@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \R^'G_)1_%O_ %T/_H9KTVO,OAY_R4?Q;_UT/_H9
MKTV@ HHHH **** "BBB@ KC?BQ_R3^]_WX__ $(5V5<;\6/^2?WO^_'_ .A"
M@#8\&_\ (EZ-_P!>47_H(K:K%\&_\B7HW_7E%_Z"*VJ "BBB@ HHHH ****
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MNH5CR :Z#PSXBA\3Z8][;P20HLSP[9",Y4]>*V*+!<J:7IL&CZ7;6%H"(+=
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M?]>47_H(K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW#L<39?\EMU'_L&I_,57NXH;/XW6']G@*]S9N;Q4Z'@X)]^!^E:NK^!KJ_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \R^'G_)1_%O\
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MLQP!^)HN;N"SB$EQ((T+J@)_O,< ?B37,>)'NM-T6.ZU>]BFBCN[>1C% 4V
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MU@-Q;7<<<D=L+AK(VKR/TSAV7[GXU;CU#4-8OIHM/FAM(;98][R1>8SNZAL
M9   (YHL!LPW<%Q)-'#('>!]D@'\+8!Q^1%35QL4FJ6]WXDN;.:WCCMI_,*O
M&6,I$*DCJ-HX]ZVM1U::#0[74X%41EHI)E89(B8C=CW&<_A1_P  #8J,31&<
MPB1#*JABFX;@#T./3@U@?\)%-#XDN(+@1C3A#)Y+@'<9(\&0$^F&X^AK/NK_
M %*ZL;^.1X;>X_LD7+.D7S#<7^7.?0 >QR:.EP.MDNX(KJ*V>0":8,8T/5@N
M,_ED5-7&>7J'VWPRD=U$UP]M-F9X^%4HA^[GD]!UK>T6^N;V&]@NFC-Q:3M
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M-I)76-%&2S' 'XTI=50NS *!DL3QB@#CI]+&HVEW<0#5WO(X5V?;DV X</M
MP,G*^_6K&I3M+<)J&AQ7WV^:.,@I$3!.O99">!C)YX(KHXK^TFB,L5U \:G!
M=9 0#Z9H>ZL[1T@DG@A=_N1LX4GZ"@#-L5-WXFOKT#]U#"EHI'1F!+-^60/S
MJ*[CFA\5O-]GF>&XL/(61$+*'#,<,1TX/>MLF*WB9B4CC7+,3@ =R34<-_:7
M$;R0W4$D<?WV20$+]2.E '-PZ?<Q^&?#<"VTBR6]Q TJ!>8P =Q/IUYJI;:0
MRF;3=1_MDA[MG'D &!U,F]6W <=LY.>*[1I8T0.[JJ'&&)P.>E$DT<(!ED1
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M?#S_ )*/XM_ZZ'_T,UZ;7F7P\_Y*/XM_ZZ'_ -#->FT %%%% !1110 4444
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MGVVZDM[J2WCNMKN8L;ED7C(R",$8!^E1+X=2-XE\YY8S<?:KAY3EYI  %S@
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M-6M0TJ_U@WVH1VT\!9[<Q0-((Y)!$Q8G(/RD[B!SVH WHO$%C);W$LCO;BV
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M!&DW^LW5]*8)YK2">>0+N*R.7P .Y'"@>U31:EK!N+ZQLC>/+]E6>'[:D:R
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M*L>'K1X?$6NNUY<R@3H-LA7!S&ISP!TZ4[:AT.EHHHI %%%% !1110 4444
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MY5Y9)VA6%GD?<6522,^_S'FJQ\-V7V2V@C:>$VS,T,L<A#IN)+<^ASTK6HH
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MDP63CY6]1\HJQJ&G0:G L5P&^1@Z.C%61AT92.AJU10!DCPW9&SNH)3/,;L
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M "BL[4=<MM,U'3K*=93+J$C1PE%! (&3GGBM&@ HHHH **** "BBB@ HHHH
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ML[I+ZR@NH@PCFC610PP<$9&: )Z*SM#URV\0:>;RS658A*\6)% .5.#W-:-
M!1110 452&K6AUDZ5YA^V"'S]FPXV9QG/3KVJ[0 4455;4K1-233VN(Q>/&9
M5AS\Q0'!./2@"U163I'B.TUR[NH;&.X:.V<QM<-'B)V!P0K=R*UJ "BBB@ H
MHHH ***SM8UJVT.&WDNEE*W%PENGEJ#\S' SSTH T:*** "BL23Q9IL,FKK,
M9HUTG9]I<QY'S#(VXR3^5;$4BS1)+&<HZAE..QH ?1110 45'Y\7F-'YB&1%
MW,@/S >N*KZ5JMKK6GQWMA(9+>0D*Q4J>#@\'GJ* +E%%% !15/5=5M=%L6N
M[Z0QP*RJ6"EN2<#@>YJWUH 6BBB@ HHHH **SK[6[;3]5T_3YEE,U^SK$54%
M1M&3DYXK1H ***8\T<;HDDB*TAP@9@"Q]O6@!]%9UCK=MJ&K:AIT*RB:P*"4
MLH"G<,C!SS4ESJUI::E9V$TA6YO-WDJ$)#;1D\]!QZT 7:*** "BBB@#S+X>
M?\E'\6_]=#_Z&:]-KS+X>?\ )1_%O_70_P#H9KTV@ HHHH **** "BBB@ KC
M?BQ_R3^]_P!^/_T(5V5<;\6/^2?WO^_'_P"A"@#8\&_\B7HW_7E%_P"@BMJL
M7P;_ ,B7HW_7E%_Z"*VJ "LGQ1%')X:U-GC1F6UEP64''RFM:HKJVBO+66VG
M7=%,A1USC((P:4E=6&G9GF^JQ(GP-MGC1%=K:WRP7K\Z]:V+.XU32?&MIIUS
MJ<M[!?6+S,LB*!&ZX^Y@<#GI70S>'--GT!-%DMR=/1558M[<!2".<Y[>M32:
M/93:I!J+Q$W4$30QON/"-U&.E4W=MDK2*1P%IJ7B2_\ !.DWEO/>3Q>=-]OD
MMBGVDH&(79NXXQ7<^&]0@U3P_:75K<S744B<2S !VP<'<!QFJQ\&Z*=-@L/L
MT@MK=F:-5GD4C<<MD@Y(/H:UK.RM]/M(K6SA2&")=J1H,!10-[GFPO\ 6KC1
M/$>IKXAFA;2KR;R8=JE<+R%?(R0>@%:(O]9U[Q38VMOJ4NGP7&E17<RHH)!W
M<A<]">F?2K&B^ +.1M0EUZPCDEEOY)H\2G#QDY7< <'OP:ZI=(LDU8:DL.+L
M0?9PX8X$><XQTZTET_KH#Z_UU.'&I:OJ^G:[K2:W)8'3)Y8X;547RU$?_/3(
MR2U0^(?%NJ:9IVD:]:S,7U"S(ETYLE4.W/G 8R IZ^U=??>#="U&^>[NM/1Y
MI"#)AF59".A90<-^(JVV@Z<^HM?/;AYV@^S98DJ(^ZA>@!]A2Z?U_6H[Z_U_
M6ARM]=WV@V7AC4CJ\UY9F18KZ1F!642#A^G0'I[5K>#[VZU1-0U.YN':WNKI
MULXF/RK$GR@CZD$U5U_PQ*/"H\.:%8Q&SGRC//<'%L,@[@#DGV J]%X2@AU#
M1IEE/V?28&CA@V\%R -Y/K@?K5=_Z_K_ ((NG]?U_P ,-\=7%]8>'QJ.G3R1
MO93)/*J?\M(@?G4^V#G\*YX>*;I/%AU9[YCX?>9K)8^-@98M^_/N<BN_N;>*
M[MI;>= \4J%'4]P1@BL=O!>AOX>70VL@=.5]XB\QL[LYSNSG]:0SB)?[3U!?
M!D]S>2+>7MY/,LCJ&,2,N0 .G"]*NS>(]6T#3/%4!O'O9=,EB6VGF4%U$@'W
ML8!QFNWFT.PN)M/ED@R^G'-MAB!'QMZ9YX]:1= TX3:A*;97;4<?:@Y++)@8
M'!XZ>E#\OZV"^W]=SD=)O]?AO)EDCUAK![.1WGU!(@8Y0,@H4/0^E4-.U/7;
M;0_"^LSZS-<-?7$=O-;NB[&1B1GIG=QUKM;#PGI&F-(;6V93)&8CNF=L(>JK
MDG ^E/'AG2QIMC8"W/V:PD62W3S&^1EZ'.<GKWIW_0DC\97<]CX/U6YM96BG
MBMV9)%ZJ<=17+Q:EJVEWOA>ZDUE[Y-898I[=E78,IG<F!D8[^M=7XKT^XU7P
MKJ5E9J&N)X&2-2V 2>G-5-!\&Z5I/V2[6Q1+^*%4+;RP1L?-M!.!DYZ4EN-_
MYG,6&L:W#HFNZ]+J$D\>FS744%H5&&PW#,>N%SP/059^W:MH;>'KY]:DU(:M
M-'%/;NB[?G7.Z/ R-M=E8:+8Z;;7%O:P!8;B1Y948E@S/][KZ^E4M.\':'I5
MZMW9V"),F?+)9F$>>NP$D+^%"Z?+_@@^OS_X!QWVS6;NR\4WJ>(9K?\ LJ[E
M,$0"D849 ?(Y4] *==>*-6U?4;&UC35(D;38KMUTU(S(SOW)<_='H/6M/2O
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MGAW2V+%K<AB-A(P>!UX]:%H#U/,)/^15O_\ L:1_Z,6O1O%?_(I:O_UYR_\
MH)IA\)Z0;22V-J?)DN_MK+YC<RYSNSGU'3I6G=VL5]9S6MPNZ&9#&ZY(RI&#
MR*EJ\;?ULD7?WK_UN>;Z;>:GHFD^$KZ/5WN8K^2&UDL]J^7L8?P\9RN.3FHS
MXA\2:E+?WNG1:M)/;WCQ000Q1&UV*V"KY.XL1GGMFNUL/!6@Z;>075IIZ)+
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M2FNOL-@+FWNV $L9/\+$#!/<'%3V=YK&FZWX9:ZU:6\CU>)EGA=%"(1&&!7
MR/ZUTT'A/1[;2[K3X;,+;W8(G^=B\O;ER=Q_.IY-"L))M.E>$E].!%L=Y^3*
M[?7GCUH6_P#7F(R_']_=:;X5EN+*=X)A-$H=.N"X!_2L?6]2U/2_%1GU>YO[
M;16>)+26S"&/<>HE!&[D^E=CJFE6FLV36E_%YL#,K%=Q7D'(Y'N*IW/A72+S
M4Q?W-IYLX8/\\C%-PZ'9G;D8ZXH6X/8B\;7EQ8>#-4NK.5H9XH"R2)U4^HKF
M5;75\1Z1I[:_<%-5LFFG/EIF,J ?W?'&<XYS7<ZCIUMJVGSV-['YEO.NR1-Q
M&1]1S47]B6/]H6=[Y)^T6<1A@;<?E0X!&,X/0=:$#..TWQ#<#PE<IJ6IW0N8
M]2>PAG@B5IYL-PH&,;B,\U1/BO5])L?$T7F7;O8P0RVYOU3S8BYP=VW@@=:[
M5O"6C/8363V8:":X-TP+MD2GJP.<@_2EM?">C69N?)LEQ=1"&<.S,)%&?O9)
MR>3SUH'_ %^/^1QTMI=V?C/PE]JUB741*LL@\T+N4F/D@@#Y3V%5;/Q%XEU-
M#J=C#JTTWVLJ($CB^R>4'P5.3NW8[^M=K8^"="TVZMKFULMDUL28G,KL5R,8
MY/3';I3Y/!^BR:@UZ;(+,S^8P21E1F_O%0=I/U%/J2;(8'COW'<5P?C+3'N?
M'GALC4;V'SWE4"-P!%M3JF1P3T/6NGTC05TO4M4OGF,T^H3"1B5QL4#"H/I4
MVL:!I^O0QQZC!Y@B;?&RN49#ZA@012ZIC[G#?9+Z?Q3XRDLM3FL1;I%)F)5+
M.PC)&21TXY ZYJY8^(M1O[WP5(]PR#4+>9[F->%D8)P2/KS76Q:#80SW\T<)
M$E^JK<'>QW@+M'?CCTJ*#PSI=L=-,-L5.FHR6O[QCL##![\\>M"_K\0>YS7A
MG4M2@\2"Q\2W.H1ZE/YC10D(;65 >-A R"!ZUW=9&G>%M)TN^-Y:VN+C!42/
M(SE >H7<3@?2M>CH'4**** /,OAY_P E'\6_]=#_ .AFO3:\R^'G_)1_%O\
MUT/_ *&:]-H **** "BBB@ HHHH *XWXL?\ )/[W_?C_ /0A795QOQ8_Y)_>
M_P"_'_Z$* -CP;_R)>C?]>47_H(K:K%\&_\ (EZ-_P!>47_H(K:H *R/$'B2
MU\-Q6LMY',Z7,X@7REW$$@XXZ]NU:]<7\1A<$: +,QBX_M2/R_,^[NP<9]J.
MP&C!XULY8]2$UI>VUSI\/GRVT\861H\9#+S@Y^M11>/]-ET[[;]GOA$[I';@
MP_-<NPSMC'\6.A/2LZ3PWK>J76MZGJ$5K!<W6GM8VUO%*6&.3N9L#J:L7OA:
M_DT+P\UHT":EHVQUCD)\MR%VLI(_0T>OD!I6GBZ"\2]C6QO8[^SC\V2QE0+*
MR]BO.#GZU#I_CG3]6FM8M-BN+F2>W:Y=4 _<*.,/SPQ/ %4X-)UXZM?^(KBW
MM5U%K/[+:6:394<YR[D#//M5;PSX2U/PIK45S%)%<P7T6=3+,%*39)WIQ]WD
MC%']?F!KQ^-[";0;#4XH;AQ?7"VT4  \P2%B"",XXP<\UM:C>C3M-N+QHI)1
M!&TACCQN8 9.,]Z\_P##FD>;\0[Z*":.;2-.F:\A\LY59IE&5R/3YC^->D,H
M=2K %6&"#W%#VT#J<U>>/=+L[;2)V2=X]4 :,HH/EJ<#<_/ !8#O4'BCQ-;)
M8ZW:"74+9M/CB>:YM NY2[#"KD]<=<]JQ]/\ Z@MOJ]G>M$;=;9[73"KY*JS
MEP3Z$';^52GPCK-SX#U>VNU@;6]3E$L@$GR<%0!N_P!U:!K1CKVYF_X2S6U6
M>;8- #J"YX/S?-CH#[UT/@F1Y?!6CO([.[6J$LQR2<=S6;<>'-0DU[4[M4C\
MFXT<6<9W\F3G@CTYZUM>%]/GTKPQIMC=A1/;P+&X4Y&0/6FMG_75D]5_71'*
MIXA;2?'OB17M[^] C@=8;=2^Q0GS-@D ?UK?D\9Z<=/L+FS2XO7U $VT$"9D
M?'WL@D 8[Y-94VD^([#Q7K>J:7;V4\-]'$B)-,5.57&[@'@<\=ZSI/AQ<6^D
MZ+L\F]N+!91/ TSPK+YAW':Z\K@_G26R'U.UT;6K;7+62:W66-HI#%+%*NUX
MG'52*9_;T \2G19(Y4G-O]H21@-DBYP0#G.1]*K>%-%&C64^=/AL9)Y=[1Q7
M#S9X !+-W^E4_&^A:EJ45I>Z"8EU2U+HID;:#&ZE6&?R/X4,$/7QWIK:<+Q8
M;IA)=/:VT:1AGN74X)0 ]/<XH/C2*73M0>VT^\_M"Q0-+8R(%D4$<-UP5]P:
MIW/@ZYL]-\/-H[0F\T7D1S$A)MRX<$CH2><U+IOAW4;K5=5U?5_(M[F^M1:1
MP0L7$2<\EL#)R:'U&ANB^-S+X3M=3U:SN(IIV6.)(T!-R[=/+ )./KCI5Y/&
MFG)87]Q>QW-D^GA3<03IB10WW< $@Y[8-<Y_PA>KWOA+3]+O(K5)](F5H")V
MV72 $')7#(2#4C> Y+W0M3@33[;2[NX6/RV%Y)<%BC;AO+=LCM3>[$MD*WB%
MM6^(/AQ%M]0L@89W:&X79O4K\IP"0>GX5U/BBY6S\,:C<//<P+' S&6VQYJ^
MZYXS6#!I/B*_\6:+JNJ6]E!%912QND,I8Y9<;N0.IQQVK=\5Z=/JWA;4K&T"
MF>X@:- QP,GWI2^$<?B5S.;QA:Z>^G:?]GU"\N;FR6XBV1AGD&!UYX;N>WO6
MMH.NVOB'31>V8D5=[1NDB[71U."I'J*QK#P_?6_BC2KZ1(_(MM*^RR$/DB3(
MZ#TXZU:\&Z-=Z+8W\5ZJ*\]_-.FQMWR,<C\:;W^_\_\ (73^NQ=U;6FTMT2/
M3;^]9E+'[+$&"@>I) _#K5*;QMI<>BV6HQ^?.M\_EVT$4>99'[KM[$8.<U3\
M1Z%JVI:]%-&([O3C#Y?V9[IX!%)G_6';]_CM659^"]8L=#T22#[-_:>D7,TB
MQ.Y\N5')R-W8XQ27F-G0W?C&"R@LQ-I^H?;[S=Y5@L8,WR]21G 'OFG7WBVW
MLFM8/L-]-?W,7FK911@RHO<MS@?G69?:5K\^JZ=XB@M;-=1MXI()K)IR4:-C
MD8?'!_"GW6DZY#KL'B&RM[1[R2T^S75F\Q"CYL@J^.WTH$6I?'>E1:&NJ'S_
M "1<BUE0IB2%\X(93TQ37\<VH:UB33M3DN[E6D6U6#]ZL:G&]@3P#V[UBW/@
MG5)=$E\QK>74+S5H[^X16Q&B@_=4GK@#\:U]7T;5K?Q?#KNC1VUP7MOLL\$\
MA3 W9# X/Y4?U^'^8?U^/^1G^"=;(T36;\QWMVK:I*(XD4O)@[<#:3QC/X5K
M#QM9+I^IW$]K>6\VF()+BUE0"0*>01S@@_6L*V\*>(K?P[>6ZS0I=3:HUW(D
M4S1K<1'&4##E<G^50_\ "$:J+?Q&L=K;0C4K%(H(EN&<*XSD%FY/UZ4=/E^@
M]&_G^ITFG>-;'4=2M;,6U[ ;R,R6LL\6U)@!D[3GM[U)8>+K;5-2DMK&TO)K
M>)VCDO1&! K+U&XG)^H&*IW'A^^DU/PK,J1^7IL;K<_/TS&%X]>14/A_1-:T
M))=%:&UN-(DDD9;H2E9$1\G!3')R>N:;)1=MO'%A<W$ %M>I9W,OD07KQ8AE
M?)  .<\D<$C!K;U*]&G:;<WC122K!&TA2/&Y@!DXSWK@M'\ 3:?+:VMUI=I=
M16\H87IOIERH.0?*Z;A^5>B,H="K %6&"#W%)[:#ZG-WGCS2[.WT>=EG>/50
M&C**#Y:G W/SP,L!WJ#Q1XEMDL=;M!+J%LVGQQ--<V@7<I=AA5R>N.N>QK'T
M_P  Z@MMJ]G>M$;=;9[73"KY*J7+@GT(.W\JE/A'6;GP'J]M=K VMZG,)9 )
M/DX*@#=_NK0-:,T+KQ=?6WC&RTB+2[J6VD@+F0!=TG3YQ\WW1GGOZ5E:3XMC
MT*[\2M>17]U%#J3F1XD+K;QX !))X'7@5MZIH^J1^)=)UC3H8+C[/;M:SPR2
M;"%8C+ X.<8Z53;POJ)T'Q;:!(O-U.XEDMOGX*LH R>W2CS]?S0+6R]/R.RA
MF2X@CFB;='(H96'<$9%<AI_BV_U/Q#K&FS:7<P06T8".0H,7R$Y<[OXNV/QK
MI](MI+/1[*VF $D,"1N <C(4 U@)HVJ67B_5;N"*":PU2)0[F3:\+*A4#;CD
M&B2U:]1+8Q_!/C*WM/#.B6U]%?MY[>1]L="8O-+'"EB<GZ]*Z'4?&EE87=U"
MMK>W,=EC[7/;Q;D@XS\QSD\<G&<5BIX3U1? FA:5Y</VNRNXIIAYGRA5<L<'
MOP:AU'P).-<U*YCT^WU*WOY/- EO98#"Q'((7AE_6F]_Z\@6QWT,T=Q!'-"P
M>.10RL.A!Y!KR_4O%NK0:AKYC\10P3V-T8K/3G@1C<#C"CC=UXKTS3[5+'3[
M>UC18TAC5 BDD+@= 3SCZUY_=^%M>:[\000Z7IDT.JW#/'=3S?-"I&,[0,Y[
M]:3WT&MM3J+KQ6FGBRMIK*ZN-5N(!,UG:IN=!CYB<D  'CDU+;>*K.^T=]0L
MH+NXV2>2]O'%^^23."I4],?E6/\ \(WK&BZE9:GI;P:A/'8)97,=Q(4,FWD.
M&P>_8U6;PCKD6C7#Q7,1O[W4/MEY#%*T22)T\I7'([<TW_7W_P"0E_7W?YFQ
M_P )M9+INIW4]K>02Z8H:YM94"R*#R".<$'US3'\>Z>MC'<K:7[>?.(+6,0X
M>Z.,Y0$\K[G%<\?!&JBR\2QQVUM%_:5K&EO$MPSA6&<J6;G\:V]<\.ZC-!H-
MYI@@-]I!!\B5L)("@5ESV]C0!6\*ZJVJ>/\ Q ^+J*-8+<>1< J8VP<_+G ^
MHZUTFMZ]::#;Q277F.\T@BAAA3=)*Y[**QO#FCZO;^*]7U;58[9%O8HE187W
M;=N1M.0,XXYJSXJT*[U.?3-0TUXOMNF3F6..8D)(",,I(Z>QI=$/J_ZZ$?\
MPF,=Q8:@+>PODU*SCW/92(JR@'HPR<$>X-4OAC)+<^&A=W"7QN+@[Y)[F7>L
MQY^9!DX';&!4VGZ#JESK&I:WJJ6\%S<V?V2&VAD+A%Y.6; R2:T_!VF7.C>$
M].T^]"K<01;7"MN&<GO30F9/B.\U:7QKI>CZ;J;6$5Q;22NRPI(25/'WA45E
MK^J6FIZKH6ORH\T-FUU!>6J;&>/!!^4G 85/XBTS6?\ A+]-UC2+.WNEMK>2
M%TEG\OEC]#4=EX7U6>\U76-9EMVU&[M&M8(("?+A3!XR>I)[U/3[QO?[@M?&
MECI6AZ()O[2O&OK=GA=HP\TI7'! /+'/:K]WXUM;:5XUL-0G:")9;OR80WV8
M,,X?GKCL,FLK2_"NI6L_A!YHX=NE6\L=SB3.UF7 QZ\U!J_@>=O$5_?Q6$&I
M07Y5BDE[+;F%@,'[O#*?SJI;B6R-^^\96%K)9PVD-UJ-Q>0^?%#:)N8Q_P!X
MY( 'UK/E\8WX\:VVDKH]V+:2#S"2J[SD@;_O<*,\]\]JB;PUJ>B:K9:GH-M9
MR;+%;.:R>9E4 '(*.03P?6K=_I>L#Q5IFN6MO;2D6OV:Z@:4KY>Y@2RG'..>
M*.O]>8=!]UX]TZVFN=MM?3VEHYCN;R&'=#$PZ@G.3CO@'%2:EXUL=.U*&Q6W
MN[N:X@6>$6T>_P Q2<<<_CGIBL3_ (1CQ!I^F:GH6G"QDT^_ED=+J60AX5D^
M\"F/F/7!S6IIWAB?3?%=C<Q[7L;32A9AV;YRP8=OH*2Z?UT!_P!?>7;3Q7;Z
MAK$UC965[.D$I@FN40>5&XZ@DG/X@5/X?_M7R+S^V3F3[7)Y'W?]3GY.GMZ\
MUS\WAC49O&,&HVEI;:8D=P9)[F"X8F[3^ZT> ,GN37;4+8'N8.N^+K30-0@L
MI[>[GGN(FDB2WCWER"!M SG//TXJ&\\;6=G/<(+._GCM #=RPQ!DMLC.&YY(
M'4#.*DOM'NKCQUI>J(J&UMK6:-R6^8,V,8%<[J/@2<:WJ5PFG6^I6]_)YH\V
M]E@,)(P00O##]:!G1ZAXPL[2]@L[2WN]1NIHA.(K1 Q6,]&))  --O\ QE:V
M=[):0V5_>SP()+E;:+=Y"D9^;D<X[#)K-;P[JNA:\NIZ#;6D\<MG':S6LLS)
MLV?=*L0>/8TO]C:_HVL:E>Z1#97":KLDE2:4H8)0N"0<'<OMP:&(OW/CC3((
M]+DA2XNH]4#?9S FXDJ/ND9SGM_.J9^)&FBUFG:QU(+:R>7>#R/^/4YQ\_./
MRS5;3O!5YI,_A=(WCGCTYIY+J3./FD'\(],FF7/A/4Y= \6VBI%YVJ732VW[
MS@J=O4]NAI@C:U'QE:Z?JJZ<EG>W=P]M]IC6VC#;US]1CUYJK;?$/2[H64D=
MO??9;N40"Y:'$:2GC8QSUSZ<4^ST&]A\7PZBZQ_9DTI;4D/SY@8'IZ>]9$7A
M'54\%Z9IICA^U6^I+<R#S.-@D+=>YP>E'7^N_P#D#V_KM_F;NH>-;*PNKJ(6
MM[<161Q=W$$6Z.#C/)SDX')P#BDOO&EG9ZJNGQ6EY>7#VPN8A;1AO,0^G/X\
MUS^H>!)UUK4ITTZVU.WOY3,/-O98#$2/F#*O##/XUN:=X>N+'QBEZD426,>E
MI:(%<DJRMG SSC'<TE_7W#8]_'6EC0;75(Q<2B[E\F&W2/,KR9P4V^HQ61H.
MMM>_$#79FCO8HX;&(M;2J0R,,YPN<9/MUJM;>"]9M=#TYX1;?VEIVHRW:1._
MR2HY/!8#@X-6HO#WB2?6-=U&22UL;F_L4AMWAD+>2XSP>,_C3_K\ \OZW-JV
M\7Q3WWV*73=1M;IXGF@BGB"F<*,D+SC/L<5S]KXRN]7\-^(9M0M;[3X[1I0M
MQ;!=T87 VC+?ZP=^WO2Z/X2U2V\2Z1J4]K!"ELDJ7!^V/,[L5QORWJ>PI6\+
MZU%H_B;1XX;:2WU!I9[:?S<$NY'R,N./K2?Z K77JC:D\5VNGP:?:1Q7VHWL
M]LLRPPQAI2F!\[\@#\^M)/X\TJ#0H]5Q<- UR+61!'B2*0G!#*>>*H_\(_K&
MDZI::OI4=M<S?V?'9W-M-*4Y7&&5L'O5.3P5J?\ 8XWM!+?W.KQZA<A6Q&@#
M<A<]<#\Z;W_KO_D3T_KM_F;UKXTL)GU".ZAN[&2PA^T2I<Q;6,7]X $_XU;T
M+7AKL)FCL+VVA*AXY+A HE4]",$_KBLRYT*]?QEJ&IK;V\]K-I@MD25^'?=G
M:PQTQWJCX>\/ZSH;ZI=VEM;VL<L(%KI@N6DB60?Q%B/E!]!213.WKB;;QC)I
MO_"3W>K/)-::=?+#$L:+E$.![9Y.>:["S:X>SA:\1$N2@,JH<JK8Y /IFN%U
M'P?JMSIOB>&..$OJ-_'/;@R<% 5SGTZ&CK_7="Z'1:7XMM-3U<Z=]FO+6=HO
M/A^T1;!-'_>7G^>#5CQ/J\^AZ#<WUM:274D:$A4QA>"=S9(^48YQS52XT:[D
M\<:;JBJGV6WLI(7.[D,Q!&!^%:FLV+:IHM[9(X1KB%XPQZ D8I2VT''?4X75
MO$ES=:3X5U.[@NK0M?QF5%'^N&S.552<J2> :Z>R\9:?<Q:DUS'<6+Z: US'
M=)M95(R&X)R#6-'H&N7.G>&X+NUMHGTF\0R%)MP>)4QO''4GM4NI>#[O5M6\
M3&5TBMM3M88H9 <D,@[CTSBJ?6W]:(2Z7_K4U+'Q;;:A<K:26E]8RSQ-+;_:
M(@OG*!R5Y//.<'!K*TOQE8Z5X7TBXN)=2O$O9)(XY9D5IBP+'#!3STP,9[5'
MX?\ ",UEJ$,UUH]I!+;QLHN4OYI2S%<95&X4'OFHM,\(:I;:9X4@FCAWZ9=R
M37 $F0%.[&/7J* Z?UV.VL;HWMC#<F": RH&\J9=KIGL1V-</XQ\:VUSX:UN
MWL8;\K"K0?;HHR(EES]W<#G\<8KT"O.+GPEXCMO#VL>'[!+&6RNY))8;B24A
M\,<E"N.N>^:EZC1LVVKP6FNVRW-[>J(M&%Q)$<&#:#RY[[_Z5H:9XMMM1L)K
M][2\M+".+SEN;A J2)ZC!)_ XJ@GAZ_3Q)%?&&"2!-'^QE'?AI,YVD8^[[UF
M6'@:]FBUB"5(M*T^^M?(2R@N&F19,_ZP9  ^@IO_ #_-DK_+\D;*^.;8Z+=:
ML^FZC%8P1B5)98E43*3C*Y/OGG%/_P"$VLC9QSI9W[M<3&&UA$.)+G SN0$_
M=QW.*R[S2?$NI>"KS0[RSL5E6V2&&:*<XF((Y((^7@59\4^$IM8ATF>!(I9=
M/!#6SRM&LJE0" Z\J1C@T,:&ZWX[-OX7O;_3;&X:ZM7,4T4R &V;@YD&>G/;
M.:D_MMKO4O#37/\ :5C-=F7_ $8!-DF%!S)@GCN,?C55?!DDWA'6+"*QMM-N
M=0 P%N9)\D8QN9ORXJ9='UF^U'PU=WMK! VG&5;A4FW#!0*I''.<=.U-;B>Q
M9F\?Z;"\T@M[Z2P@D\J:_CAS C9P><Y(!ZD#%2W_ (TM++5VTV.SO;RY%NMR
MBVT8?>I].?YU@GPIX@MM!O/#-I]A;3KF1]MZ[D/'&[9(*8Y;D\YK9TWP[<Z?
MXS:]4*;%=,CLXW+?,65NX^E+^OP*_K\39T76;77]*AU"Q+&&7. ZX92#@@CU
M!%6;R=K6TEFC@DN&12PBBQN?V&2!G\:XW0X]8\*Z9I.DBSCEN+N^E,K EDBB
M)+%LCOC'6NXH?D)'E]_XLU#7_AGK-U<6TUG)%)A)HSM4@2@;00V<@=:Z[2?%
MUI?:A%IK6]Y;S/;^="]Q%L69!U93G^>*YUO"6N)X-UCP\L%LZ22F6UG$V/,W
M2!B&&/EP*W;[0+J[\6:3>[4^R6]E-!,=^&!< # HZ?UV&_Z^]#[?QQ87%Q#B
MVO4L[B;R(;YXL0R/D@ '.<$C@D8-;UY<K964]S(&9(8VD8+U( SQ^5>?:3\/
MY=/EMK2ZTNTNXH)@XO3?3+\H;(/E=-P_*NXU[_D7M2_Z]9?_ $$TI:1N"5Y6
M,.R^(6G7AL'-I?P6U^0D-S+#B(R'^#.>O;/3WJS!XTL;C6KC3([>[,MM*T<\
MGE_NX@JYWLV> >@[UR6@Z-KGB#PGX<LIDLXM+@,5R;A7)D=5.53;C@^IS72Z
M5X9N$E\41WP5(=6N&,;(V3L*;<GT-4U:_P _T_X(D.M_'VG3R0,UM?0V5S((
MH+Z6';#(Q.!@YR >Q( -.O\ QWIVF7.HVUY#<Q7-GL*PE1NN0QPICYYR>.U8
MO_"*^(+W1;#PY?"R33K.2,M>1R$O*B'*@)CY3P,G-+KWA'6=;UBXUH-#!>V#
MH-*BW JRJ<DR''\7Z4: ;2ZM"GB^9;BYO8=FF"XDMY-OD1KNY;@YWCH>V*?I
M_C2RO[NVB:UO;:.\!-I/<1;4GP,\'.1QR,@9JC<^&[[5]?O+J\C2WM[W1_L;
M[)-S)(3D@>H'K5#P_P""I]/OK'[;I%F6LR#]M6_F;<0,!EB/ /3/;K27]?>P
M_K\$=%HGBJ#Q!,?L-E>FTRP2[= (G*G! YS^8K=KB=#\,:C:>+%U%+6VTFS"
M.)[>VN&D6Y8]&VX 7'6NVHZ!U"BBB@#S+X>?\E'\6_\ 70_^AFO3:\R^'G_)
M1_%O_70_^AFO3: "BBB@ HHHH **** "N-^+'_)/[W_?C_\ 0A795QOQ8_Y)
M_>_[\?\ Z$* -CP;_P B7HW_ %Y1?^@BMJL7P;_R)>C?]>47_H(K:H *@N+*
MVNS$;F".4PN)(RZ@[&'0CT-3USOB[4(K>"SLS+?K<7DVR&.Q<))*0"2NX\*/
M4T =%17E$VO:K#X4\31"[NDET^[A6!Y9P\L88KE2Z_>_^O5_6I-6TW4]*T9;
MS5+X7B2W,SPW"0RR/Q\BL<!5'7:.:!V/2*0@,"& (/!!KG_!KZN=-N(M:257
MBN&6$S2I)(8^" Y0D;ATKG?%VK/)<:O)IEUJ_G:9&/,>&X2*"!]N1D,<OGN.
M?:AZ M3NK+3[338?)L;6&VB)W;(D"C/K@5)<7,-I \]S*D42#+.[  ?C7%Z?
MK5U<>,="-S=,D5UHQF>/?B-I,@DXZ9KG-4E?6OAMK=Y/?74RV^IR>41,=K)Y
MB@ CNH!X':AZ?UYV)3OK_6USTB[UZ"TU[3M+:*1Y+])'21<;5" $Y[\YK4KS
MO5-,(\5>$[&UO[M5,%QFX,N^4K@$@.?RSVJK-K^K:/X=URVCOII6L]42SCNY
M_G>&)L98GOC/4T_Z_&PUK_7D>G54U34H=(TV:]N%E>*$998D+L><< =:Y&&:
MYT+QEIVF6NK76HVU];2R3)<2B1HBHR) W8'ICI6%:SZL/A=>Z[-K5\]RT)CB
M42D","7&[/4L?7/3BD'4]4C<21JZYPP!&1S3J\]\8>9=W5A8Z5J.I+K=Y$FU
M(;MDB@0?>E<#_)J+5KC58_$5KH$4FJ7<5M8+)NM;I(99WS@NSL1D#'0>O- '
MH]9>G:[#J.L:GIT<4B2:>R*[MC#;ER,5Q37^N7!\-Z/K%[/I[74DXN)XI5$D
MH3[B[UR 2.N.]7_ :>5XI\51_;'O-D\2^<Y!9L*>"1U(Z?A0A,[62Z@AGBAD
MFC26;(C0L SXY.!WJ6N \5Z3%<?$7P^TEW>1?:%FSLN"@3:HQL_NY[XZU&;B
MZUN^\22W6MW>FG2I3';PPRA%10N0[C^+/OQ1?2Y5M3T.BL7PAJ=SK7A+3KZ^
M7;<3PAGP,9/3/MGK^-<4VJZE%'<^$OM]R=3?5%BBG,A\T6S?/NW=>%!%.VMA
M=+GI]13W4%L8Q/-'&97"('8#<QZ >IKA?-N=;UOQ!'=:W=Z:FDE4MXH90F%V
MY\Q\_>S[\5BW[S>(](\':GJ=S=13W-VL+M%,8UQ\V)%'\+'U%+_@?B!ZS17F
M>I7NLWOB35-/L_[5<:='&EL+:[CBVY3/F2;R"^3]17>:%+>SZ%9R:FBI>M$O
MG!2"-W?!''Y4=+AU-"BO+&U^ZC^%]],^IS"^&HO"CF8^8/WPPH/7IV]*U+EK
MC4_B'?Z9-K=W96@T^*41PS;"6YR0>WJ<=:/Z_"X?U^-COZ*\ML/$FJZEI.@V
M5QJ,L,5Y?3VTNH)A7D2/[N&[%NF?:I[[5+_2T\6:5;ZE<W5O96 GAN7DW2P.
M>J;QR?7GFACM_7X'I=%>?V;ZCI>M^%I)-6O+H:K$RW,<S9CR(]P*C^''ZUT/
MC*#6+C1T30I2D_G*9%201O)'_$J,>A-#T$M3?HKS:77Q)X>T:6PN]1A5-:2V
MN?M4^YQC.Y&<?>7I5G5?$5Y9^)/%,EA<-.+'2XY(X0VY$DYR<=,]":'I_7E<
M$KNW];V.OU[6(M T2YU*>-Y8[=0S(F-QY XS]:NPRB:".4 @.H8 ^XKSG5[/
M9\*]0OFUB[U&:[LXY',TVY 2RD[5Z+UQQ6A8B^T?Q?H5L=4N[J'4;-S/',P*
M!E4$%!_#UZ"G;6PK]3NJ*Y?QYJMWINFV26DYM1>7D=O+= #,",>2,\ ]LUF0
MK/:^,&\.1ZK?WEC=6#32,\^Z:V8' (D'(S2_K]1G1ZOXFLM*T9M24_:H%E6'
M]PP/S%MO7..":UQS7C5O9+#\))Y8;F9I);Y4VO(72,B? (7H#W/K75_:-0\/
M^,);--0N[^*72I+OR[AMV)4./EQT!]!1_7X7#?\ KSL=W17E_AN_\1WITC4X
MEU&5;F4?:Y)KN$V[H<Y"1YRI'8 9XYK:\*QW^I>)-8N;G5;LVUCJ$L<5J'^1
MLJ/O>H&>!T%.VM@.BU77H=)U#3+26*1WU&8PHRXPI SDUJ5PWQ#&[6/"RBZ-
MKNOF7SQC*97'&>,]JR=0U'4-,B\7Z9:ZK=W4-G9I/!.\I:6!VZKO'/O[4NA5
MM5_74]/IKN(T9SG"@DXKB9]7E?Q!X-@AOW;[1 [SHLN1)^[&"P[\YZU4T6\U
M'3O$#6?B"XU!M1NDF>WD2Y#VLJC)&$'W2!0]/Q)6IV^E:G#K&FPWULDJ12@E
M5E0HPP2.0>G2KE>6V6H:I?:!X*0:K=Q37MS*D\PD)=U&[KGKP.,]*GN-;U3P
M_I_B^V@O;BZ_LYX?LTMPV]XQ(/FR3UQU&:;ZA8]+HK@-"/B*/4@(UODLI[1R
M9-0O(I\2XRCKM)(7U'2JNCW.L0IJ&D7%U>Q>)FLC*DES<B6V?G&],<+],4@1
MZ317'^!KYC<7VF7S:D-4ME1KF.[N!,O(^\C#@ ^E'BF]6XUE=.MIM6:ZBMS.
M\5E<) J*3@.SL1Z=*'H"U.PHKS&+4/$&L^#M'U!)[B:"+SOMRVUPL,\JJ2%8
M-TXQSC&:[OPY?V^I^'K*[M))Y8)8@5>X.9#V^8]S3L!IT5Y$U[K$?A"?6H];
MOQ<P:JT$2&3,80R;<,#][KWZ5T4-]-X>\5ZK:WFJWD]@FE_;'>=M[1L&P2O'
M'TZ4OZ_"X[?U\['=T5YKINIWD/BC188Y]6%GJD<FX7URDAD79E755.4/Y=:B
ML]4U.9(/";7]S_:46J-'-.)#YAM5_>;MW7D8%.PCT^BL'QM<36?@K5I[:5XI
MH[=BDB,0RGU!KEX+V\T[4_"MQ#K=S?MJQ"74,D@9"NS.Y5_AP?\ Z]):L#T:
MBO+K74-8MO#&NZ^-3NII+*XN(+>W9MT:C?C>PZL5SQV %:*SW.AZOX<:UURZ
MU(:J^RXBGD$@92N3(@_AP?3BA:_UW#^ON/0**\F6]OI?#7B'5&\1WD-SIM[-
M]GB$WRC#<*P/W@>@'0=JNWVLZSK&OK9K%J6$T^&X6&QN8[=M[C)9BQ&X \8'
M'K0-JS/3*R[?78;GQ)>:,L4@FM84F:0XVL&Z =^U<7//X@O;CPK87E_/87=W
M'<1W3P2*2P4###&5W8'7L2:F?3I[CQ?XDL;6ZGCN/[)@2*=7(DW#.#N'?(YH
M_P""(]"HKS[PUKUYXJU71(UN)46PM&EU!4<C?-G8%;UZ%L5K>/-3N[*WTNVM
M;IK*.^O4MY[M<9B0^A/0GIFFT".KHKA=9,^G:AH6@0:M>Q6=[+*9KQY]TIPN
M1&'/3/YUE:GJVHZ=I_B[3+?4[FYAT^"*2WNVDS+$S$90N.N/SI!8]/HKSL6N
MI+XMTS33KVI&#4;!I[D^8,[EQ]PX^3.>U9W_  D>L1^%;.W%S=3/)J\EB\ZR
M*LS1J3A0[<!CTR:=OZ^=@6O]>5SU6LN3788_$T.B&*0S2VS7(DXV@ XQZYK(
M\''68KR_M]2ANX[-0C6WVRXCFE4D?,I9221QD9K,\0P"[^*>FVYOY;)9=-D!
M>%PCM\WW0W;\.>*75?UT#H=]45S<1VEM+<3';'$A=SZ #)KRY_$VKV^@3V<5
MY<721ZU]@2]5U$CQ8S@.WR[L\;C5\6FL3Z1KUIJ0U.WT]+7SK<SWJ/,K!3E2
MR$DH?0^])[7_ *VN-+6W]=CL_#^N#Q!IPO8[.YMH7.8C. #(O9@ 3P?>M2O,
M;>:YTGP?X6M+74+JVAU:6-;BZ>3<804SM0GA <8'I5N:^O-)U'Q!H]OJ=U>6
ML&E-=)++)OEMY.1MW]>>HS52TO\ UL):V/0Z*\NN;S6=-\-:',=1O[J;6I(E
MF9950QKLR$C9N%+=V)R:Z;P<=9BN]0M]3ANDLUV-;?:[B.:5<CYE+*22,C(S
M1;5H.ESII+J"*>*&2:-99L^6A8!GP,G [U1TS7(=3U/4[*.*1'T^58W9L88E
M<Y%<IXJTF&X^(N@-)>7L7VA9L^7<L@3:HQL_NY[XZU0:QN;C5?&]S;ZG=V?V
M5ED06[;=SB+(+'N..E3?2_J.VMCTVBO,KOQ!J^IMX<M +UUO-.^TRK93I!)-
M)P,;V(X'7 YYKKO!LFK-H\B:VCB>*=UC,DB.YC_AW%"1N'0_2JM8FYOT5YCJ
M,NI3?\)G=IK-_ -+E#VT44N%4A >?;VZ=:O65UJ5AXD\/O)J=W=_VI92RW$,
MC#R]ZH&&Q?X>N.*0ST"BO*M%U/Q-J<-IJULFH2S/=8F+W<(M?+WD,@B)RI Z
M<9R*EOM2\0:MK&NBQ74C-8SF*V%O=1111  $&1&(+9ZY/&.E 'I3W4$=S';O
M-&L\@)2,L-S =2!4&GZK!J4UY%"DRM:3&&0R1E06'=?4>]<+=Z:;KXC:#+?7
M-W!<7%B\TJQW) 1UVY5<'A2>H'!JKJVL:E'H/BR2*_N4EM]62.!Q(?W2Y7Y1
MZ#GI3M_7SL&[_KM<]1HKA!/J'A_QC]D74;N_BN-,ENFCN&W#S4/51_"#Z"N?
MDU"^_P"$.TG6AXBO'O-0O8A-")L)@ORBJ/NXQSZ]Z$OZ^=A7T_KM<];HK&\7
M:G<Z-X4U&_L4W7$$)9,C.#ZX]NOX5RJW-UHE[X:GM=;NM2;595CN(9I ZNK+
MDN@_AV^W%):CZ'H=%<3X+2_U'5-3O;O5+N2&TU"X@AMM_P A&>K=SCL.@J_X
MMOH_M5CIL<NI&[N-[I!82K$TBJ.2SG& ,^M'8.K.GHKRA]=U:?P=M74+F.XA
MUU;-)S(&DV9Z,R\-C/T.*W(+>_C\5:OX?75KZ6&?31/')++EX92Q7*L,8'?%
M']?A</Z_&QW=%><>'=<O_$5WH&G&ZF2:P6235-KD%F0[%5O7)Y]ZZOQ;J,&G
MZ2@FGNXFN)DAB^R8$KN3PJD\#..M#!&Y67J6NPZ;J^F:?)%(\FHNZ(RXPFU<
MG-< WB+5]'L_%,$<MV&LK:*6%;N99Y(&8X;YESD8YP>E3/:?9/&'@[&LW.H^
M=YDI$\HD()CY8'L#Z=.*:5V@/0-,U6#5HII+=)E$,S0MYL90EEZD9ZCWJ[7E
M_P#PD&IQZ Z?VA-%]JU^2S>[=MQMXMW8GIZ#TK2-U>:-XDO=&M=3NKZU?2Y+
MG,TGF26\@R!\_7GT-3?2_P#6UQVUM_6]COJ*\UCUVX;PMX)(U&4W-U=PK,1,
M=\J\[@WJ.F<UI^'TO]3\8:[)-JEV+33[[$5LK_*V4'#?[([ =^:IK?R_X'^9
M-]$=O3)(TFB>.10Z."K*PR"#U!KR>VO-6A\#V_B ZW?O<Q7_ ):Q-)F,QF7:
M58'[WU/2MC4OM]_XG\4Q+J]_;065I%-%'!+MP^PG/TXY ZTF5;6W];V.^MK:
M&SMX[>VB2*&,;4C1<*H] *EKS73+_58W\'ZG-JUU/)JS>7<PNP\HKL)&% X(
MQU[U3@U7Q+JWVS4+&/46NX;QHU NXDMHU5\;&C8@].YYYXIM:V%T/5JAGNH+
M7R_M$T<7F.(TWL!N8] /4UP<R:AJWBCQ/ =7O[2"T@BDCB@EV[7,>>OID<@=
M:RM4#Z]X>\%ZEJ%Y=+/<W,44K1S%%'WOG ' ?_:I+I\OQ ]7HK-U2XETGPW=
M3VBO<2VMLS1ASN9RJ\9/?I7"?VA?:;HF@Z[;Z[=7UYJ$\*36SR!HY0_WE5/X
M=OMZ<T+5V_K4.ESTVBN(\/)?ZGXRUQYM4NQ::??8BME?Y6R@X;_9'8#O7;T
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MQK1HH QI?"&ASVD-K)IL+00LSQISA2QRW?N>U:L$$5M D,$:1Q1C:J(,!1Z
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MRV4J6<2O8JRVQ48\H,,' ]Z2?3DMY[O4M/M86U.:()OD8J'V_=!/.!^%:%%
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MT %%%% !1110 4444 %<;\6/^2?WO^_'_P"A"NRKC?BQ_P D_O?]^/\ ]"%
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MYT2.<LH X/?!S7<HBQHJ(H55&  , "G53U$M#F]/\-2Z?XL2^B:/[%%IJ62
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \R^'G_)1_%O_70_^AFO3:\R^'G_ "4?Q;_U
MT/\ Z&:]-H **** "BBB@ HHHH *XWXL?\D_O?\ ?C_]"%=E7&_%C_DG][_O
MQ_\ H0H V/!O_(EZ-_UY1?\ H(K:K%\&_P#(EZ-_UY1?^@BMJ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\R^'G_)1_%O_ %T/_H9KTVO,OAY_R4?Q;_UT/_H9KTV@ HHHH **** "BBB@
M KC?BQ_R3^]_WX__ $(5V5<;\6/^2?WO^_'_ .A"@#8\&_\ (EZ-_P!>47_H
M(K:K%\&_\B7HW_7E%_Z"*VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+IG_ $#K/_OPO^%']BZ9_P! ZS_[\+_A0!/]KM_^>\7_ 'V*/M=O_P ]XO\
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M]KM_^>\7_?8H^UV__/>+_OL5!_8NF?\ 0.L_^_"_X4?V+IG_ $#K/_OPO^%
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M +[%0?V+IG_0.L_^_"_X4?V+IG_0.L_^_"_X4 3_ &NW_P">\7_?8H^UV_\
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M 3_:[?\ Y[Q?]]BC[7;_ //>+_OL5!_8NF?] ZS_ ._"_P"%']BZ9_T#K/\
M[\+_ (4 3_:[?_GO%_WV*/M=O_SWB_[[%0?V+IG_ $#K/_OPO^%']BZ9_P!
MZS_[\+_A0!/]KM_^>\7_ 'V*/M=O_P ]XO\ OL5!_8NF?] ZS_[\+_A1_8NF
M?] ZS_[\+_A0!/\ :[?_ )[Q?]]BC[7;_P#/>+_OL5!_8NF?] ZS_P"_"_X4
M?V+IG_0.L_\ OPO^% $_VNW_ .>\7_?8H^UV_P#SWB_[[%0?V+IG_0.L_P#O
MPO\ A1_8NF?] ZS_ ._"_P"% $_VNW_Y[Q?]]BC[7;_\]XO^^Q4']BZ9_P!
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M]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\
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M]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\
M"$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT
M ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6
M_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG
M_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='1
M7.?\(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P
M9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG_03U
MO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\
M(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?X
MT?\ "$VG_03UO_P9S?XT ='17.?\(3:?]!/6_P#P9S?XT?\ "$VG_03UO_P9
MS?XT ='17.?\(3:?]!/6_P#P9S?XUMV%FFGV<=M')-(L8P'FD,CGZL>30!8K
M,U'_ )"^D_\ 7:3_ -%-6G69J/\ R%])_P"NTG_HIJ -.BBB@ HHHH ****
M"BBB@#S+X>?\E'\6_P#70_\ H9KTVO,OAY_R4?Q;_P!=#_Z&:]-H **** "B
MBB@ HHHH *XWXL?\D_O?]^/_ -"%=E7&_%C_ ))_>_[\?_H0H V/!O\ R)>C
M?]>47_H(K:K%\&_\B7HW_7E%_P"@BMJ@ HHHH **** "BBB@ HHHH S/$?\
MR+U[_P!<S6G69XC_ .1>O?\ KF:TZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS4?^0OI/_7:3
M_P!%-6G69J/_ "%])_Z[2?\ HIJ -.BBB@ HHHH **** "BBB@#S+X>?\E'\
M6_\ 70_^AFO3:\R^'G_)1_%O_70_^AFO3: "BBB@ HHHH **** "N-^+'_)/
M[W_?C_\ 0A795QOQ8_Y)_>_[\?\ Z$* -CP;_P B7HW_ %Y1?^@BMJL7P;_R
M)>C?]>47_H(K:H **** "BBB@ HHHH **** ,SQ'_P B]>_]<S5V\NX+"TEN
MKJ0101+N=ST452\1_P#(O7O_ %S-:= '._\ "?\ AG_H,6_Y-_A1_P )_P"&
M?^@Q;_DW^%=#BC% '/?\)_X9_P"@Q;_DW^%'_"?^&?\ H,6_Y-_A70XHQ0!S
MW_"?^&?^@Q;_ )-_A1_PG_AG_H,6_P"3?X5T.*,4 <]_PG_AG_H,6_Y-_A1_
MPG_AG_H,6_Y-_A70XHQ0!SW_  G_ (9_Z#%O^3?X4?\ "?\ AG_H,6_Y-_A7
M0XHQ0!SW_"?^&?\ H,6_Y-_A1_PG_AG_ *#%O^3?X5T.*,4 <]_PG_AG_H,6
M_P"3?X4?\)_X9_Z#%O\ DW^%=#BC% '/?\)_X9_Z#%O^3?X4?\)_X9_Z#%O^
M3?X5T.*,4 <]_P )_P"&?^@Q;_DW^%'_  G_ (9_Z#%O^3?X5T.*,4 <]_PG
M_AG_ *#%O^3?X4?\)_X9_P"@Q;_DW^%=#BC% '/?\)_X9_Z#%O\ DW^%'_"?
M^&?^@Q;_ )-_A70XHQ0!SW_"?^&?^@Q;_DW^%'_"?^&?^@Q;_DW^%=#BC% '
M/?\ "?\ AG_H,6_Y-_A1_P )_P"&?^@Q;_DW^%=#BC% '/?\)_X9_P"@Q;_D
MW^%'_"?^&?\ H,6_Y-_A70XHQ0!SW_"?^&?^@Q;_ )-_A1_PG_AG_H,6_P"3
M?X5T.*,4 <]_PG_AG_H,6_Y-_A1_PG_AG_H,6_Y-_A70XHQ0!SW_  G_ (9_
MZ#%O^3?X4?\ "?\ AG_H,6_Y-_A70XHQ0!SW_"?^&?\ H,6_Y-_A1_PG_AG_
M *#%O^3?X5T.*,4 <]_PG_AG_H,6_P"3?X4?\)_X9_Z#%O\ DW^%=#BC% '/
M?\)_X9_Z#%O^3?X4?\)_X9_Z#%O^3?X5T.*,4 <]_P )_P"&?^@Q;_DW^%'_
M  G_ (9_Z#%O^3?X5T.*,4 <]_PG_AG_ *#%O^3?X4?\)_X9_P"@Q;_DW^%=
M#BC% '/?\)_X9_Z#%O\ DW^%'_"?^&?^@Q;_ )-_A70XHQ0!SW_"?^&?^@Q;
M_DW^%'_"?^&?^@Q;_DW^%=#BC% '/?\ "?\ AG_H,6_Y-_A1_P )_P"&?^@Q
M;_DW^%=#BC% '/?\)_X9_P"@Q;_DW^%'_"?^&?\ H,6_Y-_A70XHQ0!SW_"?
M^&?^@Q;_ )-_A1_PG_AG_H,6_P"3?X5T.*,4 <]_PG_AG_H,6_Y-_A1_PG_A
MG_H,6_Y-_A70XHQ0!SW_  G_ (9_Z#%O^3?X4?\ "?\ AG_H,6_Y-_A70XHQ
M0!SW_"?^&?\ H,6_Y-_A1_PG_AG_ *#%O^3?X5T.*,4 <]_PG_AG_H,6_P"3
M?X4?\)_X9_Z#%O\ DW^%=#BC% '/?\)_X9_Z#%O^3?X4?\)_X9_Z#%O^3?X5
MT.*,4 <]_P )_P"&?^@Q;_DW^%'_  G_ (9_Z#%O^3?X5T.*,4 <]_PG_AG_
M *#%O^3?X4?\)_X9_P"@Q;_DW^%=#BC% '/?\)_X9_Z#%O\ DW^%'_"?^&?^
M@Q;_ )-_A70XHQ0!SW_"?^&?^@Q;_DW^%'_"?^&?^@Q;_DW^%=#BC% '/?\
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M%;.GZC:ZK9I=V,RS6[YVNO0X.#5C%+0 5F:C_P A?2?^NTG_ **:M.LS4?\
MD+Z3_P!=I/\ T4U &G1110 4444 %%%% !1110!YE\//^2C^+?\ KH?_ $,U
MZ;7F7P\_Y*/XM_ZZ'_T,UZ;0 4444 %%%% !1110 5QOQ8_Y)_>_[\?_ *$*
M[*N-^+'_ "3^]_WX_P#T(4 ;'@W_ )$O1O\ KRB_]!%;58O@W_D2]&_Z\HO_
M $$5M4 %%%% !1110 4444 %%%% &9XC_P"1>O?^N9K3K,\1_P#(O7O_ %S-
M:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !69J/_(7TG_KM)_Z*:M.LS4?^0OI/_7:3_P!%-0!I
MT444 %%%% !1110 4444 >9?#S_DH_BW_KH?_0S7IM>9?#S_ )*/XM_ZZ'_T
M,UZ;0 4444 %%%% !1110 5QOQ8_Y)_>_P"_'_Z$*[*N-^+'_)/[W_?C_P#0
MA0!L>#?^1+T;_KRB_P#016U6+X-_Y$O1O^O*+_T$5M4 %%%% !1110 4444
M%%%% &=X@C>70;U(D>1S&<*@R3]!WH_MNV_YY7W_ (!3?_$UHT4 9W]MVW_/
M*^_\ IO_ (FC^V[;_GE??^ 4W_Q-:-% &=_;=M_SROO_  "F_P#B:/[;MO\
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M_P#$UHU%+=00(SS3Q1JAPQ=P #[T 4_[;MO^>5]_X!3?_$T?VW;?\\K[_P
MIO\ XFKZ.LJ*\;*R,,AE.013J ,[^V[;_GE??^ 4W_Q-']MVW_/*^_\  *;_
M .)K1HH SO[;MO\ GE??^ 4W_P 31_;=M_SROO\ P"F_^)K1I* ,_P#MNV_Y
MY7W_ (!3?_$T?VW;?\\K[_P"F_\ B:T::'4L5# LO4 ]* *']MVW_/*^_P#
M*;_XFC^V[;_GE??^ 4W_ ,36C10!G?VW;?\ /*^_\ IO_B:/[;MO^>5]_P"
M4W_Q-:-(S!%+,0J@9))X% &?_;=M_P \K[_P"F_^)H_MNV_YY7W_ (!3?_$U
MH=:6@#._MNV_YY7W_@%-_P#$T?VW;?\ /*^_\ IO_B:T:* ,[^V[;_GE??\
M@%-_\31_;=M_SROO_ *;_P")K1IK.J %F"@G')[T 4/[;MO^>5]_X!3?_$T?
MVW;?\\K[_P  IO\ XFM&B@#._MNV_P">5]_X!3?_ !-']MVW_/*^_P# *;_X
MFM&B@#._MNV_YY7W_@%-_P#$T?VW;?\ /*^_\ IO_B:T:* ,[^V[;_GE??\
M@%-_\31_;=M_SROO_ *;_P")K1IC2QH<,ZJ>."?4X'ZT 4?[;MO^>5]_X!3?
M_$T?VW;?\\K[_P  IO\ XFM&B@#._MNV_P">5]_X!3?_ !-']MVW_/*^_P#
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M[;_GE??^ 4W_ ,35:6\6_P!7TWR(;K$4CL[26TB*H\MAU8 =2*VJ* "BBB@
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MM)O([;PC+<--)(@EF_>I@,V96 ;T'7KT[UT(AC"%1&FT]1MX-.VC;MP,>F*
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M]>47_H(K:K%\&_\ (EZ-_P!>47_H(K:H **** "BBB@ HHHH **** "BBB@
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MK>BTMII!<,AD1)87C,BCJ5W 9'TH#I<V:*YJ'X@>'YV@"7C 32>4&:%PJOG
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M0>"*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#O]+1_PK[QQ_T.+_\ ?Z6@#U.BO+/^%?>./^AQ?_O]+1_PK[QQ_P!#B_\
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M +_2T?\ "OO''_0XO_W^EH ]3HKRS_A7WCC_ *'%_P#O]+1_PK[QQ_T.+_\
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M (5]XX_Z'%_^_P!+1_PK[QQ_T.+_ /?Z6@#U.BO+/^%?>./^AQ?_ +_2T?\
M"OO''_0XO_W^EH ]3IKNL:,\C!4499F. !ZFO+O^%?>./^AQ?_O]+3A\,/$>
MH+Y.M>+)Y;8GYHU9WR/HQQ0 [X7NM_XQ\4ZE;Y:UEEPC]CEF/\N?QKT^LSP_
MX?L?#6EI8:=&5C4[F9CEG;NQ/K6G0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g111573.jpg
<DESCRIPTION>G111573.JPG
<TEXT>
begin 644 g111573.jpg
M_]C_X  02D9)1@ ! 0$!+P$O  #__@!%35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=2DE,3%]#7TU)3$Y%7TM?4TE'+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( $@ GP$!$0#_Q  >  $
M @(" P$             " D!!P8* P0% O_$ #$0   & @(! P,# P0#
M  $#! 4&!P((  D1$B$Q$T%1%!46%V%Q&(&1H2,TT?_:  @! 0  /P#O[B(
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M)Z.0-2-8K3ND<7NS,](8Y,FHS-I>%+0ZM2LIFE#,^QQILBXXXXY@1  \B(
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M!$YBK)*B8C8,;*7$1^;1PE\1+BF>5,I+DX%-;ZAP)<4):U5BF4%@=GYV,
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+XXXXXXXXXXY__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
